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Abstract 
The migration of T lymphocytes is a vital component of the immune system, 
with roles in immunosurveillance and inflammation. The role of 
Phosphoinositide 3-kinase within T lymphocyte migration is unclear, with some 
evidence that it may be a disposable signal. Here, using Staphylococcal 
Enterotoxin B activated peripheral blood mononuclear cells and the T cell line 
CEM cells, the role of Phosphoinositide 3-kinase and its downstream kinases 
was investigated. CCL22 mediated CEM cell migration and CXCL12 mediated 
peripheral blood mononuclear cell migration were shown to be independent of 
Phosphoinositide 3-kinase using several different broad-spectrum 
Phosphoinositide 3-kinase inhibitors. However, these cells were Akt-dependent, 
as demonstrated by incubation with the Akt inhibitor Akti-1/2. Differences in 
the effect of the inhibitors on Akt activity were discovered, indicating that either 
Akt can be activated in the absence of Phosphoinositide 3-kinase, or differences 
exist regarding the relative abundance of each protein within the cell.  
Th17 cells are a subtype of the T helper cell family and have been shown to be 
involved in inflammation and immune diseases. Mouse splenocytes were 
polarised to a Th17 phenotype and analysed for the surface expression of 
chemokine receptors. CCR2, CCR6 and CCR9 were shown to be expressed on 
Th17 cells and upregulated under Th17 polarising conditions. However, only 
CCR2 and CCR6 induced migration of Th17 cells. This migration was sensitive 
to Phosphoinositide 3-kinase and Akt inhibitors. This data reveals a model for 
the migration of Th17 cells to areas of inflammation, and sheds light on the role 
of Phosphoinositide 3-kinase during this process. 
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Chapter 1: Introduction 
1.1 The Immune System 
The immune system is an intricate and finely controlled collection of 
mechanisms within an organism that maintains health by limiting infection and 
disease. It can detect a wide variety of agents, from bacteria and viruses to 
helminths, while recognising an organisms own healthy cells. This ability to 
distinguish between self and non-self is one of the most important aspects of the 
immune system. In mammals, the immune system is divided into two branches, 
termed innate and acquired immunity. These systems, while separate, must 
interact closely for the proper operation of the immune system. The innate 
immune system comprises those aspects of the immune system that operate in a 
generic and non-specific manner. This system provides immediate protection for 
the host, and ‘buys time’ for the host while the acquired immune system is 
activated.  
1.1.1 Innate Immunity 
The innate immune system is thought to be an evolutionary older system than 
the acquired immune system and is the main immune system in plants and 
insects. The first line of protection is the barrier provided by skin, pulmonary 
and gut epithelia. This mechanical barrier works by preventing access to the 
organism. As this barrier cannot be completely sealed, other defence 
mechanisms such as mucus, secreted by the respiratory and gastrointestinal 
systems, and coughing serve to entrap and expel pathogens.  
If this barrier is breached, the secondary line of defence is inflammation. Blood 
vessels near to the infected tissue alter, resulting in edema and the recruitment 
of leukocytes to the infected tissue. The leukocytes then recognise foreign 
pathogens within the tissue, before undergoing phagocytosis and degrading the 
pathogens. The recognition of self and non-self within the innate immune 
system does not work by recognising every possible antigen, as in the acquired 
immune system, instead it recognises molecules shared by groups of related 
pathogens that are essential for the survival of those pathogens and are not 
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found on the surface of mammalian cells. These molecules are known as 
pathogen-associated molecular patterns (PAMPS) (Medzhitov and Janeway, Jr., 
1997) and include LPS from the gram-negative cell wall, peptidoglycan and 
lipotechoic acids from the gram-positive cell wall, the sugar mannose, bacterial 
and viral unmethylated CpG Deoxyribonucleic acid (DNA), bacterial flagellin, 
the amino acid N-formylmethionine found in bacterial proteins, double-stranded 
and single-stranded ribonucleic acid (RNA) from viruses, and glucans from 
fungal cell walls. In addition, unique molecules displayed on stressed, injured, 
infected, or transformed human cells also act as PAMPS. PAMPS are 
recognised by pattern-recognition receptors (PRRs), of which there are two 
types; endocytic PRRs, found on the surface of phagocytes and promote the 
attachment of microorganisms to phagocytes leading to their subsequent 
engulfment and destruction; and signalling PRRs, an example of which are Toll-
like receptors (TLRs). There are many different TLRs, which are responsible for 
binding different molecules on the surface of pathogens. Binding of PAMPS to 
different TLRs results in the transcription and translation of different 
inflammatory cytokines, thus tailoring the immune response to the pathogen.  
1.1.1.1 Leukocytes involved in innate immunity 
Several cell types are involved in innate immunity, including natural killer (NK) 
cells, Neutrophils and Monocytes / Marophages.  
NK cells are not part of the inflammatory response, but are a major component 
of the innate immune system as they are involved in the rejection of tumours 
and cells infected with viruses. NK cells are activated by receptors on their 
surface termed Fc receptors. These bind to the Fc portion of antibodies bound to 
infected / abnormal cells. Once activated, NK cells degranulate, releasing 
proteins such as perforin and proteases such as granzymes. Perforin forms holes 
in the membrane of the targeted cells, allowing the proteases access. The 
proteases then induce apoptosis of the cell.  
Neutrophils are a polymorphonuclear cell that normally circulates through the 
blood. In response to signals such as interleukin (IL)-8  and interferon (IFN)γ, 
18
 
they migrate from the blood through tissue to the site of infection. Having 
recognised PAMPs through their surface TLRs, neutrophils phagocytose 
pathogens, degrading them using reactive oxygen species and hydrolytic 
enzymes. In addition, neutrophils can undergo degranulation, releasing several 
different types of molecules.  
Macrophages, the differentiated form of monocytes, can be tissue based (such as 
Microglia in neural tissue and Osteoclasts in bone) or circulate through the 
blood stream where they migrate to the site of infections in response to signals 
from damaged tissue. Once at the site, they release a series of chemicals to 
attract other cells to the site of infection, and also engulf and degrade pathogens 
through phagocytosis. 
1.1.2 Acquired Immunity 
Acquired immunity (also known as adaptive immunity) is found in vertebrates 
and provides the host with the ability to recognise and remember specific 
pathogens. Therefore, the host can mount stronger challenges each time the 
pathogen is encountered. It is described by Janeway as “the optimum host 
defence system” (Janeway and Medzhitov, 2002) although this has also been 
disputed (Hedrick, 2004). The acquired immune system can be split into two 
systems, the humoral system (mediated mainly by B cells) and the cell mediated 
system (mediated mainly by T cells).  
The humoral response is mediated by secreted antibodies, produced by cells in 
the B cell lineage known as plasma cells. These antibodies bind to antigens on 
the surface of pathogens, flagging them for destruction. Antibodies consist of 
two large heavy chains and two small light chains. There are several different 
types of heavy chain, which determine the isotype of the antibody. At the end of 
the antibody is a region known as the hypervariable region. This binds to a 
target on a pathogen known as the antigen. Antibodies can be very diverse, and 
allow the immune system to recognise a wide variety of pathogens.  
19
 
Innate immunity can act as the trigger for activation of the acquired immune 
response by inducing the production of pro-inflammatory cytokines, resulting in 
further leukocytes being recruited to the site of inflammation.  Dendritic cells 
(DCs) play a leading role, with immature DCs binding conserved sequences 
within the pathogen, initiating maturation and expression of TLR (Vestweber, 
2003) and co-stimulatory molecules, such as CD80/CD86 (Akira et al., 2001). 
During T cell activation, mature DCs migrate to the lymph nodes and present 
the processed antigen (bound to the major histocompatibility molecule) to naïve 
T lymphocytes, while a second co-stimulatory signal is given via binding of B7 
to CD28 (Banchereau and Steinman, 1998; Reis e Sousa, 2001). 
The acquired immune system is very complex and as such is highly regulated. 
This complexity is only possible due to the array of specialist cells that make up 
the system, including B cells and T cells.  
1.2 B Cells 
B cells mature within the bone marrow where they express an antibody 
molecule on their membrane known as the B cell receptor (Matthias and Rolink, 
2005). When this antibody encounters a new antigen the antigen is internalised 
and processed. A fragment of the antigen is then presented to a subtype of T 
cells, known as T helper cells, in complex with a major histocompatability 
complex (MHC) molecule. If the complex is not recognised, cytokines are 
produced by the T helper cells which cause the B cell to divide rapidly and 
differentiate into either a memory B cell or a plasma cell (Fuentes-Panana et al., 
2004). A memory B cell has a longer life span than the naïve B cell but 
expresses the same antibody to protect against repeat infection (McHeyzer-
Williams 2005). Plasma cells no longer express the membrane bound antibody; 
instead they secrete it in large volumes to target the antigen (Shapiro-Shelef and 
Calame, 2005).   
1.3 T cells 
T cells, also known as T lymphocytes, are the focus of this piece of work. They 
form a major component of the immune system and can be diverse in their 
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actions. T lymphocytes are derived from bone marrow haemopoetic stem cells 
that enter and populate the thymus. T cells are classified by the heterodimer 
which comprises their T Cell Receptor (TCR), this may either be the most 
common and studied T cell, α/β TCR, or the γ/δ TCR which makes up between 
1-5 % of peripheral blood T cells (Hayday, 2000).  Although, γ/δ T cells make 
up a relatively small subgroup, they have a distinct receptor profile, and have 
been suggested to play a role in immune defence against infection, in particular 
in the gut. They have also been shown to be an important producer of IL-17 
(Roark et al., 2008a). Following TCR rearrangement there is a massive IL-7 
driven expansion and differentiation of T lymphocytes into CD4+/CD8+ double 
positive thymocytes.  Through positive and negative selection, cells are selected 
for either the CD4+ or CD8+ lineage. Positive selection selects for cells that are 
able to recognise and bind to a MHC complex while negative selection selects 
for those cells which recognise self antigens. These naïve T lymphocytes then 
leave the thumus and recirculate through the blood, homing to secondary 
lymphoid organs such as the lymph nodes. Inside these, the T lymphocytes 
screen antigen presenting cells (APCs), such as dendritic cells and macrophages, 
for peptide/MHC complexes. Those that recognise peptide/MHC molecules are 
activated and will divide into effector T lymphocytes. Each T lymphocyte that is 
activated by a particular antigen gives rise to a clonal population of cells all 
expressing the same TCR. This process is referred to as clonal selection. 
Activated T lymphocytes usually leave the secondary lymphoid organs to 
accumulate at sites of inflammation or other effector sites. Importantly, some T 
lymphocytes also become memory cells, which are long-lived antigen-specific T 
lymphocytes that become activated during a secondary immune response to a 
pathogen already encountered. They retain the TCR affinity of the originally 
activated T lymphocyte and are used to act later as effector cells.  
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Figure 1.1: Lineage decisions within T cell development. Pre T cells enter the 
thymus and undergo a series of lineage decisions, including TCR type and 
whether to become CD4+ T helper cells or CD8+ Killer Cells. Adapted from 
(Rothenberg et al., 2008) 
1.3.1 T lymphocyte activation 
Naïve T lymphocyte activation requires two separate signals to be 
accomplished. Firstly the TCR interacts with specific MHC/peptide complexes 
presented by APCs. It is largely the CD3 and ζ-chains within the TCR complex 
that are responsible for transducing signals into the cells via immunosuppressor 
tyrosine-based activation motifs (ITAMS) (Kane et al., 2000; Sun et al., 2001). 
These conserved motifs act as tyrosine kinase substrates and once 
phosphorylated, as binding sites for other kinases. In this way, the TCR 
complex is coupled to a wide variety of kinases and adaptor proteins that act to 
initiate signals that induce T lymphocyte activation. CD4, found on the surface 
of the T lymphocyte, is important for stabilising cell-cell interactions so that the 
T lymphocyte can interact with the APC.  Further stabilisation occurs through 
adhesion molecules such as leukocyte function associated antigen-1 (LFA-1) 
which binds intracellular adhesion molecule-1 (ICAM-1) on the APC. 
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Optimal T cell activation requires a second co-stimulatory signal; this ensures 
amplification of the TCR signal and prevents the T lymphocyte from becoming 
anergic. This involves the interaction of the co-stimulatory molecule CD28 
with the B7 family of proteins CD80 (B7.1) and CD86 (B7.2) on the APC.  This 
interaction facilitates IL-2 transcription, CD25 expression, entry into the cell 
cycle and enhanced cell survival.  As with the TCR, CD28 lacks direct 
enzymatic activity and therefore is presumed to signal through protein tyrosine 
kinases, such as Lck and ITK. Furthermore, the phosphorylation of CD28 by 
Lck is essential in the recruitment of the p85 regulatory subunit of PI3K, which 
in turn recruits the catalytic p110 domains (thought to be mainly p110δ 
(Okkenhaug et al., 2002)) leading to PI3K activation.  Further to this is the 
discovery of the CD28 family member ICOS (inducible costimulatory receptor), 
a receptor which, unlike the constitutively present CD28, is upregulated 
following T cell activation and functions to maintain T lymphocyte responses 
(Coyle et al., 2000; Hutloff et al., 1999). 
T cell activation is also negatively regulated, in order to limit the response of the 
T cell. This inhibitory pathway is initiated by the third member of the CD28 
family, cytotoxic T lymphocytes antigen-4 (CTLA-4) which is upregulated upon 
T cell activation (Thompson and Allison, 1997).  Ligation of CTLA-4 
terminates T cell activation, thus avoiding the detrimental overstimulation of the 
system (Sansom and Walker, 2006). 
Once activated, T lymphocytes differentiate into effector cells. CD4+ T 
lymphocytes differentiate into Th1, Th2, Th17 or Treg cells, while CD8+ cells 
differentiate into cytotoxic T lymphocytes. 
1.3.2 Differentiation of CD8+ T lymphocytes 
Cytotoxic T cells act to kill infected cells and thereby help to prevent the spread 
of viral and bacterial pathogens. Cytotoxic T cells recognise antigens bound to 
MHC class 1 molecules presented to them by DCs and all nucleated cells after 
priming.  
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Following initial activation of the CD8+ T cells, the second phase of maturation 
begins. This involves immense proliferation, normally lasting for about 5-8 
days, and can lead to an increase of more than 10,000 fold (Badovinac and 
Harty, 2002). Following proliferation, the now differentiated effector T cells 
are capable of migrating to the site of infection (Weninger et al., 2001).  The 
final phase of the CD8+ lifecycle is the initiation and maintenance of memory 
cells. This has been shown to be consistently 5-10 % of the peak detected CD8+ 
levels within the response (Kaech et al., 2002). 
1.3.3 Differentiation of CD4+ T lymphocytes 
CD4+ T lymphocytes differentiate into a wide variety of T lymphocyte subsets. 
T helper cells play an important role in establishing and maximising the 
capabilities of the immune system. There are three different subtypes of T 
helper cell, known as Th1, Th2 and Th17 depending on the cytokines they 
produce, and the type of immune system they promote. Another type of CD4+ T 
lymphocyte is the regulatory T lymphocyte (Treg), which acts to suppress the 
immune system. 
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Figure 1.2 Overview of CD4+ cell differentiation. Naïve CD4+ T lymphocytes 
are activated by binding through the TCR. The presence of cytokines determines 
the differentiation pathway of the cells, with IL-12 inducing Th1 polarisation, 
IL-4 inducing Th2 polarisation, IL-6 (and TGF-β) inducing Th17 polarisation, 
and TGF-β inducting Treg polarisation. Once polarised, the cells secrete 
multiple cytokines and play a vital role within the immune system. Adapted 
from (Dong, 2008) 
1.3.3.1 Regulatory T lymphocytes 
Regulatory T lymphocytes (Tregs), sometimes referred to as suppressor T 
lymphocytes, have been shown to play a role in the suppression of T cell 
responses and autoimmunity (Sakaguchi, 2000).  Tregs can be divided into two 
categories, known as ‘natural’ Treg cells and ‘induced’ Treg cells (Wraith et al., 
2004). Natural Tregs originate in the thymus from the same precursors as other 
T helper cells and express a transcription factor known as FoxP3 (Fontenot et 
al., 2003). In mice this marker appears to be limited to T cells with regulatory 
function, thus acting as a specific marker. Although in humans FOXP3 is 
expressed more widely than a subpopulation of T cells, studies have shown that 
humans and mice whose FOXP3/Foxp3 gene is defective, succumb to diseases 
with characteristics of autoimmunity (Wildin et al., 2001). These cells can also 
be further divided based on their expression of the IL-2 receptor CD25 
(Nicolson et al., 2006). Induced Tregs are Tregs that can be induced from naïve 
T lymphocytes in the periphery. These can also express FoxP3, although not all 
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do. Indeed, one study identified cells that had potent regulatory actions despite 
being FoxP3- (Vieira et al., 2004). 
Tregs have been shown to be generated in response to the protein TGF-β both in 
vitro and in vivo (Chen et al., 2003a; Peng et al., 2004), which leads to the 
induction of FoxP3. The suppressive activity of Tregs relies on their prior 
activation by the TCR, in a similar fashion to other CD4+ T lymphocytes. Once 
activated, the cells mediate their suppressive function through a variety of 
methods including production of IL-10 (Suri-Payer and Cantor, 2001) and TGF­
β (Nakamura et al., 2001), expression of the inhibitory receptor CTLA-4 (Read 
et al., 2006) or by ‘mopping-up’ IL-2 through expression of the high-affinity IL­
2 receptor CD25. This would prevent effector T cells from proliferating and 
differentiating (Pandiyan et al., 2007). Overall, it seems that Tregs use a variety 
of different mechanisms and pathways in order to suppress the immune system. 
It is likely that these systems vary depending on their circumstances and 
surroundings (Tang and Bluestone, 2008). Interestingly, TGF-β has been shown 
to be required for both Treg polarisation and Th17 cell polarisation, raising the 
possibility that these two cell types are very closely linked, in regulation if not 
function (Wahl, 2007). 
1.3.3.2 Th1 cells 
The presentation of antigens on APC of the innate immune system is required 
for naïve T cells to differentiate into the Th1 lineage (Hunter, 2005; Hibbert et 
al., 2003). The primary driving force behind Th1 differentiation is the cytokine 
IL-12, which is facilitated by the action IFN-α, plus IL-18 (Robinson et al., 
1997) and IL-23 (Oppmann et al., 2000). Activation of the transcription factor 
T-bet has been shown to be a ‘master’ regulator of Th1 cells (Mullen et al., 
2001). A report has also eluded to a T-bet independent pathway, although this 
process has not been not fully elucidated (Way and Wilson, 2004).  Signalling 
through IL-12 potentates IFN-γ production and upregulation of the IL-18 
receptor, giving rise to the mature Th1 effector T cell (Yang et al., 1999). 
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 Th1 cells classically produce IFNγ and TNFα. These are cytokines that 
stimulate the cellular system and lead to the activation of macrophages and NK 
cells as well as inducing NO production. 
1.3.3.3 Th2 cells 
The initiation of Th2 cell differentiation is dependent on antigen presentation by 
APCs, leading to TCR-mediated signalling. In addition, the cytokine IL-4 is 
required to bind its receptor, leading to IL-4 receptor-mediated STAT6 
activation. This in turn causes upregulation of GATA3 transcription, the 
transcription factor that has been shown to be the master regulator of Th2 cells.   
Differentiated Th2 cells produce the cytokines IL-4, IL-5 and IL-13. IL-4 causes 
the activation of B cells, leading to isotype switching the production of 
antibodies, as well as the activation of mast cells, while IL-5 is involved in 
eosinophil differentiation. As such, Th2 cells play a vital role in humoral 
immune system. 
1.3.3.4 Th17 Cells 
Th17 cells are characterised by secretion of the pro-inflammatory cytokines IL­
17, IL-6 and TNFα (Park et al., 2005). Studies using infectious mouse models 
have indicated that Th17 cells are involved in antifungal and antibacterial 
responses (Happel et al., 2003; Ye et al., 2001). In addition, there is 
considerable evidence for the involvement of Th17 cells in the pathogenesis of 
several murine models of autoimmune diseases including Experimental 
Autoimmune Encephalomyelitis (EAE) and collagen-induced arthritis 
(Komiyama et al., 2006; Nakae et al., 2003). 
Th17 cells do not express the Th1 or Th2 lineage-defining transcription factors 
T-bet or GATA3 respectively (Bettelli et al., 2007; Stockinger and Veldhoen, 
2007a). The recent identification of the thymus-specific orphan nuclear RORγt 
as the key transcription factor that specifies the Th17 lineage was the final step 
in establishing this T cell population as a unique and distinct CD4+ T cell 
population (Ivanov et al., 2006). Differentiation of murine Th17 cells from 
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 naïve T cells has been shown to require TGF-β and IL-6 (Veldhoen et al., 2006), 
and is negatively regulated by the Th1 and Th2 cytokines IFN-γ and IL-4, 
respectively (Mangan et al., 2006; Stockinger and Veldhoen, 2007b). However, 
there are important differences in the requirements for differentiation of Th17 
cells in humans and mice. For example, despite the critical function of TGF-β in 
the differentiation of mouse Th17 cells, this cytokine appears dispensable for 
IL-17 production in human cells (Evans et al., 2007). Additonally, IL-1β is a 
very effective inducer of IL-17 expression in activated human CD4+ T cells, but 
only transiently upregulates RORγt. IL-6 is a poor inducer of human Th17 
differentation, but in combination with IL-1β, promotes sustained RORγt 
expression (costa-Rodriguez et al., 2007a). Finally, IL-23 appears to play a role 
in the differentiation of naïve human T cells toward a Th17 phenotype (Chen et 
al., 2007; Wilson et al., 2007), while in the mouse it acts on memory T cells and 
is important in the maintenance of Th17 cells, promoting their responses in vivo 
(Aggarwal et al., 2003). 
1.3.3.4.1 IL-17 
The IL-17 family of cytokines consists of six cytokines termed IL-17A, IL-17B, 
IL-17C, IL-17D, IL-17E (IL-25), and IL-17F. Most study has been performed 
on IL-17A and IL-17F, and these two family members are the most closely 
related (Kolls and Linden, 2004). Multiple cell types including CD4+ αβ T cells, 
γδ T cells, NK cells, and neutrophils have been shown to produce IL-17A and 
IL-17F (Roark et al., 2008b). Studies on IL-17 have shown that it induces the 
mobilisation, recruitment and activation of neutrophils and triggers the 
production of pro-inflammatory cytokines and chemokines by a broad range of 
cellular targets including epithelial cells, endothelial cells and macrophages 
(Weaver et al., 2007). 
1.3.3.5 Reciprocal inhibition 
The specific circumstances that surround the generation of Th1, Th2 or Th17 
cells, means that not only do cells of that lineage have the ability to stimulate 
further growth and proliferation, but this is reinforced by cross regulation of the 
opposing sub group (Romagnani, 2006).  In this regard, generation of a typical 
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 Th1 cytokine such as IFN-γ, or IL-12 inhibits the production of Th2 cells and 
the corresponding humoral responses (Kips et al., 1996; Lack et al., 1996; 
Manetti et al., 1993; Parronchi et al., 1992).  Conversely, the production of Th2 
cytokines such as IL-4 inhibits Th1 development and activation (Skapenko et 
al., 2004; Ghoreschi et al., 2003); this model also extends to Th17 cells. Both 
IL-4 and IFNγ have been shown to negatively regulate the polarisation of Th17 
cells. Interestingly, IL-2, important for the proliferation of other T lymphocyte 
subsets, has also been shown to inhibit Th17 cell polarisation. (Laurence et al., 
2007) 
1.4 Cell migration 
In order for the immune system to function efficiently, white blood cells or 
leukocytes need to be able to circulate not just through the blood and lymphatic 
system but also move into and through tissue. This allows any tissue based 
infections to be detected and fought. To induce cells to leave the blood and enter 
tissue or to move towards sites of infection, several cell types such as 
endothelial cells, fibroblasts and leukocytes can produce proteins called 
chemokines in response to stimuli such as bacteria, pro-inflammatory cytokines 
and viruses. The members of the chemokine family of chemoattractants 
determine leukocyte localisation and consequently control their multiple 
functions in innate and acquired immunity.  Chemokines can regulate leukocyte 
entry into the circulation, emigration from blood, positioning in local tissue 
microenvironments and departure from the tissues. Besides influencing cellular 
movement and positioning, chemokines can rapidly induce alterations in 
leukocyte adhesive properties (by modulating integrins), regulate proliferation 
and differentiation, apoptosis, cytokine release and degranulation. 
1.4.1 Migration - The Physiological Role of Chemokines 
In order for the immune system to function efficiently, white blood cells or 
leukocytes need to be able to circulate not just through the blood and lymphatic 
system but also move into and through tissue (Goldsby et al., 2000). For 
example, during immunosurveillance T cells traffic into regional lymphoid 
organs such as lymph nodes and the gut-associated Peyer’s patch.  In addition, 
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as part of the immune response, cells are required to migrate from the blood and 
into the infected tissue. The process by which cells pass from the blood into a 
selected region is known as extravasation, and is an essential component of 
immunosurveillance and the immune response.  Briefly, interactions mediated 
by surface adhesion molecules cause leukocytes to tether to and then roll along 
the endothelium. Chemoattractants, such as chemokines presented on the 
endothelial cell surfaces by glycosaminoglycan’s (GAGs), trigger increases in 
integrin affinity and avidity thereby inducing firmer adhesion of the leukocytes 
to the endothelial cells. The leukocytes can then transmigrate through the 
vascular wall into the extravascular tissue where they are then further guided by 
chemokines and other chemoattractants into specific tissue environments.  
1.4.2 Types of Migration 
Cells of the immune system are capable of migration in several defined ways. 
The term chemotaxis refers to directed migration of a cell towards a soluble 
chemotactic source, i.e. up the chemokine gradient. Chemofugetaxis describes 
the active movement of a cell away from a chemokine source, this phenomenon 
was first described following the observation that high (but not low) 
concentrations of CXCL12 could induce chemofugetaxis in a sub-population of 
T cells and is thought to contribute to thymic emigration (Poznansky et al., 
2000). 
In vivo, chemokines exist not only as soluble peptides, but can also be surface 
bound. Haptotaxis describes the directional movement of a cell towards a 
chemotactic gradient but on an immobilised substrate, while haptorepulsion 
describes migration away from bound chemokine.   
Finally, some cells migrate in the absence of chemokine and therefore a 
chemokine gradient. This is known as chemokinesis, where cells may 
spontaneously generate cytoplasmic projections and retractions and display 
migratory properties, yet this movement of the cell is without any directionality. 
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1.5 The processes involved in directed cell migration  
Migration of any cell is made up several distinct processes. Firstly, the cells 
must sense the chemoattractant gradient and undergo polarisation, causing 
extension of protrusions or pseudopodia in the direction of migration. These 
pseudopodia then bind to the substratum, for instance the extracellular matrix, 
stabilising the cell. The cell then moves forward by contracting the cell body 
and releasing attachment sites at the rear. 
1.5.1 Extension of pseudopodia 
During random migration or chemokinesis, cytoplasm projections extend and 
contract over the surface of the cell.  Following chemoattractant binding, the 
formation of projections or pseudopodia are focused towards the front or 
leading edge of the cell due to the accumulation of signalling molecules such as 
PtdIns(3,4,5)P3. This transition and re-arrangement of intracellular signalling 
molecules is an essential element in the initiation of chemotaxis.   
1.5.2 Polarisation 
An early event within leukocyte migration is the polarisation of the cell, this 
involves the production of a ‘front’ or leading edge and ‘rear edge’ or uropod in 
leukocytes (del Pozo et al., 1995). Polarisation can also be referred to in terms 
of the positioning of the nucleus and reorientation of the microtubule-organizing 
centre and Golgi apparatus towards the leading edge. Within directional sensing, 
it is important that once a cell detects a shallow chemoatttractant gradient, this is 
amplified within the cell.  Once a chemoattractant gradient has been established, 
(for as little as 2 % between the anterior and posterior of the cell), 
reorganisation of the internal environment is triggered.  This reorganisation 
includes a change in the distribution of  F-actin from throughout the cell to a 
concentration within the leading edge of the cell, resulting in the polarised shape 
(Parent and Devreotes, 1999; Howard and Oresajo, 1985; Coates et al., 1992; 
Chung et al., 2001b). Leukocytes do possess some intrinsic cell polarity in 
which there is differential subcellular localisation of F-actin and assembled 
myosin II, this allows rapid responses to chemoattractant gradients (Chung et 
al., 2001a). 
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One of the first polarised responses in many leukocytes is the accumulation of 
PtdIns(3,4,5)P3 (PIP3) at the leading edge of the cell. This is caused by the 
activation of PI3K at the leading edge, and subsequent signalling through Rho 
GTPase that results in further accumulation of PIP3 at the leading edge and 
activation of PTEN at the sides and back of the cell. This results in the 
degradation of PIP3. The accumulation of PIP3 results in the recruitment of PH-
domain containing proteins at the leading edge of the cell.  
1.5.3 Protusion and adhesion formation 
Several different types of pseudopods exist. Lamellipodia are large, broad 
protusions that act as the motor which pulls the cell forward during cell 
migration. Filopodia however, are spike-like protusions which may instead act 
as sensors with which to explore the extracellular environment.  
These protusions are the result of actin polymerisation. Actin polymerisation 
within motile cells is of fundamental importance and is continually being 
polymerised and depolymerised within the cell, allowing for a dynamic 
environment.  Actin’s functional unit is known as globular actin or G-actin, and 
it is the polymerisation of these intrinsically polarised units (by the action of 
ATP), that once bound together generate filamentous actin (F-actin).  The 
building of new F-actin is performed by the polymerisation at one end of the 
filament, known as the ‘barbed end’ while depolymerisation occurs at the 
opposing or pointed end (Fig. 1.3). During migration the generation of a new 
filament is focussed at the leading edge of the cell and pushes the plasma 
membrane forward, resulting in a protrusion of the cell.  The continued growth 
of F-actin continues until halted by the binding of a capping protein on the 
barbed end of the filament.  This capping procedure acts to either maintain or 
stabilize the filament or promote depolymerisation.  These capping proteins can 
be located on the pointed end, where they inhibit the dephosphoylation of the 
filament, or at the barbed end, ensuring that no further G-actin monomers are 
added. In a process termed as treadmilling, the phosphorylation and 
dephosphorylation rate are comparatively equal, thus ensuring the maintenance 
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of the current filament length (Vicente-Manzanares et al., 2005; Revenu et al., 
2004a). 
Barbed End Pointed End 
Depolymerisation Polymerisation 
Severing Protein Depolymerising Protein 
Capping ProteinBundling Protein 
Figure 1.3 Actin filaments: structure and dynamics. Actin monomers known 
as G-actin bind ATP and assemble much more rapidly at the 'barbed end' 
compared to the 'pointed end'.  During treadmilling, the polymerisation rate and 
depolymeriztion rate are equal thus filament length is maintained at a constant. 
Several proteins are known to bind to actin; capping proteins may bind to the 
barbed end preventing addition of further momomers, while some as 
demonstrated are known as crosslinking proteins, allowing several filaments to 
bind together. Adapted from (Revenu et al., 2004b) 
Several other steps are also involved in migration. The leading edge must 
adhere to the underlying substratum; otherwise they will retreat back into the 
cell. Adherence is mediated by integrin family receptors. These are 
heterodimeric receptors composed of non-covalently associated α and β 
subunits, including α4 integrins such as α4β1 (VLA-4) and β2 integrins such as 
αLβ2. Chemoattractants signal to activate or functionally upregulate integrins 
from their normal low affinity state. Once activated, they preferentially localise 
to the leading edge of the cell where they await binding by ligands. Once bound 
to their ligands, they undergo conformational change and clustering, resulting in 
intracellular signalling and regulation of focal adhesion site formation.  
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1.5.4 Release of adhesion 
In order to maintain motility, cells must release the adhesions at the back of the 
cell and retract the uropod, which is dependent on the motor activity of myosin 
II. In myosin II null cells retraction of the uropod is defective thus resulting in 
ineffective chemotaxis (Clow and McNally, 1999).   
1.6 Chemokines and Chemokine Receptors 
1.6.1 Nomenclature and Structural characteristics of 
Chemokines 
Chemokines are highly conserved 8-10 kDa proteins characterized by a 4 cysteine 
motif. The majority of the known chemokines (around 43 in humans) reside 
within two major classes, the CXC chemokines (in which the two amino 
terminal cysteine residues are separated by a single amino acid residue) and the 
CC chemokines (in which two amino terminal cysteine residues are adjacent). 
There are also two other minor classes, the CX3C (three conserved amino acids 
separate the cysteines) and C (containing one cysteine) chemokine families. 
Chemokines can also be divided based upon their function. Some chemokines, 
such as CXCL12, are mainly homeostatic, meaning they are present at all times 
and have responsibility for directing leukocytes during immunosurveillance. 
Others, such as CCL5 which recruits neutrophils, are inflammatory. These are 
upregulated during infection or cell damage and are important for innate and 
adaptive immunity. However, the division of chemokines into these two camps 
is not categorical, with some chemokines falling into both camps. All 
chemokines exert their effects through chemokine receptors, part of the G-
protein coupled receptor (GPCR) family. 
1.6.2 G-protein coupled receptors 
G-protein coupled receptors, or GPCRs, comprise a large family of 
transmembrane receptors that function to convert extracellular signals into 
intracellular signals. In addition to chemokines, GPCR’s can bind a wide range 
of ligands including neurotransmitters and hormones. These cell surface 
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receptors couple to intracellular heterotrimeric G-proteins which regulate 
downstream effectors such as adenylyl cyclase, phospholipases, protein kinases 
and ion channels (Armbruster and Roth, 2005).  GPCRs are integral membrane 
proteins that possess seven membrane-spanning domains or transmembrane 
helices resulting in three intracellular loops. The extracellular parts of the 
receptor can be glycosylated and contain two highly-conserved cysteine 
residues that form disulfide bonds to stabilize the receptor structure. (Allen et 
al., 2007). 
To allow the transmission of a signal, the receptor must go through several 
processes. First, it must bind the ligand. This binding then initiates a 
conformational change within the receptor, activating it. Finally, this 
conformational change results in the activation or inhibition of secondary 
messengers within the cell.  
The linking of the activated receptor to the second messenger signalling cascade 
is provided by a heterotrimeric guanine nucleotide binding protein (G-protein) 
on the inner leaflet of the cell membrane  (Neer, 1995).  These G- proteins 
function as molecular switches within the cell and are comprised of an α, β, and 
γ subunit. In the resting state, the G-protein is inactive, not associated with the 
receptor and has a molecule of GDP bound to the α subunit. When the receptor 
binds its ligand, a conformational change in the receptor allows it to now bind 
the G-protein, which causes the displacement of the GDP molecule, replacing it 
with a GTP molecule. This exchange leads to the removal of the hydrophobic 
pocket to which G-βγ binds, thus reducing the affinity of Gα-GTP and G-βγ and 
resulting in the dissociation of the Gα-GTP from the Gβγ complex (Lambright 
et al., 1994). 
The free G-βγ subunits are now available to activate or inhibit downstream 
signalling molecules.  Termination of these effects, which occurs rapidly within 
the cell, is a result of GTP being hydrolysed back to GDP through the innate 
GTPase activity of the α subunit allowing reassociation of the α, βγ complex 
(Hamm, 1998; Sprang, 1997). 
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1.6.3 G-α and G-βγ interaction with effectors 
Activation of specific downstream effectors is achieved through the variability 
of G-proteins.  G-proteins are divided into four families based on the similarity 
of their α subunits; Gs, Gi/o, Gq, G12/13. Historically, it was assumed that it was 
only the G-α subunit that triggered intracellular signalling through well defined 
pathways such as adenylate cyclase and phospholipase C.  However, it is now 
clearly established that the G-βγ complex, couples to and triggers the activation 
of signalling cascades such as PLCβ2 and β3 (Katz et al., 1992), ACs (Tang and 
Gilman, 1991), β-adrenergic receptor kinase, PI3K (Stephens et al., 1994; Tang 
and Downes, 1997), components of the MAPK cascade (Inglese et al., 1995), 
and K+ and Ca2+ channels (Cabrera-Vera et al., 2003) .  
Class IB is the only class of PI3K shown to be activated by the dissociated G-βγ 
subunits, with the regulatory subunit p101 sensitising the catalytic subunit to G­
βγ (Stephens et al., 1997). It is further proposed that p110γ is activated via 
interaction with GTP-bound Ras which, via allosteric mechanism or altered 
orientation of p110γ in respect to its substrate, further increases its activity 
(Suire et al., 2002). Activation of class IA isoforms is thought to be via the Gαi 
activation of Src family kinases, (Ma et al., 2000).  However, although it has 
been shown that class II isoforms lie downstream of chemokine receptors their 
activation mechanism has yet to be fully elucidated (Curnock et al., 2002).  
1.6.4 Regulation of GPCR signalling 
The availability of GPCRs on the cell surface is a tightly controlled process. 
The initial step is the synthesis of the receptor in the endoplasmic reticulum, in 
which the GPCR is then packaged for transport to the surface. The mature 
glycosylated receptor can now interact with its specific ligand.  One notable 
aspect of GPCR signalling is the sensitivity of the cell following stimulation of 
the GPCR via its ligands.  This sensitivity or negative regulation is often termed 
desensitisation. 
Desensitisation of the receptor can occur rapidly after exposure to stimuli, 
reducing the responsiveness of the receptor to further stimulation.  It occurs due 
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to the action of G protein-coupled receptor kinases (GRKs) which 
phosphorylate the receptor following agonist induced conformational changes, 
this facilitates the binding of the inhibitory β-arrestin proteins that uncouple the 
receptor from the G-proteins (Vroon et al., 2006; Pao and Benovic, 2002). 
Uncoupling can also occur via second messenger dependent kinases e.g. protein 
kinase A and C. In contrast to GRK mediated uncoupling, this method has the 
capacity to desensitise any receptor in the presence or absence of ligand 
binding; it is often referred to as heterologous desensitisation and mediates a 
generalised cellular hyporesponsiveness (Kristiansen, 2004b).  The extent of 
receptor desensitisation can vary depending on the cellular system, from 
attenuation to complete termination of the signal (Ferguson, 2001b; Aramori et 
al., 1997). 
Internalisation or sequestration of GPCRs is another mechanism in which 
signalling and function through GPCRs is controlled.  In comparison to 
desensitisation this process takes longer, occurring over several minutes 
(Luttrell and Lefkowitz, 2002), however it can be dependent on β-arrestins. 
Following chemokine exposure the CCR5, CXCR1 and CXCR4 receptors have 
all been identified to undergo sequestration via β-arrestins, this may also be 
coupled to associated proteins such as clathrin which promotes the sequestration 
process (Ferguson, 2001a; Cheng et al., 2000; Kristiansen, 2004a).   
Once the GPCR has been sequestered it undergoes one of two mechanisms; 
receptor recycling or degradation.  For recycling back to the plasma membrane, 
the receptor undergoes dephosphorylation and removal of β-arrestin which 
resensitises the receptor to the ligand.  The time course for this process is 
dependent on the ligand/receptor interaction; however the kinetics behind this 
process can be adjusted with the use of modified chemokines.  This technique 
has been demonstrated to increase the time the receptor is sequestered within the 
cell before recycling (Pastore et al., 2003).  The alternative is degradation of the 
receptor via the lysosomal degradation pathway, this has been highlighted as a 
process for β2-adrenergic and CXCR4 receptor degradation (Wojcikiewicz, 
2004). 
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 1.6.5 Chemokine Receptors 
The action of chemokines on their receptors can elicit a plethora of cellular 
responses. In order to fully appreciate the importance of specific ligand / 
receptor interactions we must decipher which response can be assigned to each 
interaction. This goal is made all the more challenging by the promiscuous 
nature of chemokines, as it has been shown that individual chemokines may 
activate several receptors and each receptor may be activated by a number of 
different chemokines, indicating redundancy and versatility within the system 
(Ward and Westwick, 1998).   
1.6.6 Chemokine receptor expression 
Although cells can be categorised by the CD4 or CD8 receptor and the cytokine 
expression profile, these cells may also be characterised by the chemokine 
receptors that are present on the cell surface.   
The expression profile of receptors on T lymphocytes is indicative of 
functionally distinct T lymphocytes subsets.  Naïve T lymphocytes have a 
limited number of receptors expressed on the cell surface; the most notable are 
the CXCR4 and CCR7 chemokine receptors.  Recirculation of this naïve 
population is observed between the blood and lymph nodes, which is aided by 
the expression of CCR7 and L-selectin (Sallusto et al., 1999).    
Following activation and differentiation of the T cell, the number of receptors 
on the cell surface are upregulated, this allows migration towards an increased 
number of chemokines.  Yet the chemokine receptors that are upregulated are 
specific for the T cell subgroup.  For example, the CXCR3 chemokine receptor 
has been shown to be expressed at much higher levels on Th1 lineage than Th2 
(Sallusto et al., 1998b; Bonecchi et al., 1998b).  Two of the ligands for CXCR3, 
CXCL9 and CXCL10 have been shown to be IFN-γ inducible and as Th1 cells 
produce IFN-γ this correlates well with the observed CXCR3 expression 
(Loetscher et al., 1996). CCR1 has been shown to be expressed on Th1 while 
CCL11 and CCR3 are preferentially expressed on Th2.  There are conflicting 
reported about the expression profile of CCR5 on T cells, in some cases 
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expression was found on both Th1 and Th2 and in others higher in Th1 
(Sallusto et al., 1998a; Bonecchi et al., 1998a).  Interestingly this discrepancy 
may be explained by the activation state of the cell, as well as culture 
conditions, with CD3/CD28 down regulating CCR5, whereas culture with IL-2 
increases expression. It is important to note that these receptor profiles are not 
definitive, expression of CCR3 on Th1 and CCR5 on Th2 have been recorded.  
1.7 The Role of Phosphoinositide 3-kinase(s) in T Lymphocyte 
Migration. 
The co-ordinated and directional trafficking of T lymphocytes in lymphoid and 
peripheral tissues is a key process in immunosurveillance and immune 
responses. This involves a multi-step adhesion cascade of selectin- or integrin- 
(and their corresponding vascular ligands) supported rolling, chemokine­
mediated integrin activation and firm integrin-mediated adhesion to the 
microvasculature endothelium followed by transmigration through the vessel 
wall and further migration in extravascular tissue.  For a cell to migrate to a 
chemoattractant source it must be polarised which means that the molecular 
processes at the front (leading edge) and the back (uropod) of a moving cell are 
different. Establishing and maintaining cell polarity in response to extracellular 
stimuli appear to be mediated by a set of interlinked positive-feedback loops 
involving phosphoinositide 3-kinase (PI3Ks), Rho family GTPases, integrins, 
microtubules and vesicular transport. The relative contributions of these various 
signals depends on the cell type and the specific stimulus. These intracellular 
signals result in reorganisation of the cytoskeleton and cell adhesion causing the 
cells to send out pseudopodia and crawl up the chemoattractant gradient.  PI3K­
dependent signalling events have previously been demonstrated in several cell 
systems to contribute to several aspects of the migratory machinery including 
gradient sensing, signal amplification, actin reorganisation and hence cell 
motility. 
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1.8 The PI3K Family 
1.8.1 Phosphoinoitide 3-kinase  
Phosphoinoitide 3-kinase (PI3K) mediates the formation of D-3 
phosphoinositide lipids by transferring the terminal phosphate of ATP to the D­
3 position of the inositol head group of phosphoinositide lipids (Fig. 1.4).  
ATP 
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PI3K 
2' 
1' 
4' 
6' 
O O
O O 
1 32 
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OHOH 
OH 
OH 
5' 
3' 
Figure 1.4 Transfer of terminal phosphate of ATP to D-3 position of the 
inositol head group of phosphoinositide lipids. Adapted from 
(Vanhaesebroeck and Alessi, 2000) 
PI3K can thus potentially produce three products: phosphatidylinositol (3)­
phosphate [PtdIns(3)P], phosphatidylinositol (3,4)-bisphosphate [PtdIns(3,4)P2] 
and phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] (Fig. 1.5) 
(DuBois et al., 1998; Vanhaesebroeck and Waterfield, 1999).  
PtdIns PtdIns(4)P PtdIns(4,5)P2 
Phosphoinositide 3-kinase 
PtdIns(3)P PtdIns(3,4)P2 PtdIns(3,4,5)P3 
Figure 1.5 Formation of phosphoinositide lipids by PI3K. 
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 PI(3)P is constitutively present in eukaryotic cells and its levels are largely 
unaltered upon cellular stimulation. In contrast, PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 are generally absent from resting cells, but their intracellular 
concentration rises markedly upon stimulation via a variety of receptors 
suggesting a second messenger function. There are multiple isoforms of PI3K 
(Fig. 1.6) in mammalian cells and these are subdivided into three classes on the 
basis of the in vitro lipid substrate specificity, structure and likely mode of 
regulation (Koyasu, 2003a). 
Class 1A Regulatory Subunits 
SH2SH2 p110 bindingRhoGap Homol.SH3 
SH2 p110 binding 
SH2 p110 binding 
SH2 p110 binding 
SH2 
SH2 
SH2 
SH2SH2 p110 bindingRhoGap Homol.SH3 
p85α 
p55α 
p85β 
p55β 
p50α 
Class 1A Catalytic Subunits 
Class 1B Regulatory Subunits 
p85 Binding Ras Binding C2 Kinase 
p110α 
p110β 
p110δ 
p84 
p101 
Class 1B Regulatory Subunits 
Ras Binding C2 Kinase p110γ 
Figure 1.6 Structural characteristics of the PI3K family. Adapted from 
(Koyasu, 2003b) 
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1.8.1.1 Class I 
The Class I PI3K phosphorylate PtdIns, PtdIns(4)P and PtdIns(4,5)P2, resulting 
in the formation of PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 in vitro, 
whereas PtdIns(4,5)P2 is the main substrate in vivo. They also interact with Ras 
and form heterodimeric complexes with adaptor proteins that link them to 
different upstream signalling events.  The prototypical class IA PI3K is a 
heterodimer consisting of the 85kDa regulatory subunit (responsible for protein-
protein interactions either via protein tyrosine phosphate-binding SH2 domains 
or SH3 domains and/or proline-rich regions) and a catalytic 110kDa subunit. 
Mammals have three genes for the class IA p110 subunits, which encode 
p110α, p110β and p110δ. The existence of multiple isoforms of both 
components, which do not appear to preferentially associate, means that there is 
considerable scope for specific variation between tissues and with association to 
different receptor tyrosine kinases. The class IB PI3K is stimulated by G protein 
βγ subunits and does not interact with the SH2-containing adaptors that bind 
class IA PI3K. Instead, the first identified member of this family, p110γ, 
associates with a unique p101 adaptor molecule. 
1.8.1.2 Class II and Class III 
Class II PI3Ks are large proteins that have a catalytic domain that is 45-50% 
homologous to Class I PI3K. Class II PI3K also have a C-terminal region that 
has homology to the C2 domains that mediate calcium/lipid binding in classical 
protein kinase C isoforms (Cantrell, 2001). Class II PI3K preferentially 
phosphorylate PtdIns and PtdIns(4)P in vitro, whereas the Class III PI3K utilise 
only PI as a substrate. The mammalian homologue of Class III PI3K is likely to 
be the main source of PtdIns(3)P.   
1.8.2 Phosphatases 
The PI3K family mediate various biological effects through the action of the D­
3 phosphorylated phosphoinositide second messengers. The levels of the second 
messenger are regulated by PTEN (phosphatase and tensin homolog) and SHIP 
(Src-homology-2 containing inositide 5’-phosphatase) that can specifically 
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hydrolyse the D-3 and D-5 phosphate groups respectively from the lipid 
products and thus control the level of PtdIns(3,4)P2 and PtdIns(3,4,5)P3. 
1.8.3 Downstream targets and functions 
A number of proteins have been identified that directly bind PtdIns(3,4,5)P3 
and/or PtdIns(3,4)P2 via pleckstrin homology (PH) domains, which are lipid 
binding domains, including protein kinase B (PKB/Akt), PtdIns(3,4,5)P3­
dependent protein kinase-1 (PDK-1), Bruton’s tyrosine kinase, various PLC 
isoforms and exchange factors for the ADP-ribosylation factor family of GTP-
binding proteins.  Moreover, the D-3 phosphoinositide lipids have been linked 
to the triggering of a diverse array of cellular responses including cell survival, 
mitogenesis, membrane trafficking, glucose transport, neurite outgrowth, 
membrane ruffling, superoxide production as well as actin polymerisation and 
chemotaxis.  
1.9 Class I PI3Ks and T lymphocyte Migration. 
Most of what we understand about biochemical events in T cells moving toward 
a chemoattractant gradient has been derived from study of chemokine signal 
transduction.  Chemokines mediate at least two chemokine-mediated processes, 
namely chemokine-mediated integrin activation to mediate cell adhesion and 
chemokine-induced chemotaxis (that is likely to be integrin independent). PI3K 
activation seems to be a signalling event shared by most chemokine receptors 
expressed on T cells. Signalling via CXCR4 has been studied in most detail and 
SDF-1/CXCL12 triggers a transient PTX-sensitive accumulation of PI(3,4,5)P3 
in the Jurkat leukemic cell line.  Similar lipid accumulation in murine and 
human T lymphocytes stimulated with ELC/CCL19 and SLC/CCL21 has also 
been reported. The use of PI3K inhibitors has also revealed that in vitro 
chemotaxis across synthetic membranes of PBLs and NK cells in response to 
CXCL12 and several other chemokines such as RANTES/CCL5, can be 
severely attenuated by PI3K inhibitors. During migration and chemotaxis, there 
are at least two chemokine-mediated processes operating, namely chemokine­
mediated integrin activation to mediate cell adhesion and chemokine-induced 
chemotaxis (that is likely to be integrin independent). There is some evidence 
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that enhanced integrin mobility in chemokine-stimulated lymphocytes is 
dependent on PI3K activation. Generally however, rapid integrin activation on 
rolling lymphocytes does not depend on PI3K activation processes.  
Chemokine interaction with GPCRs on lymphocytes has been shown to depend 
predominantly on Gi proteins.  This has led to the assumption that these 
receptors are coupled to the βγ-dependent p110γ isoform. Indeed, this does 
appear to be the case, although several chemokine receptors can additionally 
activate other PI3K isoforms. Significant progress has been made in resolving 
the confusion concerning the specific role of PI3K in lymphocyte migration. 
This has been made possible by availability of mice deficient in the p110γ 
catalytic isoform as well as analysis of mice expressing a mutant, catalytically 
inactive class 1A p110δ isoform.  The in vitro migration of p110γ-deficient 
CD4+ and CD8+ T cells to CCL19 and CXCL12 and CCL21 is significantly 
decreased compared to cells from wild type mice.  In contrast, T cell responses 
were largely unaffected by p110δ deficiency. Hence, in settings where T cell 
migration required PI3K activation, the p110γ isoform appears to be the 
predominant isoform required.  This correlates with observations that p110γ 
selective inhibitors reduce numbers of CD4+ memory T cells in models of 
systemic lupus. Interestingly, B cell migration to chemokines was not 
significantly affected by p110γ deficiency, thus implicating involvement of 
other PI3K isoforms or signalling pathways in B cell migration. In this regard, 
analysis of p110δ deficient B cells showed a defect in B cell chemotaxis to 
CXCL13, whilst responses to CCR7 and CXCR4 ligands were less affected. 
Adoptive transfer experiments with B cells expressing inactive p110δ revealed 
diminished CXCR5-mediated homing to Peyer’s patches and splenic white pulp 
cords. The ability of p110δ to function downstream of chemokines receptors in 
lymphocyte chemotactic responses is consistent with the finding that a broad 
spectrum loss-of-function mutant that disrupts all class 1A catalytic isoforms, 
reduced chemotactic responses of leukemic T cells to CXCL12. Together, these 
data indicate that individual lymphoid chemokine receptors have differing 
dependence on PI3K-dependent signals for achieving ordered migration.  
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1.10 Downstream Effectors of PI3K 
The production of PIP2 and PIP3 by PI3K leads to the activation of several 
different signalling pathways and proteins. A number of these proteins can trace 
their activation back to a master kinase called protein dependent kinase 1 or 
PDK-1. Activation of this protein can lead to phosphorylation of many other 
proteins including Akt, Glycogen synthase kinase-3 and Protein Kinase Cδ. 
1.10.1 PDK-1 
PDK-1 is a 63 kDa Ser / Thr kinase ubiquitously expressed in human tissue. It is 
recruited to the membrane by its PH domain which binds PI(3,4,5)P3 and 
PI(3,4)P2, where it has been shown to phosphorylate many protein kinases 
including Akt and protein kinase C (PKC) (Toker and Newton, 2000b). Its 
regulation is still unclear, and was originally thought to be constitutively active 
however recent evidence suggests its activity to be dependent on substrate 
conformation and subcellular location, providing a good mechanism for 
discriminating between one subset of targets over another (Collins et al., 2005). 
As PDK-1 controls the activation of a large number of proteins (Fig. 1.7), it is 
known as a master kinase, crucial for the functioning of large numbers of 
cellular pathways (Lawlor et al., 2002).  For a long time after its discovery, it 
was thought that the ability of PDK-1 to phosphorylate its substrates was 
dependent on PI3K and the production of phospholipids. However, there is now 
some evidence that PDK-1 can function independently of PI3K with some 
substrates, notably PKC (Sonnenburg et al., 2001). 
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Figure 1.7 Schematic showing Protein Kinase Substrates of PDK-1. 
Structures in yellow represent the activating mechanisms which induce a 
conformational switch in the substrate allowing subsequent PDK-1 
phosphorylation of the activation loop. Examples of this switch include: 
phosphorylation of p70S6-K and p90RSK by MAPK (and possibly other 
pathways comprising TOR [target of rapamycin] and PKC); binding of the 
small GTPase Rho to PRK; PtdIns-3,4,5-P3 binding to the PH domain of 
Akt/PKB; and Ca2+ and DAG binding of newly synthesised PKC. (adapted from 
Toker and Newton, 2000) 
1.10.2 Akt/PKB 
Akt (also known as protein kinase B or PKB (Burgering and Coffer, 1995)) is a 
serine threonine kinase that is recruited to the membrane by its PH domain 
which binds PI(3,4,5)P3 and PI(3,4)P2. At the membrane it is phosphorylated 
and activated by the protein kinase: protein dependent kinase-1 (PDK-1) which 
is also recruited to the membrane by its PH domain. Phosphorylation of Akt 
occurs at two sites - Thr308 and Ser473 in the kinase activation loop, and 
hydrophobic region of the C-terminal regulatory domain (Toker and Newton, 
2000b). PDK-1 is known to be responsible for the phosphorylation of Thr308 
but the kinase responsible for the Ser473 phosphorylation remains elusive, 
although evidence now points to the mTor-RICTOR complex (Hresko and 
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Mueckler, 2005). Akt activity can be modulated by phosphatases such as PTEN 
and SHIP which reduce the levels of PI(3,4,5)P3 and PI(3,4)P2 preventing Akt 
from localising to the membrane (Stambolic et al., 1998). Akt has been shown 
to play a role in various signalling pathways including cell growth, nutrient 
metabolism, proliferation and survival. In the mould Dictyostelium and in some 
mammalian cells an essential role in chemotaxis has also been demonstrated 
(Meili et al., 1999). 
1.10.3 Glycogen Synthase Kinase-3 
Glycogen synthase kinase-3 or GSK-3 is a serine / threonine kinase that was 
first isolated as the enzyme responsible for insulin stimulated glycogen synthase 
inactivation (Doble and Woodgett, 2003). However, a much broader role for 
GSK-3 has recently been discovered, with effects on cell morphology, 
transcription factor regulation, protein synthesis and Wnt signalling (Ferkey and 
Kimelman, 2000). There are two closely related isoforms of GSK-3, named 
GSK-3α and GSK-3β and both are ubiquitously expressed, although can have 
differing roles within the cell.  
GKS-3 is rare among protein kinases in that it is constitutively active and is 
inactivated by phosphorylation in response to signals (Fig. 1.8). 
Phosphorylation occurs at Ser21 in GSK-3α and Ser9 in GSK-3β and is 
catalysed by Akt in response to PI3K activation, mitogen activated protein 
kinase-activated protein kinase 1 (MAPKAP-K1 or RSK) in response to growth 
factor stimulation, or by p70 s6 kinase-1 (Ohteki et al., 2000). Phosphorylation 
creates a primed pseudo-substrate that binds intramolecularly to the kinase 
pocket, blocking it and preventing phosphorylation of other substrates. This 
method of inactivation also gives insight into the required state of substrates 
before they can be phosphorylated. GSK-3, unlike many other kinases, has a 
preference for primed, pre-phosphorylated substrates (Doble and Woodgett, 
2003). This pre-phosphorylation is not required but greatly increases the 
efficiency of phosphorylation and is thought to work by binding a pocket within 
GSK-3, optimising the orientation of the kinase domains and placing the 
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substrate at the correct position within the catalytic groove for phosphorylation 
to occur. 
Another method of GSK-3 inactivation is via the Wnt pathway. The Wnts are a 
family of secreted protein ligands that can influence cell growth, differentiation, 
migration and fate, with at least 19 Wnts in mammals (Prunier et al., 2004). One 
of the pathways regulated by Wnt molecules is known as the Wnt/β catenin 
pathway and results in gene activation (Akiyama, 2000). In unstimulated cells 
GSK-3 is associated with axin, is active and can phosphorylate β catenin, 
targeting it for ubiquitination and degradation in the proteosome. When Wnt 
binds to its receptor on the cell surface it causes phosphorylation of a protein 
called dishevelled, releasing the protein FRAT. FRAT can then bind GSK-3, 
dissassociating it from axin, and effectively inactivating it. The Wnt pathway 
appears to be insulated from PI3K dependent GSK-3 inactivation although how 
this insulation occurs is not yet clear (Dominguez and Green, 2001). 
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Figure 1.8: Cellular pathways for inactivating GSK-3. GSK-3 inactivation 
can result from Wnt activation (left panel) leading to the ubiquitination of β­
catenin or Akt activation (right panel) resulting in the inactivation of several 
downstream pathways. 
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1.10.4 Protein Kinase C Delta 
Protein Kinase C Delta or PKCδ is a member of the protein kinase C family of 
serine threonine kinases. The PKC family can be divided into three subgroups 
called conventional, novel and atypical and are divided based on their structure 
and function. Conventional isoforms are sensitive to DAG and are Ca2+ 
responsive through their C2 domain. Novel isoforms, such as PKCδ, are DAG 
sensitive but not Ca2+ responsive as their C2 domains lack the coordinating 
residues; instead they form a phosphotyrosine binding domain. Atypical 
isoforms are both DAG and Ca2+ insensitive and instead are regulated through a 
PB1 domain which can bind proteins containing a PC motif (Poole et al., 2004).  
PKCδ is targeted to the membrane and activated through binding DAG through 
its C1 domain. In addition to this, phosphorylation at several sites including 
Tyr525 and Thr505 are thought to be important in activation and enzyme 
stability. It has been reported that phosphorylation of Thr505, which occurs via 
the master kinase PDK-1, is not a prerequisite for enzyme activity as previously 
thought (Stempka et al., 1997), but can contribute to enzyme stability and so 
increasing levels of phosphorylation of the downstream targets. Phosphorylation 
of Thr505 by PDK-1 is thought to occur independently of PI3K in some cases, 
giving PKCδ a PI3K independent role (Sonnenburg et al., 2001). PKCδ is 
ubiquitously expressed and has been implicated in many cellular processes 
including cell cycle progression, gene regulation and fibroblast contractility and 
motility, giving it a role in cell migration (Cai et al., 2005). 
1.10.5 Guanine nucleotide binding proteins: the Ras superfamily 
of small GTPases 
Guanosine Triphosphateses (GTPases) are a family of molecular players that are 
shown to be activated downstream of PI3K.  Once activated, these molecules 
relay extracellular signals to downstream effectors, producing a number of 
cellular responses, in particular cytoskeletal and membrane rearrangements 
required for cell movement (Hawkins et al., 2006). The Ras superfamily of 
small GTPases are divided into 5 families, Ras, Rho, Rab, Ran and Arf based on 
their sequence and functionality. Here we shall discuss some of the important 
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 members of these families.  These monomeric G-proteins are known as the 
molecular switches of the cell and are seen in many signalling cascades. 
GTPases can be found in two forms, in their active state they are bound to GTP 
and following hydrolysis of GTP, while in their inactive state, they are bound to 
GDP. Both forms show similar conformations but have significant differences 
in their ability to recognise specific domains (Shields et al., 2000).  
To fully appreciate the role of GTPases, it is essential to understand how these 
molecules are regulated. In the case of the GTPase family this is through the 
regulating properties of guanine-nucleotide-exchange factors (GEFs) and 
GTPase-activating proteins (GAPs).  GTPases contain a low level of intrinsic 
GTPase function converting GTP to GDP, however this is further controlled by 
GEFs and GAPs. Rho and Rab GTPases also have a further level of regulation; 
guanine nucleotide dissassociation inhibitors (GDI) (DerMardirossian and 
Bokoch, 2005). For all GTPases activation via GEFs can facilitate the 
conversion of GDP to GTP, thus activating the GTPases.  In their active state 
GTPases can now bind to and activate downstream effectors. GAPs complete 
the cycle by increasing the intrinsic GTPase activity and allowing rapid 
conversion back to the GDP bound inactive state.  For Rho and Rab subfamilies 
the GTPases are cytosolic and bound to GDIs preventing the action of GEFs, 
therefore maintaining the GTPases inactive state (Bishop and Hall, 2000; 
Boguski and McCormick, 1993).  Following dissociation from the GDI they can 
insert into the plasma membrane where they interact with GEFs and thus 
become active (Robbe et al., 2003). 
1.10.6. Ras Family 
Ras Sarcoma oncoproteins is a family comprised of Rap, Ras, Ral and Rheb, 
which can be activated by GEFs, of which the 3 main classes are Sos (Son of 
Sevenless), Ras-GRF (Ras guanyl releasing factor) and RasGRP (Ras guanyl 
releasing protein).  The best characterised pathway within this family is the 
activation of the Ras GTPases and the subsequent MAPK signalling cascade, 
which shall now be discussed. 
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1.10.7 Mitogen-activated protein kinase 
The mitogen-activated protein kinases (MAPK) pathway, is comprised of many 
different subfamiles, the best known of these are ERK (extracellular signal-
regulated kinase), JNK (c-jun-NH2-terminal kinase) and the p38 MAP kinases, 
all of which play a role in signal transduction from the plasma membrane to the 
nucleus. Although in resting cells, MAPKs largely reside in the cytoplasm, 
following activation these molecules have the capacity to phosphorylate nuclear 
substrates such as protein kinases, cell cycle regulators and transcription factors. 
The activation of MAPKs follows a cascade of subsequent phosphorylation via 
protein kinases, namely MAPK kinase kinase and MAPK kinase (Fig. 1.9). 
There are numerous different kinases involved at each tier of this process, with 
each being differentially regulated through G-proteins, scaffolds, adaptors, 
substrates and regulator proteins. These subfamilies have been implemented in 
cellular functions such as cell proliferation, differentiation, development, the 
inflammatory response and apoptosis (Weston and Davis, 2007).    
1.10.8 ERK 
ERK is the classical MAPK and is the most well known member of this family. 
Its activation is in response to stimulation via receptor tyrosine kinases, GPCRs, 
cytokine receptors and integrins.  This stimulates the recruitment of the small 
GTPase Ras, which in turn activates the serine/threonine kinase Raf, a MAPK 
kinase kinase triggering this signalling cascade.  Phosphorylation of ERK 1/2 is 
catalysed by the upstream kinases MEK 1 or MEK 2, (MAPK kinase).  Upon 
activation ERK1/2 homodimerize, and translocate to the nucleus where they 
activate additional kinases and transcription factors (Kolch, 2005).   
The action of CXCL12 on the receptor CXCR4, has been shown to activate the 
MAP kinase pathway, in particular the ERK 1/2 response.  The involvement of 
this pathway in chemotactic responses has been provided by the use of the 
MEK1/2 pharmacological inhibitor PD098059, which has been shown to 
partially inhibit CXCL12 stimulated chemotaxis (Sotsios et al., 1999). 
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Figure 1.9 Schematic representation of the structure of MAPK pathways. 
Each MAP kinase family member; p38, JNK and ERK1/2 is activated by 
successive activation of a MAPK kinase kinase and MAPK kinase. 
1.10.9 Rap1 
Rap1 is the closest homolog to the Ras GTPase and over recent years has gained 
increasing interest due to its role in cell adhesion. It has been shown that 
chemokines in particular CXCL12 and SLC (secondary lymphoid chemokine) 
can induce Rap1 mediated signals that regulate integrin activation and 
transendothethial migration (Shimonaka et al., 2003). Furthermore, murine 
models and human T cells have been shown to be dependent on Rap1 for 
chemokine and PMA induced LFA-1 activation, an integrin essential for the 
transmigration of cells across endothelium. 
1.10.10 Ras Homologous Family 
Ras Homologous (Rho) family have also been shown to be key regulators of 
chemokine mediated signalling that induce actin organisation, cell cycle and 
gene expression. This family is comprised of over 20 members, the most well 
studied being Rho, Rac and CDC42 which in regard to actin reorganisation 
result in distinct filamentous actin structures (Wennerberg et al., 2005). In order 
to ensure efficient signalling and control, these GTPases are regulated at 
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multiple points through the signalling cascade, through control of GEF and 
GAP and regulation of cellular location and expression levels.  
1.10.10.1 Rho 
The activation of Rho to promote stress fibre formation and focal adhesion 
assembly has been found to be dependent on activation of both Rho 
kinase/ROCK (Rho-associated coiled-coil forming kinase) a serine/threonine 
protein and mDia. Phosphorylation of the myosin light-chain phosphatase via 
Rho inhibits dephosphorylation of the myosin light chains and increasing 
myosin II activity and stress-fibre formation and contractility.  Activation of 
mDia allows binding to the barbed ends of the actin filament, enhancing 
elongation and blocking binding of capping proteins (Riento and Ridley, 2003; 
Watanabe et al., 1999). The action of Rho and ROCK at the rear of the cell 
regulates the assembly of contractile actin and myosin.  This has been 
demonstrated to play a key role in both actin assembly and contractility, and 
mediating uropod retraction, an essential role in migrating leukocytes.  In 
comparison, the polymerisation of actin and production of lamellipodia and 
filopodia by Rac and Cdc42 is provided at the front or leading edge of the cell. 
1.10.10.2 Rac 
Rac1 has been demonstrated to be involved in lamellipodium extension 
following the ligation of chemokine receptors; inhibition of Rac prohibits cell 
migration. Further to these actin dependent processes, Rac has also been shown 
to be involved in translational activation, protein synthesis and cell survival 
(Etienne-Manneville and Hall, 2002). In resting cells Rac is cytoplasmic, yet 
following activation by GEFs, which are the same as for the Ras family, Sos, 
Ras-GRF and RasGRP, they are located to the leading edge of the cell and 
critical in the formation of lamellipodium (Kraynov et al., 2000).  Although 
observations are context dependent, it has been observed in macrophages that 
constitutively active Rac has the potential to inhibit cellular migration.  This 
process is through lamellipodia extension over the entirety of the cell, instead of 
focused at the leading edge This demonstrates a requirement in the neutrophils 
for gradient sensing and orientation (Sun et al., 2004).    
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1.10.11 Cdc42 
During migration Cdc42 can be located at the leading edge and also at the Golgi 
apparatus, where it is thought that it enables the generation of cell polarity.  This 
polarity is thought to be generated via Cdc42s reorientation of the MTOC 
(microtubule-organising centre) and the Golgi in the orientation of migration. 
This rearrangement of the intracellular environment may lead to cellular polarity 
through the control of secretory and endocytic transport to the leading edge, 
thus maintaining the forward protrusions (Raftopoulou and Hall, 2004). 
Furthermore this GTPase is also required for the promotion of directed 
production of actin microspikes and filopodium formation at the leading edge of 
the cell. The activation of Cdc42 triggers activation of WASP (Wiskott-Aldrich 
syndrome protein), in turn activating Arp2/3 (actin-related protein 2/3) a 
signalling molecule known to promote actin polymerisation (Millard et al., 
2004). 
1.11 Aims of the Study 
Chemotaxis of T lymphocytes is a critical step of immune surveillance and the 
immune response. Indeed, altered levels of chemotaxis have been observed in a 
range of diseases including multiple sclerosis, arthritis and psoriasis. As such, it 
is vital that the signalling pathways involved in chemotaxis are well 
characterised, enabling the discovery of possible future drug targets. PI3K was 
previously thought to have a central role in chemotaxis. However, previous 
work performed within the laboratory revealed that PI3K may be a dispensable 
signal (Cronshaw et al., 2004), and that its importance is determined by 
chemoattractant, cell type and/or differentiation state (Ward, 2006).  
In addition, recently published work has revealed the existence of another 
subtype of T helper cells. These cells, known as Th17 cells, had been shown to 
be involved in several autoimmune diseases. However, no work had been 
performed to determine the chemokine receptor expression profile of Th17 
cells, or the signalling pathways that mediated chemotaxis.  
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Therefore, the aims of the project were as follows:  
•	 Using pharmacological tools, gain more insight into the role of PI3K in 
T lymphocyte chemotaxis by exploring the role of downstream kinases 
in cell migration. 
•	 Generate Th17 cells and determine what chemokine receptors are 
expressed on the cell surface 
•	 Determine the role of PI3K, if any, in the migration of Th17 cells.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Cell Isolation and Culture Materials 
Cell culture media, RPMI-1640, foetal bovine serum, penicillin and 
streptomycin, L-glutamine, HEPES, trypan blue,  phosphate buffer saline 
(without Ca2+ and Mg2+) and falcon tubes were purchased from GIBCO® 
(Paisley, UK). Lymphoprep (Ficoll-paque 1.077 g/ml density) and Nycoprep 
1.077A were purchased from Axis-Shield (Cambridgeshire, UK). Tween-20, 
Staphylococcal Enterotoxin B, 2-Mercaproethanol and recombinant hTGF-β1 
were purchased from Sigma-Aldrich (Gillingham, UK) and Dynalbeads® 
CD3/CD28 T cell expander beads from Invitrogen (Paisley, UK). Recombinant 
mIL-1β, IL-2, IL-6 and TNF-α were purchased from Peprotech (London, UK). 
CD4+ and pan-T cell isolation kits and LS columns were purchased from 
Miltenyi Biotech (UK). Recombinant mIL-23 and anti-IFN-γ Ab (clone 
no:37895) were purchased from R&D systems (Abingdon, UK). Anti-IL-4 Ab 
(clone no:11HB11) was produced in-house at UCB (Slough, UK). 
Recombinant human IL-2 was purchased from Chemicon (Hampshire, UK).  All 
plastics were obtained from Nunc (UK).  
2.1.2 Antibodies 
proteinSer235/236Rabbit polyclonal anti-phospho-S6 ribosomal antibody 
(catalogue no: 2211), S6 Ribosomal Protein (5G10) and anti-phospho AktSer473 
(catalogue no: 9271) were purchased from Cell Signalling Technologies (NEB, 
Hitchin, UK). Anti-CD4-TC (clone no:RM4-5), anti-IFNγ-FITC and anti-IFNγ­
AF610 (clone no:XMG1.2) were purchased from Invitrogen (Paisley, UK). Goat 
polyclonal pan Akt (catalogue no: sc1618) was obtained from Santa Cruz 
Biotechnologies (Santa Cruz, USA).  Anti-CCR5-PE (clone no:C34-3448) and 
anti-IL-17-PE (clone no:TC11-18H10.1) were purchased from BD Biosciences 
(Oxford, UK). Monoclonal Anti-human CXCR4-fluorescein (clone 12G5), 
Mouse IgG1 isotype control (clone 11711), Anti-CCR3-FITC (clone no:83101), 
anti-CCR6-FITC (clone no:140706) and anti-CCR9-FITC (clone no:242503) 
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were purchased from R&D systems (UK). Anti-CCR7-PE (clone no:EBI-1) was 
purchased from e-Bioscience (San Diego, USA). Anti-CCR2 (clone no:MC-21) 
was a kind gift from Professor Matthias Mack (University of Regensburg, 
Germany). Anti-Rat IgG-FITC was purchased from Sigma-Aldrich. All other 
isotype antibodies were purchased from Invitrogen or BD Biosciences. 
Secondary Antibodies for immunoblotting were purchased from DAKO 
(Glostrup, Denmark).  
2.1.3 Chemokines 
Human recombinant CXCL12 (catalogue no: 350-NS) and mouse recombinant 
CCL25 were purchased from R&D Systems (Abingdon, U.K.). All other 
chemokines were purchased from Peprotech (London, U.K.).  
2.1.4 Assay systems and kits 
Chemo Tx® System was purchased from Neuro Probe (Gaithersburg, USA). 24­
well Transwell® chemotaxis plates were purchased from Corning (New York, 
USA). Molecular weight markers were purchased from Bio-Rad (UK). The 
Enhanced chemiluminescence detection kit and X-OMAT film were purchased 
from Amersham International (UK).  The nitrocellulose membrane, 0.45 µM 
pore was obtained from BDH (UK).  The filter paper used in immunoblotting 
was obtained from Whatman (Maidstone, UK).  Marvel was purchased from the 
local supermarket. Omnia® Lysate Assay for Akt/PKB was purchased from 
Invitrogen. Human Human Phospho-MAPK Array Kit was purchased from 
R&D systems limited.  
2.1.5 Inhibitors 
LY294002 and Wortmannin were purchased from Sigma (Poole, UK). Akti-1/2 
and Rottlerin were purchased from Calbiochem (Gibbstown, USA). IC87114 
(patent WO 0181346) and ZSTK474 (patent WO 037812) has been described 
elsewhere and was synthesised solely for this study. 
2.1.6 Mice 
DO11.10 mice (John Radcliffe Hospital, Oxford, UK), carrying a transgenic 
TCR specific for the OVA323–339 peptide, BALB/c mice (Charles River 
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Laboratories, Kent, UK), D910A / D910A mice (a kind gift from Dr Klaus 
Okkenhaug, Babraham Institute, UK) and PKCδ knockout mice were kept under 
barrier conditions. All experiments were performed in accordance with the 
Animals (Scientific Procedures) Act 1986. 
2.2 Cell Types and Culture Conditions 
All human cell lines and primary cells were routinely maintained in RPMI 1640 
medium supplemented with antibiotics and 10 % (v/v) foetal bovine.  Cells were 
cultured every 2-3 days as required and maintained at 37 °C and 5 % CO2. 
Murine cells were routinely maintained in RPMI 1640 medium supplemented 
with penicillin (10 u/ml), streptomycin (10μg/ml), L-Glutamine (2mM), HEPES 
buffer (25mM), 0.00035% v/v 2-mercaptoethanol and 10% v/v foetal calf serum 
(FBS), and new medium was added on day 3 post culture. Cells were 
maintained at 37 °C and 5 % CO2. Prior to experimental procedures, cell 
viability was determined using trypan blue to stain any dying cells.   
2.2.1 CEM Cells 
CEM cells were obtained from The European Collection of Cell Cultures 
(ECACC). The cells were maintained in 175cm2 flasks in RMPI 1640 medium 
supplemented with 10 % foetal calf serum (FBS), 10 % non essential amino 
acids, 10 u/ml penicillin and 10 µg/ml streptomycin (complete medium). Cells 
were grown to a maximum of 2 x 106 cells / ml and diluted with fresh complete 
medium to 5 x 105 / ml cells every two to three days.  Cells were maintained in 
a humidified incubator at 37 °C and 5 % CO2. 
2.2.2 Isolation of PBMCs by density gradient centrifugation  
Blood was collected from healthy volunteers in heparinised syringes (500 U/50 
ml) and diluted 1:1 with RPMI 1640 medium.  35 ml of the blood/RPMI mix 
was then carefully layered over 15 ml of lymphoprep in a 50 ml falcon tube 
before being centrifuged at 1500 rpm at room temperature for 30 minutes with 
the brake off.  Following centrifugation, the interface layer between the plasma 
and the lymphoprep, as seen in Fig 2.1, which contains the lymphocytes and 
monocytes was swiftly removed by aspiration. 
59
 
Red Blood Cells 
Lymphoprep 
PBMCs 
Plasma 
Figure 2.1 Diagram of PBMC separation with Lymphoprep after 
centrifugation.  The diagram is representative of the separated cell layers 
observed after whole blood undergoes centrifugation with Lymphoprep. 
2.2.4 Ex-vivo activation and clonal expansion of T lymphocytes 
Freshly isolated PBMCs were washed 3 times in RPMI-1640 and re-suspended 
at 1 x 106 /ml RPMI complete medium.  Mononuclear cells were activated with 
Staphylococcal Enterotoxin B (SEB) 1 µg/ml or CD3/CD28 antibodies 
immobilized on beads (at a ratio of 1 bead per cell).  When using CD3/CD28 
antibodies, macrophages were first removed from the mononuclear cell 
popularion by plastic adherence. Following activation T-lymphocytes were 
expanded by addition of IL-2 every 2-3 days (20 ng/ml) extra complete medium 
was added when required. Cells were maintained up to a maximum of 14 days. 
2.2.5 Isolation of CD4+ T lymphocytes from murine splenocytes. 
DO11.10 mice were humanely culled using a schedule 1 method and their 
spleens removed. The spleen was disaggregated using a cell strainer with a 
40μm pore size and the resulting cell mixture was resuspended in 10mls 
complete medium. Cells were centrifuged at 1800rpm for 5 minutes before 
being resuspended in 2mls red blood cell lysis buffer and incubated at room 
temperature for 5 minutes with occasional shaking. Cells were washed twice in 
complete medium, and the cell pellet resuspended in 10mls complete medium. 
Cells were checked for viability and counted using a haemocytometer after 
mixing 20μl of cell suspension with 20μl of Trypan Blue. Dead cells were 
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stained blue due to the uptake of trypan blue. Cell viability was always above 
90%. 
Cells were counted and resuspended at 1 x 107 cells / 40μl MACS buffer (PBS, 
0.5% w/v Bovine Serum Albumin (BSA) and 2mM EDTA). 10μl of the Biotin-
Antibody Cocktail from the MACS CD4+ T cell isolation kit was added / 1 x 
107 cells and incubated on ice for 10 minutes. 30μl of MACS buffer and 20μl 
Anti-Biotin Microbeads from the MACS CD4+ T cell isolation kit were added / 
1 x 107 cells and incubated on ice for a further 15 minutes. Cells were washed 
once in MACS buffer then resuspended in 500μl MACS buffer and applied to a 
MACS LS column. The column was washed through with MACS buffer and the 
resulting effluent collected. This represents the enriched CD4+ T cells. Cells 
were washed twice and resuspended at 1 x 106 / ml in complete medium. 
For PKCδ-/- C57BL/6 mouse spleens, cells were counted and resuspended at 1 x 
107 cells / 40μl MACS buffer (PBS, 0.5% w/v Bovine Serum Albumin (BSA) 
and 2mM EDTA). 10μl of the Biotin-Antibody Cocktail from the MACS Pan T 
cell isolation kit was added / 1 x 107 cells and incubated on ice for 10 minutes. 
30μl of MACS buffer and 20μl Anti-Biotin Microbeads from the MACS CD4+ 
T cell isolation kit were added / 1 x 107 cells and incubated on ice for a further 
15 minutes. Cells were washed once in MACS buffer then resuspended in 500μl 
MACS buffer and applied to a MACS LS column. The column was washed 
through with MACS buffer and the resulting effluent collected. This represents 
the enriched pan T cells. Cells were washed twice and resuspended at 1 x 106 / 
ml in complete medium. 
2.2.6 Generation of APC’s 
Balb/c mice were humanely culled using a schedule 1 method and their spleens 
removed. The spleen was disaggregated using a cell strainer with a 5μm pore 
size and the resulting cell mixture was resuspended in 10mls complete medium. 
Cells were centrifuged at 1800rpm for 5 min before being resuspended in 2mls 
red blood cell lysis buffer and incubated at room temperature for 5 minutes with 
occasional shaking. Cells were washed twice in complete medium, and the cell 
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pellet resuspended in 10mls complete medium. Cells were checked for viability 
and counted using a haemocytometer after mixing 20μl of cell suspension with 
20μl of Trypan Blue. Cell viability was always above 90%. Cells were counted 
and resuspended at 5 x 107 / ml in complete medium and 50μg / ml mytomycin 
C added. Cells were then incubated at 37°C for 30 minutes, washed four times 
in complete medium and resuspended at 5 x 106 / ml in complete medium. 
2.2.7 Polarisation of Th17 cells.  
Equal volumes of CD4+ T cells and APC’s were co-cultured, with resulting final 
volumes of 5 x 105 / ml and 2.5 x 106 / ml respectively. The co-culture was 
divided into two and 200ng / ml Ovalbumin peptide323-339 and 10ng / ml IL-2 
were added to one batch and incubated at 37°C in an atmosphere of 5% CO2. 
These cells were known as Th0. 200ng / ml Ovalbumin peptide323-339, 1ng / ml 
TGF-β1, 20ng / ml IL-6, 10ng / ml IL-1β, 10ng / ml TNF-α, 10ng / ml IL-23, 
10μg / ml anti-Interferon gamma (IFN-γ) antibody and 10μg / ml anti-IL-4 
antibody were added to the other batch and incubated at 37°C in an atmosphere 
of 5% CO2. These cells were known as Th17 cells. After 3 days 10ng / ml IL-2 
was added to both the Th0 and Th17 cells. On day 7, 35ml of cells were 
carefully layered on 15ml nycoprep 1.077A (Axis Shield) and centrifuged at 
1500 rpm at room temperature for 20 minutes with the brake off. Healthy cells 
were collected from the interface and used. 
2.2.8 Freezing/Thawing of cells 
For storage, 10 x 106 cells/ml in exponential growth were re-suspended in freeze 
medium containing 10 % dimethylsulphoxide (DMSO), and 90 % foetal calf 
serum.  The cell suspension was transferred to cryotubes (1 ml/tube), cooled 
overnight at 1°C / minute in ethanol to -80 °C and transferred to liquid nitrogen 
tanks for long-term storage.  For resuscitation of cells from liquid nitrogen, cells 
were rapidly defrosted for one minute in a 37 °C water bath, washed once in 
RPMI and re-suspended in 50 mls complete medium and cultured as stated 
previously. 
62
 
2.3 Immunoblotting 
2.3.1 Sample Generation 
1-2 x 106 activated T lymphocytes or 5 x 106 Th17 cells per point were washed 
twice in RPMI 1640 and incubated at 37 °C in serum free RPMI for 60 minutes. 
If required, cells were incubated with inhibitors diluted in RMPI 1640 for the 
final 30 minutes of this period. Cells were left unstimulated or stimulated with 
chemokines at the required concentrations diluted in RPMI 1640.  Stimulations 
were terminated by aspiration of the supernatant followed by the addition of ice 
cold lysis buffer (50 mM Tris-HCL pH 7.5, 150 mM sodium chloride, 1 % 
Nonidet P40, 10 % Glycerol, 5 mM EDTA, 1 mM sodium vanadate, 1 mM 
sodium molybdate, 10 mM sodium fluoride, 40 μg/ml PMSF, 0.7 μg/ml 
Pepstatin A, 10 μg/ml Aprotinin, 10 μg/ml leupeptin, 10 μg/ml soyabean trypsin 
inhibitor). Lysates were rotated at 4 °C for twenty minutes, followed by 
centrifugation at 14,000 rpm for 10 minutes.  The supernatants (containing 
protein) were removed and diluted with 5x loading buffer (10 % SDS, 50 % 
glycerol, 200 mM Tris HCl pH 6.8, Bromophenol blue), heated to 95 °C for 5 
minutes and stored at -20 °C until used. 
2.3.2 Protein Separation, Membrane Transfer and Visualisation 
Solubilised proteins were electrophoresed on a one dimensional 7.5% or 10 % 
sodium dodecyl sulphate - polyacrylamide gel (SDS-PAGE).  This was carried 
out using the Bio-Rad Mini Protean II system (Biorad Labs, UK).  20μl of 
sample was loaded into a stacking gel and run at 80 volts (V) in running buffer 
containing 25 mM Tris base, 192 mM Glycine and 0.1 % (w/v) SDS.  Upon 
reaching the resolving gel, samples were electrophoresed at 180 V. The proteins 
were transferred by electroblotting for 60 minutes at 40 mV onto nitrocellulose 
membrane 0.45 µM soaked in semi-dry transfer buffer (70 % H20, 20 % 
methanol, 10 % blot buffer (39 mM Glycine, 48 mM Tris base and 0.0375 % 
SDS). Membranes were incubated for 60 minutes at room temperature in block 
buffer, (Tris Buffered Saline (20 mM Tris-HCl pH 7.6, 150 mM sodium 
chloride) with 0.1 %Tween (TBS-Tween) containing 5 % non-fat milk), with 
slight agitation and rinsed twice for 5 minutes in TBS-Tween.  The membrane 
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was incubated in the specified 1° antibody dilution 1:500 - 1:1000, in TBS-
Tween supplemented with 0.01% sodium azide and 5 % non-fat milk, overnight 
at 4 °C with slight agitation. The membrane was washed three times for 5 
minutes in TBS-Tween, and incubated in the 2° antibody coupled to horseradish 
peroxidase (HRP) diluted 1:10,000 in block buffer, for 60 minutes at room 
temperature before being washed in TBS-Tween three times for 5 minutes. 
Visualisation of the proteins was performed by incubating the membrane in 5 ml 
of Enhanced Chemiluminescent reagent (ECL), for one minute and exposing to 
Kodak X-OMAT film. 
2.3.3 Membrane Stripping and reprobing 
The membrane was rehydrated in TBS for 10 minutes and then placed in 50 ml 
of stripping buffer (100 mM 2 Mercaptoethanol, 2 % SDS, 62.5 mM Tris-HCL 
pH 6.7) to remove bound antibody; and incubated at 60 °C for 30 min.  After 
extensive washing with TBS-Tween, the membrane was incubated for 60 
minutes at room temperature in block buffer, washed three times in TBS-
Tween, and re-probed with the relevant primary antibody and the 
immunoblotting procedure is carried out as described above.  
2.4 Detection of Protein Phosphorylation Levels using the 
Phospho-array 
2.4.1 Sample Generation 
Analysis of protein activation was performed using a Human Phospho-MAPK 
Array Kit (R&D Systems). 1 x 107 cells were washed twice in RPMI 1640 and 
incubated at 37 °C in serum-free RPMI for 60 minutes.  If required, cells were 
incubated with inhibitors diluted in RMPI 1640 for the final 30 minutes of this 
period. Cells were left unstimulated or stimulated with chemokines at the 
required concentrations diluted in RPMI 1640.  Stimulations were terminated by 
aspiration of the supernatant followed by the addition of Lysis Buffer (supplied 
with the kit) and incubated at 4°C for 30min, shaking. Cell debris was pelletted 
by centrifugation at 14000rpm for 10 minutes and the supernatant transferred to 
a clean tube and frozen at -20°C until required.  
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BA 
Figure 2.2: An R&D systems Human Phospho-MAPK Array Kit A: The 
contents of the kit, showing the different buffers provided (left) and the four 
membranes in their tray (bottom right). B: A representative diagram of a 
developed membrane. The black dots are where an antibody has bound protein, 
resulting in the production of light following incubation with ECL. 
2.4.2 Determination of Protein Concentration 
Lysates were thawed and protein concentration determined using a BCA Protein 
Assay (Pierce). 25μl of lysate or known concentrations of BSA were added to a 
96 well plate along with 200μl of working reagent (supplied with protein assay 
kit) and mixed thoroughly for 30 seconds before being incubated at 37°C for 30 
minutes. The plate was cooled to room temperature and absorbance at 562nm 
read on a plate reader. The protein concentrations were calculated by linear 
regression from the standard curve using GraphPad Prism. 
2.4.3 Visualisation of Protein Phosphorylation Levels. 
The array was incubated for one hour in 1.5mls of Array Buffer 1, which was 
then removed and 1.5mls of Array Buffer 1 containing 250μl of lysate added. 
The array was incubated overnight at 4°C, rocking. The array was washed three 
times in 20ml wash buffer before 1.5ml of Array Buffer 2/3 containing 15μl of 
Detection Antibody Cocktail Concentrate was added and the array incubated for 
two hours at room temperature on a rocking platform shaker. Array was washed 
three times in 20ml wash buffer and 1.5 ml of Streptavidin-HRP diluted 1:2000 
in Array Buffer 2/3 added and incubated for 30 minutes at room temperature on 
a rocking platform shaker. Array was washed three times in 20ml wash buffer 
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and exposed to 3mls of ECL chemiluminescent reagent for 1 minute before 
being exposed to Kodak X-OMAT film for 2-10 minutes. 
2.4.4 Densitometric Analysis 
Densitometric analysis was performed to analyse these assays. Optical 
densitometry was measured using the Adobe® Photoshop and values were 
expressed as average pixel density for each spot. 
2.5 Protein Kinase Activity Assays 
2.5.1 Extraction of proteins from cells. 
1-2 x 106 activated T lymphocytes or 5 x 106 Th17 cells per point were washed 
twice in RPMI 1640 and incubated at 37 °C in serum free RPMI for 60 minutes. 
If required, cells were incubated with inhibitors diluted in RMPI 1640 for the 
final 30 minutes of this period. Cells were left unstimulated or stimulated with 
chemokines at the required concentrations diluted in RPMI 1640. Stimulations 
were terminated by aspiration of the supernatant followed by the addition of ice 
cold PBS and subsequent centrifugation at 1500rpm for 5 minutes. The PBS 
was removed by aspiration and the cell pellet resuspended in 100μl of ice cold 
“Cell Extraction Buffer” provided with the assay kit. The cells were rotated at 
4˚C for 30 minutes before centrifugation at 13000rpm for 20 minutes, also at 
4˚C. The clarified cell extracts were then transferred to clean tubes in 
preparation for the kinase assay. 
2.5.2 Preparation and Performance of the Kinase Assay.  
Protein concentration was determined as described in section 2.5.2. Substrate 
peptide, ATP solution, DTT solution, kinase reaction buffer and kinase inhibitor 
cocktail were prepared as per the instruction in the product manual, then 5μl of 
each was mixed with 15μl of dH2O and incubated for 5 minutes at reaction 
temperature. 5μl (15μg) of cell lysate was added in duplicate to a 96 well plate, 
the reaction mixture added and well mixed. Readings were taken using a 
fluorescent plate reader (λex 360/λem 485) every 30 seconds for 60 minutes. 
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Results were plotted as change in fluorescence intensity over time, 
corresponding to rate of phosphorylation by target kinase. 
2.6 Flow Cytometry 
2.6.1 Detection of extracellular ligands 
Cells were washed twice in RPMI 1640 and counted before being resuspended 
at 2 x 106 / ml in FACS buffer (PBS, 0.25% w/v BSA). 1ml of cells were added 
to FACS tubes, centrifuged at 1500 rpm for 5 minutes and the resulting cell 
pellet resuspended in 100μl of 10μg / ml antibody and incubated at 4°C for 30 
minutes in the dark. Cells were washed twice in 1ml of FACS buffer and 
resuspended in 500μl FACS buffer. Data were acquired on a Beckman Coulter 
EPICS XL machine using EXPO32 ADC software or BD FACSCanto II using 
BD FACS Diva software. 
2.6.2 Detection of intracellular ligands 
Cells were stimulated with 50ng / ml PMA, 500ng / ml Ionomycin and 4μl / 
6mls of GolgiStop (BD Biosciences) for 4 hours at 37°C in an atmosphere of 
5% CO2. Cells were carefully layered on 15ml nycoprep 1.077A (Axis Shield) 
and centrifuged at 1500 rpm at room temperature for 20 minutes with the brake 
off. Healthy cells were collected from the interface, washed in phosphate-
buffered saline (PBS) and counted before being resuspended at 1 x 106 / ml in 
Extracellular Staining Buffer (PBS, 1% FBS and 0.9% w/v Sodium Azide) and 
1ml added to each FACS tube. Cells were centrifuged at 1500 rpm for 5 
minutes, resuspended in 100μl of 10μg / ml antibody in Extracellular Staining 
Buffer and incubated at 4°C for 30 minutes in the dark. Cells were washed twice 
and resuspended in 1ml of Extracellular Staining Buffer before 250μl of 
Fixation/ Permeabilisation Solution (BD Biosciences) was added and the cells 
were incubated on ice for 20 minutes in the dark. Cells were then washed twice 
in Perm/Wash buffer (BD Biosciences) and resuspended in 100μl of 10μg / ml 
antibody in Perm/Wash Buffer and incubated on ice for 30 minutes in the dark. 
Cells were washed twice in Perm/Wash Buffer and resuspended in 500μl 
Extracellular Staining Buffer. Data were acquired on a Beckman Coulter EPICS 
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XL machine using EXPO32 ADC software or BD FACSCanto II using BD 
FACS Diva software. 
2.7 Cell Migration Assays 
2.7.1 Neuroprobe Chemotaxis. 
Cells were washed twice in chemotaxis medium (RPMI 1640 w/o phenol red, 
0.25% w/v BSA) before resuspension at 1 x 107 / ml. Cells were incubated for 
60 minutes at 37˚C in the presence of inhibitors if required. Neuroprobe 
ChemoTX® chambers (Neuroprobe) were blocked with 29μl of chemotaxis 
medium / well and incubated for 30 minutes at 37°C before 29μl of the 
appropriate chemokine in chemotaxis medium was added and the 5μm 
membrane placed carefully on top. 25μl of cells were placed on the membrane 
and the cells incubated for 3 hours at 37°C in an atmosphere of 5% CO2 while 
migrating. The filter was then discarded and the cell suspension transferred to a 
FACS tube containing 250μl of Extracellular Staining Buffer and 50μl 
Flowcount Beads (Beckman Coulter). Data were acquired on a Beckman 
Coulter EPICS XL machine using EXPO32 ADC software or BD FACSCanto 
II using BD FACS Diva software. 
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Figure 2.3: Diagram of a Neuroprobe Chemotaxis Plate including a cartoon 
of how it works. 
2.7.2 Transwell Chemotaxis 
Cells were washed twice in chemotaxis medium (RPMI 1640 w/o phenol red, 
0.25% w/v BSA) before resuspension at 1 x 107 / ml. Cells were incubated for 
60 minutes at 37˚C in the presence of inhibitors if required. Transwell 
Chemotaxis Plates (Costar) were blocked in 600μl chemotaxis medium / well 
for 30 minutes at 37°C before 600μl of the appropriate chemokine in 
chemotaxis medium was added and the 5μm membrane placed on top.  100μl of 
the cell suspension was placed on top of the filter and the cells allowed to 
migrate for 3 hours at 37°C in an atmosphere of 5% CO2. The filter was then 
discarded and cells from the bottom well of four wells were pooled, washed in 
complete medium and resuspended in 1ml of chemotaxis medium. When 
required, 100μl was removed for use in an ELISpot assay and the rest were 
stimulated for 3 hours with 50ng / ml PMA, 500ng / ml Ionomycin and 0.66μl / 
ml of GolgiStop at 37°C in an atmosphere of 5% CO2. Cells were washed and 
resuspended in 1ml of Extracellular Staining Buffer, transferred to a FACS tube 
and pelletted. Cells were then resuspended in 100μl of 10μg / ml extracellular 
antibody and incubated at 4°C for 30 minutes in the dark, before being washed 
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and resuspended in 400μl of 4% paraformaldehyde solution and incubated at 
4°C for 15 minutes in the dark. Cells were washed three times and resuspended 
in 500μl of extracellular staining buffer and stored at 4°C overnight.  The next 
day, cells were spun down, resuspended in 500μl of Perm/Wash Buffer and 
incubated at 4°C for 15 minutes in the dark. Cells were spun down and 
resuspended in 100μl of 10μg / ml intracellular antibody in Perm/Wash Buffer 
and incubated on ice for 30 minutes in the dark. Cells were then washed twice in 
Perm/Wash Buffer and resuspended in 450μl of Extracellular Staining Buffer 
and 50μl Flowcount Beads (Beckman Coulter). Data were acquired on a 
Beckman Coulter EPICS XL machine using EXPO32 ADC software. 
2.8 Secreted Cytokine Detection 
2.8.1 Luminex Cytokine Detection 
Cytokine specific capture antibodies against IL-17, IFN-γ, TNF-α, IL-4, IL-5, 
and IL-10 were bound to fluorescently distinct LiquiChip Carboxy Beads 
following manufacturers instructions, mixed together and diluted 1:1000 in 
reagent buffer (PBS, 1% BSA). 50μl of bead mix was combined with 50μl of 
cell culture supernatant in a 96 well filter plate and incubated at room 
temperature for two hours, shaking. The beads were washed twice with 100μl of 
wash buffer (PBS, 0.05% v/v Tween-20) and 50μl of cytokine-specific 
biotinilated antibody diluted 1:100 in reagent buffer was added. The plate was 
incubated in the dark for one hour, shaking and then washed twice with 100μl 
wash buffer. 50μl of Streptavidin-HRP (1:1000 dilution in reagent buffer) was 
added and the plate incubated at room temperature for a further 30 minutes in 
the dark. The plate was washed twice with wash buffer and the beads 
resuspended in 100μl of wash buffer. The mean fluorescent intensity (MFI) of 
each distinct bead type was acquired using a Luminex100IS machine and 
analysed using Developer Workbench Software (Qiagen). The cytokine 
concentration was estimated using a standard curve generated from known 
concentrations of each cytokine. 
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2.9 Cell Death Assay 
Healthy cells were resuspended at 2x 106 / ml in wash medium and incubated 
with kinase inhibitors for the required period of time.  100μl of cells were mixed 
with 100μl of Trypan blue and 20μl was placed on a haemocytometer. The 
number of dead cells (those that had taken up the dye and thus were stained 
blue) were then counted under a microscope. 
2.10 Statistical analysis 
Statistical analysis was performed using students’ t-test or one way analysis of 
variance (ANOVA) with Dunnets correction where necessary.  These 
calculations were carried out to test for statistical significance following 
chemotactic or basal migration assays. A statistical cut-off of P = 0.05 was 
used. These calculations were performed using the GraphPad Prism version 4.0 
software. 
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DOWNSTREAM KINASES 
IN T LYMPHOCYTE 
MIGRATION 
72
 
Results I: The role of PI3K and downstream kinases in human T 
lymphocyte migration 
3.1 Background 
Phosphoinositide 3-Kinase  (PI3K) is a lipid kinase important in several 
intracellular pathways including cell growth, proliferation, survival and motility. 
Indeed, PI3K has been shown to be essential in several models of chemotaxis 
including Dictyostelium (Sasaki et al., 2007; Funamoto et al., 2001) and 
neutrophils (Puri et al., 2005; Sasaki et al., 2000). Several studies in 
Dictyostelium have been performed, imaging the location of PI3K and the 5’ 
phosphatase PTEN in migrating cells (Janetopoulos et al., 2005; Huang et al., 
2003). These studies showed that in an unstimulated resting cell, class I PI3K 
was found mainly in the cytosol while PTEN was localised to the membrane. 
However, upon sensing a chemoattractant gradient, PTEN dissociates from the 
membrane while PI3K localises to the leading edge of the cell, where it 
produces PI(3,4,5)P3 (Merlot and Firtel, 2003), recruiting and activating Rho 
GEF proteins and PH domain containing proteins such as Akt, setting up a 
signalling cascade resulting in chemotaxis. Studies of T lymphocyte migration 
involving the broad spectrum PI3K inhibitors LY294002 and Wortmannin, or 
using knockouts of the P110δ or P110γ genes in mice (Reif et al., 2004) have 
shown that there is impaired movement in cells, a loss of gradient sensing and a 
general impaired ability to mount an immune response. In humans however, 
there is some evidence that PI3K is a dispensable signal (Cronshaw et al., 2004), 
and that its importance is determined by chemoattractant, cell type and/or 
differentiation state (Ward, 2006). Activation of PI3K results in the subsequent 
activation of a number of protein kinases within the cell (Cantley, 2002). The 
role of these has not been fully explored in chemokine-induced human T 
lymphocyte migration and may help to shed further light on the role of PI3K. 
This section of the study aims to gain more insight into the role of PI3K in T 
lymphocyte migration, using both T lymphocyte cell lines and primary 
peripheral blood mononuclear cells (PBMCs), and to determine whether any of 
the downstream kinases also play a role in migration.   
3.2 Activation of PI3K in T lymphocytes by chemokines 
Direct measurement of PI3K activation via assessment of 3’-phosphoinositide 
lipid generation is technically formidable, so a surrogate readout is often used. 
Akt, or Protein Kinase B, is a protein kinase that resides within the cell 
cytoplasm. Activation of PI3K leads to the formation of Phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) in the cell membrane, allowing Akt to bind to the 
membrane via its PH domain. Once there, it is phosphorylated at Thr308 by the 
protein kinase PDK-1, and subsequently by an unknown protein, thought to be 
mTOR-RICTOR (Sarbassov et al., 2005), at position Ser473. This dual 
phosphorylation allows a conformational change in the protein causing 
activation of Akt. Flow cytometry was used to confirm the presence of 
chemokine receptors on the surface of the T lymphocyte cell line CEM cells, 
previously shown by work carried out within the Ward group to express two 
chemokine receptors, only one of which induced PI3K dependent migration 
(Cronshaw et al., 2004), and on human PBMCs. Staining of CEM cells with 
FITC-tagged anti-CXCR4 antibodies and PE-tagged anti-CCR4 antibodies 
revealed the presence of both receptors on the cell surface, with 45% of cells 
expressing CXCR4 and 59% of cells expressing CCR4 (Fig. 3.1A-B). CCR4 has 
previously been shown to be expressed only in very small quantities on PBMCs 
(Yamamoto et al., 2000), and so was not tested for in the PBMC populations, 
however staining for CXCR4 revealed that 62% of cells expressed the receptor 
(Fig. 3.1C). Many chemokine receptors show promiscuity for ligands, binding 
several different chemokines. To date, CXCR4 has only been shown to have a 
single ligand, known as CXCL12 or SDF, while CCR4 binds a range of 
chemokines including CCL22 (MDC), CCL3 (MIP-1) and CCL17 (TARC). 
While some evidence suggests that there may be an alternative receptor for 
CCL22 (Proost et al., 2006), it is generally accepted that CCL22 is a specific 
ligand for CCR4. Therefore, CXCL12 and CCL22 were used to stimulate 
CXCR4 and CCR4 respectively in these assays. 
Using an antibody specific for Akt phosphorylated at Ser473, the effect of 
stimulating the cells with different concentrations of the chemokines was 
explored. Incubation of CEM cells with increasing concentrations of CXCL12 
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(Fig. 3.1D) or CCL22 (Fig. 3.1E) induced the dose dependent phosphorylation 
of Akt, indicating that PI3K is activated upon chemokine / chemokine receptor 
interactions. Incubation of Day 10 SEB activated PBMCs with CXCL12 showed 
the same result (Fig. 3.1F). To confirm that this effect was PI3K dependent, a 
broad-spectrum inhibitor of PI3K, LY294002, was used. LY294002 is a 
commonly used inhibitor of PI3K that works by binding to the ATP-binding site 
of PI3K. Pre-incubation of either cell type with 10μM LY294002 for 30 minutes 
prior to stimulation with chemokines significantly reduced phosphorylation of 
Akt (Fig. 3.1D-F), confirming the activation of PI3K by chemokines. 
Interestingly, LY294002 was never able to fully abrogate CXCL12-incuced 
phosphorylation of Ser473. This latent phosphorylation could be due to the 
MAPK-family of proteins, who are also able to activate the mTOR-RICTOR 
complex. 
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Figure 3.1 Activation of PI3K by stimulation of PBMCs and CEM cells 
through CXCR4 and CCR4. Flow cytometry was used to determine the 
expression of CXCR4 (A) or CCR4 (B) on CEM cells and CXCR4 on SEB 
activated PBMCs (C). Cells were washed into FACS buffer at 2 x 106 / ml, 1ml 
added to a FACS tubes and incubated with 100μl of fluorescently tagged 
antibody. After 30 minutes, cells were washed and data acquired on a BD 
FACSCanto II machine. The green line indicates the isotype control antibody, 
while the red line shows binding of the antibody in question. Immunoblotting 
was used to determine whether binding of chemokines to CXCR4 (D) or CCR4 
(E) on CEM cells or CXCR4 (F) on SEB activated PBMCs. WCLs of the 
various cell types were generated as described in Materials and Methods. All 
data are representative of at least three separate experiments.  
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3.3 Characterisation of PI3K inhibitors by Immunoblotting 
Although LY294002 is a well established PI3K inhibitor, questions have 
recently been raised about its specificity. A paper by Gharbi et al, (Gharbi et al., 
2007) investigated the specificity of several commonly used PI3K inhibitors 
including LY294002 and the original PI3K inhibitor, Wortmannin. The study 
revealed that in addition to it’s inhibitory effects on PI3K, LY294002 also 
inhibited the kinase casein kinase 2 (CK2), GSK-3β and p97/VCP, an ATPase, 
at concentrations similar to that used to inhibit PI3K.  To control against this, 
wortmannin and a new PI3K inhibitor known as ZSTK474 were also used to 
investigate the role of PI3K in chemotaxis. ZSTK474 is an s-triazine derivative 
that possesses greater selectivity and potency compared to LY294002 (Yaguchi 
et al., 2006). This compound has been shown to inhibit all of the class I PI3K 
isoforms, and does so in an ATP competitive manner (Kong and Yamori, 2007). 
Using the phosphorylation of Akt at Ser473 as a marker of PI3K activation, 
immunoblotting was used to investigate the effects of the three inhibitors on 
PI3K activation and to determine the optimum concentrations and incubation 
times of the inhibitors for use in later studies. These experiments were 
performed in both CEM cells and SEB activated PBMCs in order to reveal any 
difference in the efficacy of the inhibitors on these cells.  
Incubation of day 10-12 SEB activated PBMCs with LY294002 for 30 minutes, 
prior to stimulation with 10nM of the CXCR4 ligand CXCL12, revealed that 
inhibition of phosphorylation occurs at 10-30μM (Fig. 3.2A). When 10μM of 
LY294002 was incubated with the cells for varying time points, 15-30 minutes 
was shown to be the best time point. When these experiments were repeated 
with Wortmannin, a concentration of 300nM was shown to be most effective 
(Fig. 3.2B). However this concentration was slightly higher than expected, and 
may have off-target effects at this concentration. Theorising that this result could 
be due to the short incubation time of the inhibitor (15 minutes), a concentration 
of 100nM was used to determine the best incubation time. Results showed that 
inhibition of phosphorylation could be achieved, if the compound was incubated 
for a longer time-point of 30 to 60 minutes. Therefore incubation of 100nM 
wortmannin for 30 minutes was used in future experiments. In the original 
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publication of ZSTK474 it was shown that it was more potent that LY294002 
(IC50 of 37nM for ZSTK474 and 790nM for LY294002) (Yaguchi et al., 2006), 
however when used in these cells, the compound was shown to be of a similar 
potency to LY294002, with 10μM inhibiting phosphorylation of Akt (Fig. 3.2C). 
When this concentration was investigated for optimum incubation times, it 
proved difficult to get reliable reproducible results. Generally, inhibition of Akt 
phosphorylation occurred almost immediately, showing reduction after 1-2 
minutes, and then wore off before regaining effect after 15-30 minutes. The 
reasons for this are unknown and were not reported in other publications. To 
ensure complete penetration of the cell by ZSTK474, 30 minutes was used as the 
standard incubation time.  
Incubation of CCL22-stimulated CEM cells with the PI3K inhibitors, while 
revealing some differences in incubation times, showed general similarities in 
the inhibitor profiles. LY294002 inhibited phosphorylation of Akt at Ser473 at a 
concentration of 10μM, and after 15-30 minutes incubation (Fig. 3.3A). This was 
slightly more effective than in PBMCs, although not greatly so, and was 
unexpected. CEM cells lack the 3’phosphatase PTEN (Sakai et al., 1998), a 
phosphatase responsible for the removal of phosphates from the D3 position on 
phosphoinositides, thereby opposing the activity of phosphoinositide 3-kinase 
(PI3K). This causes continuous and sustained activation of PI3K within the 
cells, and is the likely reason for the cells being leukemic. It was thought that 
this sustained activation would result in a requirement for increased 
concentration of inhibitors; however this is not the case for LY294002. 
Wortmannin inhibited phosphorylation at the same concentration in CEM cells 
as in PBMCs (Fig. 3.3B). Again, this concentration was quite high and could be 
due to the short incubation time (15 minutes). Indeed, when used at 100nM, 
wortmannin showed complete inhibition of Akt after 30-60 minutes incubation. 
ZSTK474 was again less efficacious than expected, requiring a concentration of 
10μM to inhibit phosphorylation (Fig. 3.3C). However, the kinetics of this 
inhibitor was much easier to discern in CEM cells, with complete inhibition 
occurring after 30 minutes.  
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Figure 3.2 The effect of PI3K inhibitors on Akt phosphorylation. Day 10-12 
SEB activated PBMCs were incubated with LY294002 (A) Wortmannin (B) or 
ZSTK474 (C) at the times and contentrations shown, then stimulated with 10nM 
CXCL12 for 5 min. Cells were subsequently lysed as described in Materials and 
Methods, and lysates (1 x 106 cells per lane) resolved by SDS-PAGE gel, 
transferred to nitrocelluose membranes, and immunoblotted with a phospho-
specific Akt antibody with affinity for the active Ser473 Phosphorylated form of 
Akt, and protein was visulaised with ECL. The blots were stripped and reprobed 
with pan-Akt antibody to verify equal loading and efficiency of protein transfer. 
Data are representative of at least three separate experiments.  US: unstimulated, 
S: stimulated. 
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Figure 3.3 The effect of PI3K inhibitors on Akt phosphorylation. 
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Figure 3.3 The effect of PI3K inhibitors on Akt phosphorylation. CEM cells 
were incubated with LY294002 (A) Wortmannin (B) or ZSTK474 (C) at the 
times and contentrations shown, then stimulated with 10nM CXCL12 for 5 min. 
Cells were subsequently lysed as described in Materials and Methods, and 
lysates (1 x 106 cells per lane) resolved by SDS-PAGE gel, transferred to 
nitrocelluose membranes, and immunoblotted with a phospho-specific Akt 
antibody with affinity for the active Ser473 phosphorylated form of Akt, and 
protein was visulaised with ECL. The blots were stripped and reprobed with 
pan-Akt antibody to verify equal loading and efficiency of protein transfer. Data 
are representative of at least three separate experiments.  US: unstimulated, S: 
stimulated. 
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3.4 Effect of PI3K inhibition on T lymphocyte chemotaxis 
Once the kinetics of the PI3K inhibitors and their efficacy in inhibiting PI3K had 
been determined, the effects of LY294002, Wortmannin and ZSTK474 on 
chemokine induced migration of T Lymphocytes was investigated. Studies using 
the T lymphocyte cell line, CEM cells, revealed that increasing concentrations of 
the CCR4 agonist CCL22 induced dose-dependent migration of these cells in 
chemotaxis assays, with 10nM CCL22 effecting greatest migration. When cells 
were pre-incubated with 10µM LY294002 for 30 minutes, a concentration 
previously shown to result in PI3K inhibition, no effect on cell migration was 
observed (Fig. 3.4A). Exposure of cells to the CXCR4 agonist CXCL12 also 
resulted in dose-dependent migration, with 10nM CXCL12 also inducing 
maximal response. Interestingly, when these cells were incubated with 10µM 
LY294002 for 30 minutes prior to stimulation with CXCL12, migration was 
partially inhibited (Fig. 3.4A). The basal migration of these cells, migration that 
occurs in the absence of chemokine, was unaffected, indicating that it was the 
directional sensing of these cells and not their motility that was impeded.  
Similar results were seen when using Wortmannin (Fig. 3.4B) and ZSTK474 
(Fig. 3.4C). In each case the pre-incubation with the inhibitor, at 100nM and 
10µM respectively, at doses previously shown to inhibit the action of PI3K had 
no effect on CCL22-stimulated migration. However, when the cells were 
stimulated with CXCL12, inhibition of PI3K resulted in a significant decrease in 
cell migration, although not complete inhibition. Again, no effect on basal cell 
migration was observed. Interestingly, pre-incubation with ZSTK474, a PI3K 
inhibitor resported to be more specific than LY294002 and Wortmannin showed 
less effect on migration, although still significantly inhibited it, possibly 
indicating that at least some of the inhibition of migration could result from off-
target effects. 
Day 10 SEB activated PBMCs were also employed to determine whether PI3K 
has a role in T lymphocyte migration. Stimulation of the cells with increasing 
concentrations of CXCL12 resulted in dose-dependent migration of the cells 
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(Fig. 3.5). This migration showed a different profile to CEM cell migration, with 
maximal migration occurring at 3nM CXCL12. When the cells were pre-
incubated with LY294002 (Fig 3.5A), wortmannin (Fig 3.5B) or ZSTK474 (Fig 
3.5C), no effect was seen on cell migration, a result different to that observed 
with CEM cells, where the PI3K inhibitors inhibited CXCR4 mediated 
migration. This result indicates a difference in CXCR4 mediated signalling 
pathways between CEM cells and activated PBMCs. As PBMCs do not express 
CCR4, experiments to determine the effect of PI3K inhibition on CCL22­
stimulated migration were not performed.  
To determine whether the lack of efficacy of LY294002, wortmannin and 
ZSTK474 in CCL22 mediated migration of CEM cells and CXCL12 mediated 
migration of SEB activated PBMCs was due to the concentrations of inhibitor 
used, higher concentrations of the compounds were tried, including at 
concentrations where the inhibitors were no longer specific. CEM cells were 
incubated with a range of concentrations from 0.3μM to 100μM of the three 
PI3K inhibitors for 30 minutes, and then assayed for their ability to migrate to 
1nM CCL22. Analysis of the results revealed that no significant inhibition of 
migration was seen at concentrations of 30μM for LY294002 and ZSTK474 and 
10μM for wortmannin; concentrations much higher than normal for these 
compounds (Fig 3.6A). Inhibition was seen at 100μM, but this is likely 
explained by the high concentrations of DMSO that the inhibitors were 
dissolved in killing the cells. As expected, a normal inhibitory profile was 
observed for CEM cells migrating to CXCL12 (Fig 3.6B), already shown to be 
sensitive to PI3K inhibitors. When this experiment was repeated using SEB 
activated PBMCs migrating to CXCL12, no inhibition was seen at 
concentrations of 30μM for LY294002 and ZSTK474 and 10μM for wortmannin 
(Fig 3.6C). Again, inhibition was observed at 100μM and was likely due to the 
high concentrations of DMSO. 
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Figure 3.4 The effect of broad-spectrum PI3K inhibitors on CCL22 and 
CXCL12 mediated CEM cell migration. CEM cells were cultured as described 
in Materials and Methods before being treated with LY294002 for 30 min (A), 
Wortmannin for 20 min (B) or ZSTK474 (C) for 30 min. Cells were placed in 
Neuroprobe chemotaxis chambers containing the indicated concentrations of 
CCL22 or CXCL12 and allowed to migrate for 2 hours. Migrated cells were 
then counted using FlowCount Beads on a BD FACSCanto II using BD FACS 
DiVa software. Results are expressed as mean ± SEM, n=4.   
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Figure 3.5 The effect of broad-spectrum PI3K inhibitors on CXCL12 
mediated T lymphocyte migration. Day 10-12 SEB activated PBMCs were 
cultured as described in Materials and Methods before being treated with 
LY294002 for 30 min (A), Wortmannin for 20 min (B) or ZSTK474 (C) for 30 
min. Cells were placed in Neuroprobe chemotaxis chambers the indicated 
various concentrations of CXCL12 and allowed to migrate for 3 hours. Migrated 
cells were then counted using FlowCount Beads on a BD FACSCanto II using 
BD FACS DiVa software. Results are expressed as mean ± SEM, n=4.   
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Figure 3.6 The effect of PI3K inhibitors on cell migration. A migration assay 
was used to determine whether high doses of PI3K inhibitors result in inhibition 
of chemotaxis. CEM Cells (A,B) or Day 10-12 SEB activated PBMCs (C) were 
cultured as described in Materials and Methods before being treated with PI3K 
inhibitors at the indicated doses for 30 minutes (LY294002 and ZSTK474) or 20 
minutes (wortmannin). Cells were placed in Neuroprobe chemotaxis chambers 
containing various concentrations of CCL22 (A) or CXCL12 (B,C) and allowed 
to migrate for 3 hours. Migrated cells were then counted using FlowCount Beads 
on a BD FACSCanto II using BD FACS DiVa software. Results are expressed 
as mean ± SEM, n=4.   
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3.5 Characterisation of the Akt inhibitor Akti-1/2 
To confirm the differing requirements for PI3K in CEM cell and T lymphocyte 
migration mediated by the chemokine receptors CCR2 and CXCR4, the role of 
Akt in mediating migration was investigated. As Akt lies downstream of PI3K 
and is thought to be the main effector of PI3K activation, the role of Akt within 
the cell is assumed to be the same as PI3K and thus the phenotype of any 
inhibition of Akt should mimic PI3K inhibition. Traditionally, inhibition of Akt 
was very difficult, as most inhibitors had many off-target effects, especially with 
similar kinases, such as the MAPK family.  
A new type of Akt inhibitor has been synthesised (Zhao et al., 2005b), with a 
different mechanism of action to other Akt inhibitors. Although not yet fully 
determined, it does not act through the ATP binding pocket, and instead is 
though to bind the hinge region of the protein between the active site and the PH 
domain. Once bound, the inhibitor prevents the kinase from unfolding upon 
binding to the phospholipid membrane, and thus preventing the active site from 
binding to downstream kinases. Previous studies have revealed that although 
Akti- 1/2 does not bind to or inhibit PDK-1 or the mTOR-RICTOR complex; it 
does prevent the phosphorylation of Akt at sites Ser473 and Thr308 (Barnett et 
al., 2005). This allows easy determination of Akt inhibition by analysis of 
phosphorylation at these sites. 
To test the efficacy of this inhibitor, as well as determine the optimum 
concentration and incubation time points for the inhibitor, CEM cells and SEB 
activated PBMCs were pre-incubated with Akti- 1/2 before stimulation with 
10nM CXCL12 for five minutes. Incubation of CEM cells with increasing 
concentrations of the inhibitor revealed that complete inhibition of Ser473 
phosphorylation occurred at 1-10µM after incubation for 30 minutes (Fig. 3.7A). 
When the cells were incubated with 10µM Akti- 1/2, incubation times of 1 
minute were shown to be sufficient to abrogate Ser473 phosphorylation. 
Similarly, when activated PBMCs were incubated with Akti-1/2, it was revealed 
that concentrations of 1µM and incubation times of one minute were sufficient 
to inhibit Akt, showing that the inhibitor has strong efficacy (Fig. 3.7B). 
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A phosphor-array assay was used to help confirm the specificity of this inhibitor. 
This assay works on similar principles to immunoblotting, but tests the 
phosphorylation state of many different kinases at the same time.  A phosphor-
array against members of the MAPK family was used, as this family was the 
most likely to be affected by inhibitors of Akt. SEB activated PBMCs were 
incubated with 10µM Akti- 1/2 for 30 minutes prior to stimulation with 10nM 
CXCL12 for 5 minutes. Alongside this, cells were incubated with DMSO at the 
same quantity as in the inhibitor, to act as a vehicle control prior to stimulation 
with 10nM CXCL12 for 5 minutes. The cells were lysed and the resulting 
lysates incubated with the array which contained phosphor-specific antibodies 
pre-bound to nitrocellulose membrane. Subsequent analysis of the spots revealed 
that of the 17 kinases tested, the only ones that were significantly inhibited by 
the Akti-1/2 inhibitor were Akt1, Akt2, Akt3, GSK-3α and GSK-3β (Fig. 3.8). It 
was expected that phosphorylation levels of GSK-3 would also be affected, as 
these kinases lie downstream of Akt. It was interesting that Akt3 was also 
inhibited, as the Akti-1/2 inhibitor has not previously been shown to bind to this 
protein, and this result should be noted when interpreting future results. The 
inhibitor showed no effect on the MAP kinases, proving the specificity of this 
inhibitor. Levels of the total Akt proteins were not affected, nor HSP27 (a 
control protein), indicating that the inhibitor has no detrimental effects on the 
cell by causing immediate cell death. To confirm this result using more rigorous 
assays, its effects on cell death were investigated using a Typan blue assay. 
Day 10 SEB activated PBMCs, and CEM cells were incubated with 10µM Akti­
1/2 for various time points up to four hours in RPMI 1640. Cells were then 
washed twice in media, and stained with Trypan Blue. Trypan Blue is a blue dye 
that cannot pass through the intact cell membrane, therefore only cells with a 
permeated membrane, e.g. those who are dead or dying, will be stained blue. 
The cells were placed in a haemocytometer, and the number of healthy cells 
counted. No statistically significant difference was seen between cells treated 
with the inhibitor, and those left untreated, for either CEM cells (Fig. 3.9A) or 
PBMCs (Fig. 3.9B). This result indicates that the inhibitor has no effect on cell 
survival for the incubation times used. 
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Figure 3.7 The effect of Akt inhibition on Akt phosphorylation. Day 10-12 
SEB activated PBMCs (A) or CEM cells (B) were incubated with Akti-1/2, then 
stimulated with 10nM CXCL12 for 5 min. Cells were subsequently lysed as 
described in Materials and Methods, and lysates (1 x 106 cells per lane) resolved 
by SDS-PAGE gel, transferred to nitrocelluose membranes, and immunoblotted 
with a phospho-specific Akt antibody with affinity for the active Ser473 
Phosphorylated form of Akt, and protein was visulaised with ECL. The blots 
were stripped and reprobed with pan Akt antibody to verify equal loading and 
efficiency of protein transfer. Data are representative of at least three separate 
experiments.   
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Figure 3.8 The inhibition of MAPK-family Kinases by Akti-1/2. A phospho-
array assay was used to determine the off target effects, if any, of Akti-1/2 on 
the MAPK family. Day 11 SEB activated PBMCs were cultured as described in 
Materials and Methods. On day 11 of culture, after 24hrs in the absence of IL-2, 
cells were incubated with 10μM Akti-1/2 or DMSO (control) for 30 minutes 
prior to 5 minutes stimulation with CXCL12. The cells were then lysed and the 
lysate incubated with the nitrocellulose membrane as described in Materials and 
Methods. Unbound cell lysate was washed off, and the membrane targeted with 
HRP-tagged secondary antibody. ECL was used to visualise the proteins. The 
developed films were scanned onto a computer, and the pixel density of the 
spots was calculated using Adobe® Photoshop. All antibodies shown are 
phospho-antibodies with the exception of those labelled “pan” and the control 
protein, HSP27. Results are expressed as Mean ± SEM, n=3. Students t-test, * 
p<0.05, ** p<0.01. 
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Figure 3.9 The effect of Akti- 1/2 on cell death. A cell death assay using 
Trypan Blue was utilised to determine the effect of Akti-1/2 incubation over a 
prolonged period of time on cell mortality. CEM cells (A) or Day 10-11 SEB 
activated PBMCs (B) were incubated with Akti-1/2 for 30, 60 or 240 minutes, 
or not exposed to the inhibitor, before 50μL of cells were mixed with 50μL of 
Trypan Blue. The number of stained (dead) cells was counted using a 
haemocytometer as described in Materials and Methods. Results are expressed 
as Mean ± SEM, n=5.  
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3.6 The Role of Akt in T lymphocyte chemotaxis 
To investigate the role of Akt in T lymphocyte migration, and confirm the 
differing requirements for Akt between SEB activated PBMCs and CEM cells, 
both types of cells were preincubated with the inhibitor prior to their use in a 
chemotaxis assay.  
Cells were pretreated with varying concentrations of Akti-1/2 from 0.3µM to 
30µM for 30 minutes. The cells were then washed in RPMI 1640 before their 
addition to a Neuroprobe Chemotaxis plate. Four different concentrations of 
chemokine were used in the assay as well as a control. Each concentration of 
inhibitor was run in triplicate against each concentration of chemokine, and each 
experiment was repeated a minimum of four times. After the cells had migrated 
for three hours, the number of migrated cells was assessed using Flow 
Cytometry and FlowCount beads. 
Analysis of the results revealed that pre-incubation with the inhibitor 
significantly inhibited the migration of CEM cells (Fig. 3.10). Interestingly, this 
occurred for both CXCL12 and CCL22 mediated migration, and not just for 
CXCL12 as with PI3K inhibition. The number of cells that migrated to 10nM of 
the chemokines (the maximum migration) was used to determine the percentage 
maximum migration for each inhibitor. This information was then used to 
construct an IC50 graph for each chemokine. IC50 is a measure of the 
concentration of inhibitor needed to inhibit 50% of the response, and is used as 
a measure of the inhibitors potency. CCL22 mediated migration of CEM cells 
was inhibited with an IC50 of 7.3µM (Fig. 3.10A), while CXCL12 mediated 
migration was inhibited with an IC50 of 9.15µM (Fig 3.10B). These values, 
while not particularly potent, reveal that this inhibitor causes significant 
inhibition of migration. 
Using Akti-1/2 in T lymphocyte migration revealed that Akt has an important 
role in CXCL12 mediated migration. Pre-incubation of day 10-12 SEB activated 
PBMCs with varying concentrations of the inhibitor resulted in significant dose-
dependent inhibition of migration, with 30µM of the inhibitor almost 
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completely abrogating the migratory response (Fig 3.11). Using the maximal 
migration concentration of 1µM CXCL12 to plot an IC50 graph revealed that 
Akti-1/2 inhibited migration of PBMCs with an IC50 of 0.86µM, indicating that 
Akti-1/2 is more potent at inhibiting T lymphocyte migration than CEM cell 
migration. 
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Figure 3.10 The effect of the broad-spectrum Akt inhibitor Akti- 1/2 on 
CCL22 and CXCL12 mediated CEM cell migration. Chemotaxis assays 
were used to determine the role of Akti-1/2 in CEM cell migration. CEM cells 
were cultured as described in Materials and Methods before being treated with 
Akti- 1/2 for 30 min. Cells were placed in Neuroprobe chemotaxis chambers 
containing various concentrations of CCL22 (A) or CXCL12 (B) and allowed to 
migrate for 2 hours. Migrated cells were then counted using FlowCount Beads 
on a BD FACSCanto II using BD FACS DiVa software. Results are expressed 
as mean ± SEM, n=3.   
96
 
C
el
l N
um
be
r 
6000 
4000 
2000 
0 
0 
0.3 
1 
3 
10 
30 
0 0.1 1 10 100 1000 
CXCL12 (nM) 
0 
20 
40 
60 
80 
100 
1nM CXCL12 
IC50 = 0.86μM
%
 M
ax
im
um
 M
ig
ra
tio
n 
-8 -7 -6 -5 -4 -3 
Log [Akti- 1/2] 
Figure 3.11 The effect of the broad-spectrum Akt inhibitor Akti-1/2 on 
CXCL12 mediated T lymphocyte migration. A chemotaxis assay was used to 
determine the role of Akti-1/2 in T lymphocyte migration. Day 10-12 SEB 
activated PBMCs were cultured as described in Materials and Methods before 
being treated with Akti- 1/2 for 30 min. Cells were placed in Neuroprobe 
chemotaxis chambers containing various concentrations of CXCL12 and 
allowed to migrate for 3 hours. Migrated cells were then counted using 
FlowCount Beads on a BD FACSCanto II using BD FACS DiVa software. 
Results are expressed as mean ± SEM, n=3.   
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3.7 The effect of PI3K and Akt inhibitors on Akt activity 
The surprising result that PI3K inhibitors had no effect on CCL22 mediated 
CEM cell migration or CXCL12 mediated T lymphocyte migration, while 
inhibition of Akt, a kinase downstream of PI3K, abrogated chemotaxis, required 
further investigation. It was theorised that this result could be explained if, 
although both PI3K inhibitors and Akt inhibitors have been shown to have 
similar effects of Akt phosphorylation, they had differing effects on Akt 
activity. To test this, a system that directly measured Akt activity, as opposed to 
Akt phosphorylation, was utilised. The Omnia® Lysate Assay system uses 
fluorophores attached to substrate peptides specific for Akt. Upon 
phosphorylation of the peptide by Akt, a change in fluorescence occurs, 
allowing measurement of Akt activity. 
Measurement of Akt activity in CCL22-stimulated CEM cells incubated with 
LY294002 revealed that only high concentrations of the compound resulted in 
inhibition (Fig 3.12A). These concentrations were greater than those used in the 
chemotaxis assays, and may have off-target effects. This result was the same for 
Wortmannin (Fig 3.12B) and ZSTK474 (Fig 3.12C) as well. Interestingly, Akti­
1/2 was more potent at inhibiting Akt activity than PI3K inhibitors, inhibiting 
Akt at concentrations similar to those used in chemotaxis assays, and at 
concentrations where the inhibitor is believed to be specific (Fig 3.12D). When 
this experiment was repeated for CEM cells stimulated with 10nM CXCL12, 
which induced migration that was inhibited by PI3K inhibitors, the results 
revealed that all of the inhibitors reduced Akt activity in a statistically-
significant way, at concentrations similar to those used in the migration assays. 
Indeed, LY294002 reduced Akt activity at concentrations as low as 1µM (Fig 
3.13A), while Wortmannin reduced Akt activity at 100nM (Fig 3.13B) and 
ZSTK474 at 1µM (Fig 3.13C). Akti-1/2 was slightly more potent against 
CXCL12-stimulated cells compared to CCL22-stimulated cells, with significant 
inhibition beginning to occur at 1µM (Fig 3.13D). 
Analysis of Akt activity in CXCL12-stimulated SEB activated PBMCs revealed 
that while the levels of Akt activity are lower in unstimulated cells and higher in 
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stimulated cells when compared to CEM cells (Fig 3.14), the effect of PI3K and 
Akt inhibitors on Akt activity was similar to CCL22-stimulated CEM cells, the 
other PI3K-independent migration model. Only incubation with high 
concentrations of LY294002 (Fig 3.14A), Wortmannin (Fig 3.14B) and 
ZSTK474 (Fig 3.14C) resulted in a reduction in Akt activity, at concentrations 
higher than those used in chemotaxis assays. Akt-1/2 significantly reduced Akt 
activity at concentrations from 1µM, a concentration where the compound is 
still selective and similar to those that caused inhibition of migration.  
These results help to explain the differences between the inhibitors and their 
effects of cell migration, and also demonstrate a difference between Akt 
phosphorylation and Akt activity, revealing that Akt phosphorylation is not 
necessarily the best way of measuring Akt activity.   
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Figure 3.12 The effect of PI3K and Akt inhibitors on Akt activity of CEM 
cells. 
Please see the next page for legend 
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Figure 3.12 The effect of PI3K and Akt inhibitors on Akt activity of CEM 
cells. An Akt activity assay was used to determine the efficacy of Akt and PI3K 
inhibitors in Akt inhibition. CEM cells were incubated with LY294002 (A) 
Wortmannin (B) ZSTK474 (C) or Akti-1/2 (D) for 30 min then stimulated with 
10nM CCL22 for 5 min and lysed. Resulting Akt activity was assessed using 
Akt activity assay as described in Materials and Methods. Results shown as 
change in the rate of phosphorylation, which corresponds to change in the rate 
of flourescence of target peptides by Akt. Results are expressed as mean ± 
SEM, n=4. One-way ANOVA * p<0.05, ** p<0.01. Stim, Stimulated 
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Figure 3.13 The effect of PI3K and Akt inhibitors on Akt activity of CEM 
cells. An Akt activity assay was used to determine the efficacy of Akt and PI3K 
inhibitors in Akt inhibition. CEM cells were incubated with LY294002 (A) 
Wortmannin (B) ZSTK474 (C) or Akti-1/2 (D) for 30 min then stimulated with 
10nM CXCL12 for 5 min and lysed. Resulting Akt activity was assessed using 
Akt activity assay as described in Materials and Methods. Results shown as 
change in the rate of phosphorylation, which corresponds to change in the rate 
of flourescence of target peptides by Akt. Results are expressed as mean ± 
SEM, n=4. One-way ANOVA ** p<0.01. Stim, Stimulated 
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Figure 3.14 The effect of PI3K and Akt inhibitors on Akt activity of 
PBMCs. Please see the next page for legend 
104 
Figure 3.14 The effect of PI3K and Akt inhibitors on Akt activity of 
PBMCs. An Akt activity assay was used to determine the efficacy of Akt and 
PI3K inhibitors in Akt inhibition. PBMCs were incubated with LY294002 (A) 
Wortmannin (B) ZSTK474 (C) or Akti-1/2 (D) for 30 min then stimulated with 
10nM CCL22 for 5 min and lysed. Resulting Akt activity was assessed using 
Akt activity assay as described in Materials and Methods. Results shown as 
change in the rate of phosphorylation, which corresponds to change in the rate 
of flourescence of target peptides by Akt. Results are expressed as mean ± 
SEM, n=4. One-way ANOVA ** p<0.01. Stim, Stimulated 
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3.8 The role of GSK-3 in T lymphocyte migration 
GSK-3 is a protein kinase shown to be phosphorylated by Akt at Ser9. GSK-3 is 
unusual among protein kinases in that in its unphosphorylated state it is active, 
and it’s phosphorylation that causes it to become inactive. GSK-3 has a role in 
inhibiting glycogen synthase and thus leading to an increase in glucose, 
essential for energy production and a process that is important in cell migration. 
Therefore, GSK-3 was investigated to determine whether it was involved in cell 
migration, and to help confirm a role for Akt. 
In 2003, the inhibitor 6-Bromoindirubin-30-oxime (BIO) was released (Meijer 
et al., 2003a). This inhibitor showed much stronger selectivity for GSK-3 than 
classic inhibitors for GSK-3 such as lithium, Staurosporine or Flavopiridol and 
for this reason was used to investigate the role of GSK-3 in cell migration. As 
phosphorylation of GSK-3 by Akt leads to a loss of GSK-3 activity, use of 
GSK-3 inhibitors can be said to mimic the actions of Akt. As such, it also makes 
a good tool to investigate the role of Akt and its effect on GSK-3 in migration. 
To test the effect of BIO on GSK-3 inhibition, concentrations of the inhibitor 
from 0.3µM to 30µM were incubated with CEM cells for either 30 or 60 
minutes. The effect on GSK-3 was assessed using beta-catenin. As the inhibitor 
prevents phosphorylation of GSK-3, direct assessment of its activity is difficult 
to determine. However, GSK-3 is also involved in a different pathway to the 
PI3K/Akt/GSK-3 pathway. This pathway, the Wnt/beta-catenin pathway, is 
involved in gene transcription. GSK-3, bound to APC (adenomatosis polyposis 
coli), becomes complexed with beta-catenin and Axin (a scaffolding protein). 
This complex increases the activity of GSK-3, resulting in an increase in the 
phosphorylation of beta-catenin. When beta-catenin is phosphorylated, it 
becomes targeted for degradation through the ubiquitination pathway. 
Therefore, inhibition of GSK-3, through the actions of BIO, prevents the 
phosphorylation and subsequent degradation of beta-catenin, leading to an 
increase in the levels of beta-catenin. This increase can be measured using 
immuno-blotting and an antibody that binds beta-catenin, providing a method 
for determining BIO’s activity. This assay revealed that BIO inhibits GSK-3 
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and prevents the subsequent phosphorylation of beta-catenin, at concentrations 
of 3µM and 10µM, although this effect is less strong at 30µM (Fig 3.15). The 
optimal incubation time was 30 minutes, to prevent toxicity on the cells.  
The effect of BIO and subsequent inactivation of GSK-3 on T lymphocyte 
migration was investigated using both CEM cells, and day 10-12 SEB activated 
PBMCs. Interestingly, although not unexpectedly as Akt activation and 
therefore GSK-3 inhibition is required for migration, incubation of BIO actually 
increased levels of migrating CEM cells to CCR4 in a concentration-dependent 
fashion, with 10µM of the compound providing maximal response (Fig 3.16). 
As BIO mimics the effect of Akt activation, this increase in migratory levels 
underscores the importance of Akt in migration. 
One explanation for the increase in the number of migrating cells could be that 
GSK-3 has a role in chemokinesis (random cell movement) rather than 
chemotaxis (directional cell migration). In the migration assay, the increase in 
migrating cells was significant only during chemotaxis, i.e. when chemokine 
was present, and not during chemokinesis. However to confirm this, a 
chequerboard analysis was performed. This analysis uses a standard chemotaxis 
assay, but with varying concentrations of chemokine in both the upper and 
lower chambers. In those wells where the concentration of chemokine in both 
the upper and lower wells is the same, then there can be no chemokine gradient, 
and any resulting movement in cells to the bottom chamber must be due to an 
increase in chemokinesis.  
Analysis of the results from this assay using CCL22-stimulated CEM cells 
revealed that in the absence of BIO, CEM cells migrate normally to CCL22 
(vertical yellow bar) and that some of the CCL22 induced cell movement is 
chemokinetic (diagonal yellow bar), although to a much lesser extent than 
chemotaxis, as determined by comparing cell numbers (Fig 3.17). When this 
experiment was repeated in the presence of 1µM BIO, the number of cells that 
migrated was significantly increased, but the number of cells that underwent 
chemokinesis stayed the same, indicating that GSK-3, and therefore Akt, are 
involved in the directional movement of cells. 
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Figure 3.15 The effect of BIO on intercellular beta-catenin. Immunoblotting 
was used to determine the optimum concentration and incubation time of BIO in 
CEM cells. CEM cells were incubated with the GSK-3 inhibitor BIO at the 
times and contentrations shown, then lysed as described in Materials and 
Methods. Lysates (1 x 106 cells per lane) were resolved by SDS-PAGE gel, 
transferred to nitrocelluose membranes, immunoblotted with a anti-beta-catenin 
antibody and protein was visulaised with ECL. The blots were stripped and 
reprobed with pan Akt antibody to verify equal loading and efficiency of protein 
transfer. Data are representative of at least three separate experiments.   
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Figure 3.16 The effect of the GSK-3 inhibitor BIO on CCL22 mediated 
CEM cell migration. A chemotaxis assay was used to determine the role of 
GSK-3 in CEM cell migration. Rested CEM cells were cultured as described in 
Materials and Methods before being treated with GSK-3 for 30 min. Cells were 
placed in Neuroprobe chemotaxis chambers containing various concentrations 
of CCL22 and allowed to migrate for 2 hours. Migrated cells were then counted 
using FlowCount Beads on a BD FACSCanto II using BD FACS DiVa 
software. Results are expressed as mean ± SEM, n=3.   
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Top Well CCL22 
0nM 0.1nM 1nM 10nM 
Bottom Well 0nM 4577 4207 3802 2540 
CCL22 0.1nM 15157 7690 4358 1256 
1nM 30010 19710 16390 1237 
10nM 20603 20097 16820 15343 
Top Well CCL22 + 1uM BIO 
0nM 0.1nM 1nM 10nM 
Bottom Well 0nM 3130 3950 2397 1982 
CCL22 0.1nM 27230 8300 5057 4417 
"+ 1uM BIO" 1nM 51803 46657 17426 9783 
10nM 30883 19290 17897 14590 
Table 3.1 The effect of BIO on cell chemokinesis. Two chequerboard analyses 
were performed to determine whether the increase in cell migration after 
incubation of cells with BIO is a result of an increase in cell chemokinesis. 
Rested CEM cells were cultured as described in Materials and Methods before 
pre-treatment with 1μM BIO for 30 min (lower table) or left untreated (upper 
table) for 30 min. Cells were placed in Neuroprobe chemotaxis chambers 
containing various concentrations of CCL22 in both upper and lower chambers 
and allowed to migrate for 2 hours. Migrated cells were then counted using 
FlowCount Beads on a BD FACSCanto II using BD FACS DiVa software. 
Results are expressed as number of migrating cells. Data are representative of 
four separate experiments.  
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3.9 The role of PKCδ in migration 
Previous studies within the Ward laboratory revealed a role for a calcium 
independent, diacylglycerol (DAG) dependent protein kinase in CCR4 mediated 
migration of CEM cells (Cronshaw et al., 2006). Protein Kinase C delta (PKCδ) 
is a serine/threonine kinase that plays a role in growth regulation and tissue 
remodelling.  It is one of the novel isoforms of PKC which are activated by 
DAG and lipid binding alone, as opposed to conventional isoforms which 
require the presence of Ca2+ in addition to DAG and lipid binding, and atypical 
isoforms which are activated solely by phosphorylation. As PKCδ fits the 
criteria, and has previously been implicated in cell migration (Fanning et al., 
2005b; Iwabu et al., 2004b), it was investigated regarding its role in T 
lymphocyte chemotaxis.  
In addition to PKCδ’s dependence on PI3K for activation through its production 
of PIP3, which is subsequently broken down by phospholipase C to form DAG; 
essential for activation, it should also be noted that most PKC’s require 
phosphorylation at the activation loop in order to prime and stabilise the kinase 
in an active form. PDK-1 has been shown to be responsible for phosphorylation 
of PKCδ at Thr505 on the activation loop (Steinberg, 2004; Le Good et al., 
1998). Although there is some debate as to whether this phosphorylation is 
important in activation of the kinase, or just for its subsequent stabilisation 
(Stempka et al., 1997b), it does appear that PI3K, via the downstream kinase 
PDK-1, is involved in PKCδ activation. Therefore, a role for PKCδ in 
chemotaxis could also help to confirm a role for PI3K. 
To confirm whether PKCδ is present in T cells and activated during chemotaxis, 
CEM cells were stimulated with the chemokine CCL22 for 2 minutes. The cells 
were then lysed and immunoblotted with an antibody that recognises Thr505, 
the residue phosphorylated by PDK-1. Analysis of the result revealed that 
phosphorylation of Thr505 occurs after stimulation with 0.3nM and 1nM 
CCL22 (Fig 3.17). To confirm whether this result was PI3K dependent, cells 
were also pretreated with 10µM LY294002 prior to stimulation. Interestingly, 
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although LY294002 did partially reduce phosphorylation, it was not fully 
abrogated. 
Rottlerin is marketed as a PKCδ-selective inhibitor that uncouples 
mitochondria, decreasing cellular ATP and thus indirectly blocking PKCδ. To 
test whether PKCδ was involved in chemotaxis of CEM cells, Rottlerin was 
used in a chemotaxis assay. CEM cells were pre-incubated with several different 
concentrations of Rottlerin, and then allowed to migrate to 1nM CCL22. 
Analysis of the results revealed that Rottlerin significantly inhibited chemotaxis 
in a dose dependent manner, indicating that PKCδ was important in migration 
(Fig. 3.18). 
Subsequent to this result, several papers were published questioning the 
selectivity of Rottlerin towards PKCδ (Soltoff, 2007), and indicating that it may 
in fact target other kinases (Alonso et al., 2008). As there are currently no other 
selective inhibitors of PKCδ, an alternative method had to be used to determine 
the role of PKCδ in chemotaxis. Research performed within the lab has 
demonstrated the limitations of siRNA for migration assays of suspension cells 
(Smith et al., 2007) and so this system was not used. Therefore, PKCδ null mice 
were employed to determine the role of PKCδ in migration. 
Spleens from both PKCδ-/- and wildtype C57Bl/6 mice were disaggregated and 
the red blood cells lysed. T cells were negatively selected from the remaining 
population of cells using a MACS murine T cell sorting kit. The murine PBMCs 
were cultured in ConA and IL-2 for 3 days to activate them, prior to their use. 
An antibody was not available to test the expression of CCR4 on these cells, but 
previous studies had already identified CCR4 as being present on murine T cells 
(Youn et al., 1997). The cells were placed in a chemotaxis assay with varying 
concentrations of murine CCR4 and after 3 hours, the number of migrated cells 
was counted using flow cytometry. Analysis of the results revealed that CCL22 
caused the splenocytes to migrate but that significantly fewer cells from the 
knockout mice migrated to both chemokines (Fig. 3.19). As the only difference 
between the cells is the lack of PKCδ, this result reveals a role for PKCδ in T 
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lymphocyte migration. Interestingly, migration was not completely abrogated, 
indicating the presence of a non PKC delta-dependent pathway.  
Anti-Phospho­
PKCδ  Thr505 

Anti-PKCδ
 
78kDa 
78kDa 
C 0.3 1 C 0.3 1 

nM CCL22 
+ 10μM LY294002 
Figure 3.17 The effect of CCL22 stimulation on PKCδ phosphorylation.   
Immunoblotting was used to determine whether stimulation with CCL22 results 
in phosphorylation of PKC delta at Thr505, and the role of PI3K in this process. 
CEM cells were incubated with the LY294002 for 30 minutes at the 
contentration shown, then lysed as described in Materials and Methods. Lysates 
(2.5 x 106 cells per lane) were resolved by SDS-PAGE gel, transferred to 
nitrocelluose membranes, blotted with a phospho-specific PKCδ antibody with 
affinity for the active Thr505 phosphorylated form of PKCδ, and protein was 
visulaised with ECL.. The blots were stripped and reprobed with pan PKCδ 
antibody to verify equal loading and efficiency of protein transfer. Data are 
representative of at least three separate experiments.   
113
 
C
el
l N
um
be
r 
9000
 
8000
 
7000
 
6000
 
5000
 
4000
 
3000
 
2000
 
1000
 
0 
0 -7 -6 -5 -4 
log [Rottlerin] 
Figure 3.18 The effect of the PKC delta inhibitor Rottlerin on CCL22 
mediated CEM cell migration. A migration assay was used to determine 
whether PKCδ is important in CEM cell migration. CEM cells were cultured as 
described in Materials and Methods before being treated with Rottlerin for 30 
min at the concentrations shown. Cells were placed in Neuroprobe chemotaxis 
chambers containing 1nM CCL22 and allowed to migrate for 2 hours. Migrated 
cells were then counted using FlowCount Beads on a BD FACSCanto II using 
BD FACS DiVa software. Results are expressed as mean ± SEM, n=3.   
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Figure 3.19 The ability of wildtype and PKCδ-/- murine splenocytes to 
migrate to CCL22. A migration assay was used to determine whether PKCδ is 
important in the migration of murine splenocytes. Murine splenocytes were 
disaggregated, sorted and cultured as described in Materials and Methods. The 
cells were starved of IL-2 for 24 hours prior to use. Wildtype and knockout cells 
were placed in Neuroprobe chemotaxis chambers containing varying 
concentrations of CCL22 and allowed to migrate for 3 hours. Migrated cells 
were then counted using FlowCount Beads on a BD FACSCanto II using BD 
FACS DiVa software. Results are expressed as mean ± SEM, n=4.   
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3.10 Summary 
•	 Using the T lymphocyte cell line CEM cells and SEB activated 
lymphocytes; this study has shown that stimulation by the chemokines 
CXCL12 and CCL22 results in activation of PI3K. 
•	 In addition, stimulation with these chemokines results in robust 
migratory responses in both cell types. However, CCL22 mediated 
migration of CEM cells and CXCL12 mediated migration of PBMCs are 
unaffected by inhibition of PI3K using a panel of PI3K inhibitors. 
•	 Using an inhibitory compound specific for Akt, studies revealed that Akt 
was critical for migration of both cell types to CXCL12 and for CEM 
cell migration to CCL22. The different effects on migration between Akt 
and PI3K inhibitors were shown to be as a result of their differing effects 
on Akt activity. 
•	 GSK-3, a protein downstream of PI3K in several signalling pathways 
was shown to be also involved in migration. Inhibition of GSK-3 
resulted in an increase in the number of migrating cells, and this was 
shown to be because of an increase in chemotaxis and not chemokinesis. 
•	 Another protein thought to be downstream of PI3K signalling, PKCδ, 
which previous studies indicated had a role in migration, was shown to 
be activated by CCL22. Using murine splenocytes, a role for PKCδ in 
the migration of PBMCs was observed. 
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3.11 Discussion 
The aim of this part of the study was to gain insight into the role of 
Phosphoinositide 3-Kinase  (PI3K), and other kinases shown to be downstream 
of PI3K in several signalling pathways, in T lymphocyte migration. This 
involved investigating several different inhibitors for their effects on cell 
migration, including inhibitors of PI3K, Akt and GSK-3. However, before this 
work could be carried out, the expression of chemokine receptors on T 
lymphocytes, as well as the optimum concentration of PI3K inhibitors had to be 
determined. 
3.11.1 The contribution of PI3K to CEM cells and PBMC 
chemotaxis. 
The dependence of PI3K in the role of directed cell migration has been well 
established (Hannigan et al., 2004; Barber and Welch, 2006; Sasaki and Firtel, 
2006), although previous studies have revealed that PI3K was a dispensable 
signal during CEM cell and activated PBMC migration (Cronshaw et al., 2004; 
Smith et al., 2007). These studies had been performed using the broad spectrum 
inhibitors of PI3K; LY294002 and Wortmannin, which have been shown to 
have off target effects, including mTOR, CK2 and polio-like kinase. (Gharbi et 
al., 2007; Liu et al., 2005). Recently, a PI3K inhibitor that inhibits all PI3K 
isoforms, but shows no activity against protein kinases has been developed 
(Yaguchi et al., 2006). This compound, ZSTK474, was used alongside 
LY294002 and Wortmannin to determine the role of PI3K in T lymphocyte 
migration. This revealed that although all three inhibitors reduced Akt 
phosphorylation, a surrogate marker for PI3K activity, they failed to inhibit 
migration of CEM cells to CCL22 or SEB activated PBMCs to CXCL12. 
Interestingly, CEM cell migration to CXCL12 was dependent on PI3K. This 
demonstrates a difference in chemokine receptor signalling pathways within a 
cell, as well as a difference between the same chemokine receptor in different 
cells. 
Several other studies have also noted PI3K independence during chemotaxis. 
Smit et al. (Smit et al., 2003a) have showed that CXCR3-mediated migration of 
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T cells was regulated through a phospholipase C-dependent pathway as opposed 
to a PI3K/Akt pathway. In this study, the authors suggested that migration could 
still be mediated through a PI3K class II isoform, however LY294002 has been 
shown to inhibit this class of PI3K making this explanation unlikely. Another 
study (Lacalle et al., 2004) showed that PTEN, the phosphatase that converts 
PIP3 into PIP2, regulates motility but not directionality in chemotaxis. This 
indicates a role for PI3K in migration but not directed migration.  
SEB activated PBMCs are cultured in IL-2 prior to use. Culture in IL-2 has been 
shown to lead to a loss of the requirement for PI3K during chemotaxis while 
maintaining the requirement during chemokinesis (Smit et al., 2003b; Smith et 
al., 2007). Therefore the lack of PI3K-dependent migration may be a result of 
culture in IL-2 as opposed to a fundamentally different pathway. Further work 
exploring the migration of PBMCs using other chemokine receptors would be 
needed to confirm this.  
3.11.1.1 If not PI3K then what? 
If PI3K is not responsible for the migration of these cells, what is? One 
candidate for the role is the Rac-specific Guanine Nucleotide Exchange Factor 
DOCK-2. Mice that lack the gene for DOCK-2 show a lack of migration of 
lymphocytes to several chemokines, while PI3K/Akt signalling was unaffected 
(Fukui et al., 2001). In addition, studies using these mice revealed that T 
lymphocytes can still mount a chemotactic response through p110γ in the 
absence of DOCK-2. Interestingly, in neutrophils, where PI3K has been shown 
to play a vital role in migration, DOCK-2 is not present (Nishihara et al., 1999). 
Another possibility is Phospholipase C (PLC). A study in 2007 used mice 
lacking the PLCβ isoforms of PLC to demonstrate significantly impaired T 
lymphocyte migration. This corresponds with another study (Cronshaw et al., 
2006), which also showed the importance of PLC; however the two studies 
differed on the importance of calcium mobilisation during this process. 
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Finally, a recent paper has implicated PKCθ as an important kinase in PI3K­
independent chemotaxis. Using a PKCθ-specific inhibitor, they discovered that 
PKCθ was vital for migration in the PI3K-independent model of migration 
using CXCL12-mediated chemotaxis of IL-2 cultured T lymphocytes (Shahabi 
et al., 2008). 
3.11.2 A role for Akt in T lymphocyte migration 
Akt has long been described as a kinase downstream of PI3K. Phosphorylation 
of Akt is often used as a marker of PI3K activity, and many publications make 
reference to the PI3K / Akt pathway. To confirm the PI3K independence of 
CCR4-mediated CEM cell migration and CXCR4-mediated PBMC migration, 
an inhibitor against the two most common isoforms of Akt; Akt1 and Akt2, was 
used (Lindsley et al., 2005; Zhao et al., 2005b). Use of this inhibitor revealed 
that chemotaxis in all three models of cell migration was significantly reduced. 
To confirm that the loss of migration was not due to cell death, a trypan blue 
cell death assay was performed that showed the inhibitor had no effect on cell 
mortality during the incubation period.  
One possible explanation for this effect is that Akti-1/2 is having off target 
effects. To test this, Akti-1/2 was screened against a panel of kinases and was 
shown to have no effect. However, a paper has recently been published showing 
that this inhibitor does have the ability to potentiate protease-activated factor 1 
(PAR-1). While this protein is only found in platelets, and to a lesser extent on 
myocytes and neurones (Macfarlane et al., 2001), and so is unlikely to explain 
this result in T lymphocytes, it does raise the question of what other off-target 
effects there are. As the inhibitor is still new, little independent work has been 
undertaken to confirm its selectivity, but this is something that will need to be 
completed before this result can be fully confirmed.  
Another explanation for this result could be that Akt is being activated 
independently of PI3K. A paper published in 2001 (Sonnenburg et al., 2001) 
revealed that PDK-1, the kinase shown to phosphorylate Akt at Thr308, 
phosphorylated PKCα independently of PI3K and PIP3. However, this paper 
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also specifically mentions that Akt phosphorylation was inhibited during this 
process. Another paper looked at the activity of PDK-1 and Akt in nematode 
worms. Using gain-of-function and loss-of-function mutants, they showed the 
interdependence of the nematode homologues of PDK-1 and Akt, which could 
be active even in the absence of AGE-1, the nematode homologue for PI3K 
(Gami et al., 2006).  However, aside from these two articles, there is no mention 
of PI3K-independent Akt activation. Therefore, other explanations for this result 
were sought. 
3.11.2.1 Differences in effect on Akt activity 
It was theorised that this result could be explained by differences in the effect of 
the inhibitors on Akt activity. While Akt activity had already been measured 
through phosphorylation, a more quantitative system that directly measured Akt 
activity was utilised. This system, which measures Akt’s ability to 
phosphorylate a target peptide, revealed significant differences in the ability of 
the PI3K inhibitors and the Akt inhibitor to affect Akt activity. This can also be 
seen in the Immunoblots showing phosphorylation of Akt. The Akt inhibitor 
sharply decreased Akt activity as well as quickly and potently inhibiting Akt 
phosphorylation in all three models of chemotaxis. In the PI3K-dependent 
CXCL12 stimulation of CEM cells, the effects of the PI3K inhibitors were 
similar to those of the Akt inhibitor, but in CCL22 stimulated CEM cells, and 
CXCL12 stimulated PBMCs, incubation with PI3K inhibitors only had a mild 
effect on Akt activity, while the Akt inhibitor completely abrogated it.  
These results give rise to two possible explanations. Firstly, as mentioned 
above, Akt could be activated independently of PI3K, yet play a vital role in the 
migration of T lymphocytes. The second option could be a difference in the 
quantity of each kinase within the cell (Fig. 3.20). If Akt is a pinch-point in the 
signalling cascade, then an inhibitor that targeted here would have a much 
greater effect than one targeted at a kinase that was present in much greater 
quantities. Further work will have to be performed to test this hypothesis. The 
effect of PI3K inhibitors on PI3K activity in these systems should be 
investigated to determine whether PI3K is still active. In addition, using siRNA 
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or a similar system, PI3K should be inactivated in a PI3K independent model of 
chemotaxis. If the Akt inhibitor still had an effect, it would be a good indication 
that Akt is activated by kinases other than PI3K. Either way, this data 
demonstrates the importance of using Akt inhibitors alongside PI3K inhibitors 
when investigating the PI3K/Akt pathway. 
Signal from chemokine 
receptor 
Amount of PI3K inhibitor 
needed to abrogate signal 
PI3K 
Relative amounts of 
protein within the cell 
Akt 
Amount of Akt inhibitor 
needed to abrogate signal 
Signal to migratory 
machinery 
Figure 3.20 Schematic diagram showing proposed pinch-point hypothesis. 
If an imbalance exists between the amount of PI3K and Akt within a cell, then a 
much greater concentration of inhibitor is required to achieve the same effect a 
small amount of inhibitor would have on a different target.  
3.11.3 The role of GSK-3 in T lymphocyte chemotaxis 
GSK-3 was the first physiological target of PKB to be identified and is a key 
player in PKB signalling. It is unusual in that phosphorylation by Akt 
inactivates GSK-3 (Woodgett, 2005). To investigate the role of GSK-3 within T 
lymphocytes, a specific inhibitor of GSK-3, BIO, was used (Meijer et al., 
2003b). Inhibition of GSK-3, via BIO, should have the same effect as if Akt 
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had been activated. It was therefore theorised that incubation with BIO would 
promote chemotaxis.  
Using the CCL22-mediated chemotaxis of CEM cells model, it was shown that 
incubation with the GSK-3 inhibitor significantly promoted chemotaxis. This 
result is not without precedent. Studies using fibroblasts from mice that lack a 
functional GSK-3β isoform show increased wound healing, accelerated wound 
closure and increased fibrogenic responses (Kapoor et al., 2008).   
One of the ways that GSK-3 could mediate its inhibitory effect on migration is 
through NFAT. NFAT (nuclear factor of activated T cells) is a transcription 
factor implicated in the migration of cells (Yoeli-Lerner et al., 2005). In T 
lymphocytes, GSK3β phosphorylates serine motifs on NFATc1, inhibiting DNA 
binding and promoting its nuclear export (Beals et al., 1997). Therefore, the 
inactivation of GSK-3 by Akt allows NFAT access to the nucleus, where it can 
promote transcription and aid migration (Chow et al., 2008).  
GSK-3 is also important in cell polarity. Cells must undergo highly polarised 
reorganisation of cytoskeletal elements prior to directional migration 
(Gundersen et al., 2004). One of these re-arrangements is that the microtubule 
system and the MTOC move to the front of the cell, resulting in the transport of 
structural proteins to the leading edge of the cell. This system depends on the 
inactivation of GSK-3. When GSK-3 is phosphorylated, it is unable to 
phosphorylate the tumour-suppressor gene product Apc. This allows Apc to 
associate with the microtubules and regulate microtubule dynamics and 
therefore polarisation (Etienne-Manneville and Hall, 2003).  
3.11.4 A role for PKCδ in T lymphocyte migration. 
Previous studies within the laboratory had identified a PLC-dependent, Ca2+­
dependent protein that was important in CEM cell migration (Cronshaw et al., 
2006). Protein Kinase C Delta (PKCδ) is a member of the novel class of PKC 
isoforms. This class require DAG, but not Ca2+ for activation. In addition, PKCδ 
has been shown to be phosphorylated at Thr505 by PDK-1, and while this is not 
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a prerequisite for activation (Stempka et al., 1997a); it does indicate a role for 
PI3K in this process. 
CCL22 mediated stimulation of CEM cells resulted in phosphorylation of PKCδ 
at Thr505, indicating that it is involved in migration. Rottlerin, an inhibitor for 
PKCδ, since shown to be not very specific, inhibited migration in a dose-
dependent manner. Due to a lack of alternative pharmacological tools, mice 
lacking PKCδ were used to confirm a role for PKCδ in T lymphocyte migration. 
Migration of murine splenocytes to CCL22 revealed that the PKCδ null cells 
underwent significantly less migration than the wildtype mice, showing that 
PKCδ is indeed involved in migration. 
Other studies have shown similar results. Studies have shown that PKCδ is 
important for the migration of smooth muscle under mechanical stress (Li et al., 
2003). In addition, CCL15, the ligand for CCR1 and CCR3 which have been 
shown to be expressed on neutrophils, monocytes and lymphocytes, have been 
shown to induce migration of human osteogenic sarcoma cells through a PLC / 
PKCδ dependent process (Ko et al., 2002). 
3.12 Conclusions 
In this part of the study, I have demonstrated that CCR4-mediated migration of 
CEM cells and CXCR4-mediated migration of PBMCs occurs even in the 
presence of PI3K inhibitors. However, CXCR4-mediated migration of CEM 
cells was unable to migrate in the presence of PI3K inhibitors. This 
demonstrates a difference in receptor signalling pathways within a cell type, as 
well as a difference in signalling pathways for the same chemokine receptor in 
different cell types. This was achieved using the standard broad-spectrum 
inhibitors of PI3K; LY294002 and Wortmannin, as well as a new, more 
specific, inhibitor of PI3K; ZSTK474. 
Subsequent to this, I determined that inhibition of Akt using a novel, specific 
inhibitory compound abrogated chemotaxis in all models – regardless of 
whether they had previously been shown to be PI3K-independent. This was 
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found to be due to a difference in the ability of PI3K inhibitors and Akt 
inhibitors to inhibit Akt activity. There are two possible explanations for this 
result. Firstly, that Akt is activated independently of PI3K, through PKC and / 
or PDK-1. Secondly, it could be due to a difference in the relative amounts of 
each protein within the cell. Therefore a little Akti-1/2 could have a far greater 
effect than larger concentrations of the PI3K inhibitors. Further research would 
have to be performed to determine if this is the case. This data then 
demonstrates the importance of using both PI3K and Akt inhibitors before 
ascribing any response to the PI3K / Akt pathway. 
In this part of the study it was also determined that GSK-3 and PKCδ play an 
important role in T lymphocyte migration. Inhibition of GSK-3 with the 
compound BIO resulted in an increase in the migration of CEM cells to CCL22. 
GSK-3 is phosphorylated by Akt and inactivated, so inhibition by BIO mimics 
Akt activation. In addition, PKCδ was shown to be activated upon chemokine 
binding, and using PKCδ null mice, shown to be important in the migration of 
murine splenocytes to CCL22. 
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CHAPTER 4: RESULTS II -
THE ROLE OF PI3K IN 
MURINE TH17 CELL 
POLARISATION AND 
MIGRATION 
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Results II: The role of PI3K in murine Th17 cell polarisation 
and migration 
4.1 Background 
CD4+ T helper cells are important in the regulation and function of the adaptive 
immune system and have classically been characterised as either Th1 or Th2 
subsets depending on their cytokine production profile (Mosmann et al., 2005). 
Th1 cells, which produce IFNγ, IL-2 and TNF-α, are associated with defence 
against intracellular pathogens (cell-mediated immunity), while Th2 cells, 
which produce IL-4, IL-5, IL-10 and IL-13, mediate defense against 
extracellular parasites (humoral immunity) (Sher and Coffman, 1992; Abbas et 
al., 1996). Recently, a novel T helper cell subtype has been described, Th17, 
and is characterised by IL-17, IL-6 and TNF production (Harrington et al., 
2005; Park et al., 2005). It is now understood that these cells form a separate 
lineage from Th1 and Th2 cells, one that bridges the innate and adaptive 
immune systems.  
Upon differentiation, polarised Th1 and Th2 CD4+ T cells have been shown to 
preferentially express different chemokine receptors. Typically, CXCR3, 
CXCR6 and CCR5 are preferentially expressed on Th1 cells (Qin et al., 1998), 
with CCR3, CCR4, CCR8 and the PGD2 receptor CRTH2, expressed on Th2 
cells (Sallusto et al., 1998c; Nagata et al., 1999). This differential chemokine 
receptor expression can be used to characterise the different T helper subsets, 
and is thought to be important in the specific and discrete homing of these cells, 
which could explain specific roles for these cells in inflammatory diseases. For 
example, IFNγ, a Th1 cytokine, induces the release of ligands for CXCR3, a 
receptor that is upregulated on Th1 cells. In a similar fashion, CCL17 levels are 
increased in skin diseases such as atopic dermatitis (Saeki and Tamaki, 2006), 
recruiting Th2 cells via CCR4 to these sites of cutaneous inflammation 
(Campbell et al., 1999). 
Th17 cells have been implicated in several mouse models of autoimmune 
diseases such as EAE and collagen-induced arthritis. These diseases have also 
had chemokine receptors implicated in their pathogenesis, while several isoform 
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specific chemokine inhibitors are being developed to target these diseases. 
Several papers have recently been published, identifying CCR2 and CCR6 as 
being present on human Th17 cells, however no studies have investigated 
chemokine receptor expression on murine Th17 cells, crucial for the modelling 
of these diseases, nor the role of protein and lipid kinases in Th17 cell 
migration. Using Th17 cells derived from murine DO11.10 splenocytes, this 
section of the study aimed to gain more insight into the chemokine receptor 
expression of murine Th17 cells, and the kinases that govern chemokine 
induced migration in these cells. 
4.2 Generation of Th17 cells 
Several papers have been published investigating the optimum conditions for 
generation of Th17 cells from murine splenocytes. Work performed by Andrew 
Johnson at UCB, Cambridge, and based on the original study by Veldhoen et al 
(Veldhoen et al., 2006) produced a protocol based on splenocytes from 
DO11.10 mice. The DO11.10 strain of mice express a transgene for a TCR 
clonotype, specific for the chicken Ovalbumin epitope 323-339 (OVA323-339) 
(Murphy et al., 1990). The vast majority of peripheral DO11.10 T cells express 
the transgenic TCR. OVA323-339 is presented to T cells by the major 
histocompatibility complex (MHC) class II molecule I-Ad, which preferentially 
activates CD4+ T cells. Therefore co-culture with non-proliferative APCs and 
OVA323-339 activates DO11.10 CD4+ T cells in vitro, in an antigen specific 
manner.  
In addition to activation by Ovalbumin peptide, generation of Th17 cells 
requires polarisation by cytokines including TGF-β, the pro-inflammatory 
cytokines IL-6, IL-1β and TNFα, IL-23 to maintain the Th17 phenotype of 
memory CD4+ T cells, as well as antibodies neutralising the cytokines IFN-γ 
and IL-4. CD4 enriched DO11.10 T cells were cultured with Ova Peptide, 
supplemented with cytokines and antibodies and incubated for 7 days. Th17 cell 
proportions were compared to non-polarised cultures (Th0) using 3-colour 
intracellular flow cytometry. Cells were stimulated with PMA and Ionomycin to 
stimulate cytokine production before being stained against extracellular CD4, 
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fixed, permiabilised and stained against intracellular IFN-γ and IL-17 (Fig. 
4.1A+B). Although some reports have described a small proportion of IL-17+ 
IFN-γ+ cells, (Suryani and Sutton, 2007) most papers, and this study, define 
Th17 cells as CD4+, IL-17+, IFN-γ- cells. Under Th17 polarising conditions, the 
proportion of IL-17+ IFN-γ- cells was significantly elevated (16.9%±0.9, n=12) 
compared with nonpolarised (Th0) cultures (3.4%±0.3, n=12) (Fig. 4.1C). 
The Luminex assay is a multiplex system that can measure the concentration of 
several different cytokines in a single sample. Distinct microspheres are 
conjugated to antibodies specific for the cytokines of interest. These spheres are 
incubated with cell culture supernatant, and then bound cytokines are detected 
with a secondary biotinylated antibody. PE-streptavadin is incubated with the 
microspheres, and then the mean fluorescent intensity (MFI) of each distinct 
microsphere type is detected using the Luminex machine. The MFI is then 
compared to a standard curve of known cytokine concentrations to determine 
the concentration of cytokines in the sample. Using this system, analysis of 
secreted cytokines within the cell culture supernatants revealed a significantly 
higher concentration of IL-17 in Th17-polarised conditions (7401 pg/ml±1723 
pg/ml, n=4) compared with nonpolarised conditions (230 pg/ml±36 pg/ml, n=4) 
(Fig. 4.1D). In addition, levels of IFN-γ were significantly lower under Th17 
polarising conditions (73 pg/ml±5 pg/ml, n=4) compared with nonpolarising 
conditions (737 pg/ml±179 pg/ml, n=5).  
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Figure 4.1 Phenotype of CD4+ T cells cultured under Th17 or Th0 
polarising conditions. CD4+ DO11.10 splenocytes were cultured under Th17 
polarising conditions or Th0 non-polarising conditions. On day 7 post-isolation, 
cells were stimulated for 3 hours with 50 ng/ml PMA, 500 ng/ml ionomycin, 
and GolgiStop, and then stained with antibodies against CD4, IL-17 and IFNγ to 
determine the proportion of Th17 cells. Representative flow cytometry plots 
from cells cultured under Th17 polarising conditions (A) or non-polarised Th0 
cells (B) are shown. Mean intracellular flow cytometry data from eight separate 
experiments is also shown (n=8; C). Cell culture supernatant from cells cultured 
for seven days was analysed using Luminex, as described in Materials and 
Methods, to determine the concentrations of soluble IL-17 and IFN-γ (n=4; D). 
Results are expressed as mean ± SEM ** p<0.01, *** p<0.001. FL2 and FL3; 
Fluorescence 2 and Fluorescence 3 respectively. 
4.3 	 Expression of chemokine receptors on the surface of Th17 
polarised cells 
Other subsets of CD4+ T cells, such as Th1 cells and Th2 cells, have been shown 
to express specific chemokine receptors on their surface. These receptors have a 
distinct role in targeting the cells towards inflammation and have been identified 
as possible drug targets. In addition, they act as useful markers for the 
identification of these cells. While the surface expression of chemokine 
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receptors is well documented in Th1 and Th2 cells, and the expression of 
chemokine receptors on human Th17 cells is also becoming clearer, their 
expression on murine Th17 cells has yet to be investigated. The impact of Th17 
polarising conditions on chemokine receptor surface expression was 
investigated by staining cells with antibodies against the CC chemokine 
receptors CCR2, CCR3, CCR5, CCR6, CCR7 and CCR9 (Fig. 4.2A) and the 
CXC chemokine receptors CXCR2, CXCR3, CXCR4 and CXCR5 (Fig. 4.2B). 
The whole cell population was stained to identify the impact of Th17 polarising 
versus non-polarising culture conditions on the proportion of cells expressing 
these receptors. No significant difference between non-polarised Th0 cells and 
cells cultured under Th17 polarising conditions was observed in the proportions 
of cells expressing the CC chemokine receptors CCR3, CCR5 or CCR7 or the 
CXC chemokine receptor CXCR5. However, the percentage of cells expressing 
CCR2, CCR6, CCR9, CXCR2 and CXCR4 was significantly increased on cells 
cultured under Th17 polarising conditions compared to non-polarised cells. As 
the proportions of CXCR2 and CXCR4 were low (3% and 5% respectively), it 
was decided not to pursue these further as the low levels of expression would 
make it difficult to assess any impact on functional readouts. Interestingly, the 
percentage of cells expressing the CXCR3 receptor was significantly decreased 
under Th17 polarising conditions when compared to nonpolarising conditions 
(31% and 72% respectively). 
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Figure 4.2 Surface expression profile of chemokine receptors on CD4+ T 
cells cultured under Th17 or Th0 polarising conditions. Extracellular flow 
cytometry was used to determine the expression of CC chemokine receptors (A) 
and CXC chemokine receptors (B) on the surface of CD4+ splenocytes cultured 
under Th17 and Th0 polarising conditions. CD4+ DO11.10 splenocytes were 
cultured under Th17 polarising conditions or Th0 non-polarising conditions as 
outlined in Materials and Methods. On day 7 post-isolation, cells were aliquoted 
into FACS tubes and stained with fluorescently conjugated anti-CC and anti-
CXC chemokine receptor antibodies. Data were acquired on a Beckman Coulter 
EPICS XL machine using EXPO32 ADC software. Results are expressed as 
mean ± SEM. n=4, * p<0.05, ** p<0.01, *** p<0.001. 
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4.4 	 The functional responsiveness of CCR2, CCR6 and CCR9 
on Th17-polarised cells 
Although increased expression of chemokine receptors was observed on cells 
cultured under Th17 polarising conditions, further study was required to 
determine whether these receptors were biochemically functional. Migration 
assays were used to determine whether chemokine binding could induce 
migration of the cells. The ligands CCL20 and CCL25 are specific chemokines 
for CCR6 and CCR9 respectively, and were used in this assay. CCR2 lacks a 
specific chemokine and so two chemokines, CCL2 (binds CCR2 and CCR4) 
and CCL12 (binds CCR2 and CCR5) were used. Th17-polarised cells (Fig. 
4.3A) and non-polarised cells (Fig. 4.3B) were incubated for 3 hours in a 
chemotaxis assay with varying concentrations of CCL2, CCL12, CCL20 and 
CCL25. Migrated cells were counted on a flow cytometer using fluorescent 
beads to quantify the number of migrated cells. Concentration-dependent 
migration of cells occurred in response to CCL2, CCL12, and CCL20 for 
nonpolarised and Th17-polarised cells, while CCL25 only induced migration of 
Th17-polarized cells, albeit with less efficacy than the other agonists. Migration 
of nonpolarised cells in response to CCL25 was not observed. 
Other methods of determining whether chemokine receptors are functional 
include activation of Akt and loss of surface receptor expression. This 
biochemical read-out was therefore used to explore whether CCR2, CCR6 and 
CCR9 detected on Th17 cells were biochemically functional. Direct 
measurement of PI3K products in primary cells is technically formidable, so 
phosphorylation of proteins downstream of PI3K, such as Akt, is often used as a 
surrogate readout of PI3K signalling output. Stimulation of cells cultured under 
Th17 polarising conditions with ligands for CCR2 (CCL2), CCR6 (CCL20) and 
CCR9 (CCL25) resulted in the concentration-dependent phosphorylation of 
residues Ser473 and Thr308 on Akt, with maximal phosphorylation occurring at 
1nM CCL25 and CCL20 and 0.1nM CCL2 (Fig. 4.4A). 
Chemokine receptors undergo constitutive trafficking to and from the plasma 
membrane under basal conditions, leading to degradation or recycling to the cell 
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surface, which have been shown to be greatly enhanced upon ligand binding to 
functional receptors (Neel et al., 2005a). The ability of CCL2, CCL20 and 
CCL25 to induce the loss of surface expression of their receptors was therefore 
investigated. Cells cultured under Th17-polarising conditions were stimulated 
with the chemokines at the concentration shown to induce maximal chemotaxis. 
After stimulation for between 1 minute and 60 minutes, cells were washed into 
ice-cold FACS buffer to prevent receptor recycling, then stained for the 
chemokine receptors and analysed using flow cytometry. Stimulation of cells 
cultured under Th17 polarising conditions with CCL2, CCL20, and CCL25 
(Fig. 4.4B) induced a loss of surface expression of their respective receptors in a 
time-dependent manner. Stimulation with CCL2 resulted in a 63.2%±5.8 loss of 
surface expression of CCR2, while CCL25, stimulation caused a 56%±3 
reduction in surface expression of CCR9. Interestingly, incubation of Th17­
polarised cells with CCL20 only resulted in a 42%±3.3 loss of surface 
expression of CCR6. 
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Figure 4.3 Chemokine induced migration of CD4+ T lymphocytes cultured 
under Th17 or Th0 polarising conditions. Chemotaxis assays were used to 
determine whether cells cultured under Th17 or Th0 polarising conditions 
migrated to chemokines that bind CCR2, CCR6 and CCR9. CD4+ DO11.10 
splenocytes were cultured under Th17 polarising conditions (A) or Th0 
polarising conditions (B) were placed in the upper chamber of a 24 –well 
Transwell chemotaxis plate above lower chambers containing varying amounts 
of CCL2, CCL12, CCL20 or CCL25 as described in Materials and Methods. 
Migration across a 5μm pore membrane was determined after 3 hours at 37oC. 
Fluorescent beads were added to samples prior to data acquisition to quantify 
number of migrated cells. Results are expressed as mean ± SEM, n=4. 
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Figure 4.4 Interactions between chemokine receptors and their ligands in 
Th17 polarised CD4+ splenocytes induce phosphorylation of Akt and loss of 
surface receptor expression. Immunoblotting and flow cytometry were used to 
determine whether CCR2, CCR6 and CCR9 detected on Th17 polarised cells 
were biochemically functional. CD4+ DO11.10 splenocytes were cultured under 
Th17 polarising conditions for seven days, then stimulated with CCL25, CCL20 
or CCL2 at the concentrations indicated (A). Cells were subsequently lysed as 
described in Materials and Methods, and lysates (1.6 x 106 cells per lane) 
resolved by SDS-PAGE gel, transferred to nitrocelluose membranes, and 
immunoblotted with a phospho-specific Akt antibody with affinity for the active 
Ser473 phosphorylated form of Akt or a phospho-specific Akt antibody with 
affinity for the active Thr308 phosphorylated form of Akt, and protein was 
visulaised with ECL. The blots were stripped and reprobed with pan-Akt 
antibody to verify equal loading and efficiency of protein transfer. Data are 
representative of at least three separate experiments.  
1 x 106 cells cultured under Th17 polarising conditions were stimulated with 
CCL2, CCL20 or CCL25 (B) at stated concentrations and incubation periods at 
37˚C, washed into ice-cold PBS, and then stained at 4˚C with fluorescently 
conjugated anti-chemokine receptor antibodies as described in Materials and 
Methods. Data were acquired on a Beckman Coulter EPICS XL machine using 
EXPO32 ADC software. Results are expressed as mean ± SEM, n=4. C, 
Control. 
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4.5 	 The role of PI3K and Akt in chemokine receptor signal 
transduction on Th17-polarised cells 
The result from Fig. 4.4A revealed that Akt is phosphorylated upon stimulation 
of Th17-polrised cells by chemokines. This result indicated that PI3K and Akt 
are involved in the signal transduction of chemokine receptors on Th17­
polarised cells. However, in the previous chapter it was seen that 
phosphorylation of Akt does not necessarily correspond to Akt activity. To 
confirm that Akt is activated by chemokines in this system, and that PI3K is 
involved, the Omnia® Lysate Assay system was used. The Omnia® Lysate 
Assay system uses fluorophores attached to substrate peptides specific for Akt. 
Upon phosphorylation of the peptide by Akt, a change in the rate of 
fluorescence occurs. This change in fluorescence corresponds to a change in the 
rate of phosphorylation by Akt, allowing measurement of Akt activity. 
Measurement of Akt activity in Th17-polarised splenocytes revealed that 
stimulation with 10nM CCL2 significantly increased the rate of phosphorylation 
by Akt. Pre-incubation of CCL2-stimulated cells with LY294002 significantly 
reduced the rate of phosphorylation by Akt from 13.8±0.5 to 8.5±0.5 (Fig. 4.5A, 
n=4) at 10μM. Similarly, pre-incubation with the Akt inhibitor Akti-1/2 also 
reduced Akt activity in this system, from 15.2±0.6 to 7±0.7 (Fig. 4.5B, n=4) at 
10μM. 
Stimulation of cells with 10nM CCL20 also significantly increased Akt activity. 
This activity was decreased by LY294002 or Akti-1/2 in a comparable fashion 
to CCL2 stimulation, with 10μM LY294002 reducing activity from 15.0±0.7 to 
8.7±0.7 (Fig. 4.5C, n=4) while 10μM Akti-1/2 reduced activity from 13.9±0.8 to 
8.7±0.3 (Fig. 4.5D, n=4). 
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Figure 4.5 Activation of Akt is induced by chemokine receptor – ligand 
interactions in Th17 polarised CD4+ splenocytes and is sensitive to 
inhibition of PI3K. Please see next page for the legend. 
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Figure 4.5 Activation of Akt is induced by chemokine receptor – ligand 
interactions in Th17 polarised CD4+ splenocytes and is sensitive to 
inhibition of PI3K. An Akt activity assay was used to determine whether 
stimulation of CCR2 or CCR6 causes and increase in Akt activity, and whether 
this was a PI3K dependent process. CD4+ DO11.10 splenocytes were cultured 
under Th17 polarising conditions for seven days, then incubated with 
LY294002 (A,C) or Akti-1/2 (B,D) for 30 min then stimulated with 10nM 
CCL2 (A,B) or 10nM CCL20 (C,D) for 5 min and lysed. Resulting Akt activity 
was assessed using Akt activity assay as described in Materials and Methods. 
Results shown as change in the rate of flourescence, which corresponds to 
change in the rate of phosphorylation of target peptides by Akt. Results are 
expressed as mean ± SEM, n=4. One-way ANOVA  ** p<0.01. 
138
 
4.6 Chemokine-induced migration of Th17 cells 
Having shown that cells polarised under Th17-polarising conditions show 
upregulated surface chemokine receptor expression of CCR2, CCR6 and CCR9, 
and that ligands for these receptors induce PI3K / Akt dependent migration, the 
ability of these agonists to induce migration of Th17 cells was investigated. As 
no specific marker for Th17 cells existed with which to isolate and purify the 
cells without killing them, an alternative method to identify migrated Th17 cells 
was used. CD4+ splenocytes cultured under Th17-polarising conditions, or 
nonpolarising conditions, were suspended in chemotaxis media and incubated in 
a transwell chemotaxis chamber with varying concentrations of chemokine. 
After three hours, cells were recovered from the bottom of the chamber and 
stimulated for three hours with 50 ng/ml PMA, 500 ng/ml Ionomycin and 0.66 
μl/ml of GolgiStop to induce intracellular cytokine production and prevent 
subsequent exocytosis of the cytokines. The cells were then incubated with a 
fluorescent extracellular antibody against CD4, then fixed with 
paraformaldehyde and stored at 4ºC overnight. The cells were then permeated 
and incubated with fluorescent intracellular antibodies against IL-17 and IFNγ. 
Known quantities of fluorescent beads were added to the sample prior to data 
acquisition using a flow cytometer. This allowed the number of migrated cells 
to be counted. In addition, the antibody staining allowed the proportion of Th17 
and IFNγ+ cells within the sample to be assessed. Using these two pieces of 
data, the number of Th17 and IFNγ+ cells that migrated could then be 
calculated.  
Analysis of the results revealed significant concentration-dependent migratory 
responses to CCL2, CCL12 and CCL20, with 100nM CCL2 (Fig. 4.6.1A) 30nM 
CCL12 (Fig. 4.6.1B) and 3nM CCL20 (Fig. 4.6.1C) causing maximal migration. 
These results, and the migratory profiles, are similar to those observed for total 
Th17-polarised cell migration. Interestingly, CCL25 elicited no significant 
migratory response in Th17 cells, indicating that although increases in surface 
expression of CCR9 were observed in Th17-polarised cell populations, the 
increases were unlikely to be on Th17 cells. None of the agonists examined 
caused significant migration of IFNγ+ cells, indicating that the increase in CCR9 
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expression is on the approximately 74% of cells that are neither IL-17+ or 
IFNγ+. Significant changes in the proportions of Th17 cells in culture after 
migration were also observed. Migration to CCL2 (Fig. 4.6.2A), CCL12 (Fig 
4.6.2B) and CCL20 (Fig 4.6.2C) all resulted in significantly higher proportions 
of Th17 cells in the post-migration culture than the pre-migration culture. This 
indicated that in addition to the cells migrating expressing CCR2 and CCR6, 
they also migrate in preference to other cells expressing those receptors. No 
change in Th17 cell proportions was observed after migration to CCL20 (Fig. 
4.6.2B) 
To confirm the finding that CCR9 is not expressed on Th17 cells, 3-colour flow 
cytometry was used. Th17-polarised cells were labelled for the chemokine 
receptor as well as IL-17 and IFNγ. Due to a lack of commercially available 
antibodies with different fluorophores, we were unable to stain for CD4 and the 
chemokine receptor at the same time. However, previous results indicated that 
all IL-17+ cells were CD4+ as well, and so this was thought to be acceptable. 
The IFNγ- population was selected for, then the proportion of cells that 
expressed either the chemokine receptor, IL-17 or both were analysed. The data 
revealed that although CCR2 was expressed on 25% of Th17 polarised cells 
(Fig. 4.2A), only 11.9% ± 0.4% of IL-17+ cells coexpressed CCR2 
(representative plot Fig 4.7A). CCR6 was also expressed on 25% of total cells 
within polarised Th17 cultures (Fig. 4.2A), and only 10.9% ± 0.5% of IL-17+ 
cells coexpressed CCR6 (representative plot Fig 4.7B). Contrary to what was 
expected, a similar proportion of Th17 cells expressed CCR9 as CCR2 and 
CCR6, with 11.3% ± 0.8% of Th17 cells coexpressing the receptor 
(representative plot Fig 4.7C). This indicates that the lack of migration of Th17 
cells to CCL25 is not due to a lack of receptor expression on Th17 cells. 
Overall, these data suggest that surface expression of the chemokine receptors 
examined does not fully define the Th17 population, and would not be suitable 
as a marker for Th17 cells. The relatively low level of chemokine receptor 
expression on Th17 cells, coupled with a lack of commercially available 
antibodies conjugated to an appropriate range of fluorophores, prevented further 
investigation into the coexpression of CCR2, CCR6 and CCR9 on Th17 cells.  
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Figure 4.6.1 Number of Th17 cell migrated to CCR2, CCR6 or CCR9 
ligands. 
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Figure 4.6.2 Proportion of Th17 cell in culture after migration to CCR2, 
CCR6 or CCR9 ligands. 
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Figure 4.6.1 Number of Th17 cell migrated to CCR2, CCR6 or CCR9
 
ligands. 

Figure 4.6.2 Proportion of Th17 cell in culture after migration to CCR2,
 
CCR6 or CCR9 ligands. 

Chemotaxis assays were used to determine whether Th17 cells (IL-17+) or IFN­
γ+ cells migrated to ligands for CCR2, CCR6 and CCR9. Cells cultured under 
Th17 polarising conditions were placed in the upper chamber of a 24 –well 
Transwell chemotaxis plate above lower chambers containing varying amounts 
of CCL2 (A), CCL12 (B), CCL20 (C) or CCL25 (D) as described in Materials 
and Methods. Migration across a 5µm pore membrane was determined after 3 
hours at 37oC. Migrated cells were stimulated for 3 hours with 50 ng/ml PMA, 
500 ng/ml ionomycin, and GolgiStop, and stained with antibodies against CD4, 
IL-17 and IFNγ. Fluorescent beads were added to samples prior to data 
acquisition to quantify number of migrated cells. Results are expressed as mean 
± SEM. n≥4. One-way ANOVA, * p<0.05, ** p<0.01. 
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Figure 4.7 Chemokine receptor expression on Th17 cells. Flow cytometry 
was used to determine the proportion of Th17 cells that express each chemokine 
receptor. CD4+ DO11.10 splenocytes were cultured under Th17 polarising 
conditions. On day 7 post-isolation, cells were stimulated for 3 hours with 50 
ng/ml PMA, 500 ng/ml ionomycin, and GolgiStop, then stained with antibodies 
against IFNγ, IL-17 and either CCR2 (A), CCR6 (B) or CCR9 (C). Data were 
acquired on a Beckman Coulter EPICS XL machine using EXPO32 ADC 
software. The proportion of IL-17+ cells coexpressing CCR2, CCR6 or CCR9 is 
the value in the top right quadrant (chemokine receptor+/IL-17+) calculated as a 
percentage of the sum of the two right-hand quadrant values (chemokine 
receptor+/IL-17+ and chemokine receptor-/IL-17+). Hence, 17% of cells are IL­
17+ (15+2%) in A; therefore, 2% of 17% is ~ 11% (see text for further values). 
Flow cytometry plots and values shown are representative of 3 separate 
experiments. 
144
 
4.7 	 The role of PI3K / Akt in CCR2 and CCR6 mediated Th17 
cell migration 
Although PI3K and Akt have been shown to be activated in response to 
chemokine induced stimulation of Th17 polarised cells, their role in the 
migration of Th17 cells has yet to be explored. Data from the previous chapter 
demonstrated that some T cells, albeit human, have differences in their 
sensitivity to PI3K inhibitors and Akt inhibitors during migration. To determine 
the role of PI3K and Akt in migration, Th17-polarised cells were pre-incubated 
with various does of LY294002 or Akti-1/2 for 30 minutes prior to incubation in 
a Transwell chemotaxis chamber with 100nM CCL2 or 3nM CCL20. These 
concentrations induced maximal migration in Fig. 4.6, and so would provide a 
good migration response against which to observe any inhibition. Ligands for 
CCR9 were not used, as no significant migration of Th17 cells had been 
observed when using these previously. 
The PI3K inhibitor LY294002 significantly inhibited migration of Th17 cells in 
response to 100nM CCL2 and 3nM CCL20 with pIC50 values of 5.73 ± 0.22 
(Fig 4.8A) and 5.68 ± 0.18 (Fig 4.8B) respectively. These data are consistent 
with the affinity estimates reported for LY294002 in other cell systems (Ito et 
al., 2007), and also correlates with the Akt activity studies (Fig. 4.5). 
Interestingly, LY294002 is more potent in this system than was observed using 
human CEM cells or SEB activated T lymphocytes. Akti-1/2 significantly 
inhibited the migration of Th17 cells in response to 100nM CCL2 and 3nM 
CCL20, with pIC50 values of 5.75 ± 0.08 (Fig 4.8A) and 5.78 ± 0.13 (Fig 4.8B) 
respectively. These results demonstrate that migration of Th17 cells in response 
to ligands for CCR2 or CCR6 is mediated by PI3K/Akt and is sensitive to 
inhibitors of these kinases. 
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Figure 4.8 The effect of PI3K and Akt inhibition on Th17 cell migration. 
Chemotaxis assays were used to determine whether CCR2 and CCR6 mediated 
migration of Th17 cells is PI3K / Akt dependent. Cells cultured under Th17 
polarising conditions were incubated with LY294002 or Akti-1/2 for 30 minutes 
at the concentrations shown prior to being placed in the upper chamber of a 24 – 
well Transwell chemotaxis plate above lower chambers containing 100nM 
CCL2 (A) or 3nM CCL20 (B) as described in Materials and Methods. Migration 
across a 5μm pore membrane was determined after 3 hours at 37oC. Migrated 
cells were stimulated for 3 hours with 50 ng/ml PMA, 500 ng/ml ionomycin, 
and 0.66 μl/ml GolgiStop, and stained with antibodies against CD4, IL-17 and 
IFNγ. Fluorescent beads were added to samples prior to data acquisition to 
quantify number of migrated cells. Results were transformed using Graphpad 
Prism to plot the percentage inhibition of migration caused by each inhibitor. 
This graph was then used to determine the pIC50 of each inhibitor for each 
chemokine. Results are expressed as mean ± SEM, n=4. 
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4.8 The role of PI3K in Th17 cell polarisation 
Having demonstrated that PI3K is important in the migration of Th17 cells, its 
role in the polarisation of Th17 cells was also investigated. In 2006, a paper was 
published (Okkenhaug et al., 2006) that revealed a role for the p110δ isoform of 
PI3K in the polarisation of murine CD4+ splenocytes into a Th1 or Th2 
phenotype. To investigate whether this was true for Th17 cells, another CD4+ 
cell type, a combined pharmacological and gene targeting strategy was utilised. 
IC87114 is a p110δ-specific inhibitor developed by ICOS, a subsidiary of Eli 
Lilly. Studies have shown this inhibitor is specific for p110δ against other PI3K 
isoforms at the 5μM to 10μM range (Sadhu et al., 2003), making it a very useful 
compound with which to investigate this isoform.  
CD4+ splenocytes from DO11.10 mice were cultured under Th17 polarising 
conditions. On the indicated day, 10μM IC87114 was added to the culture. On 
day 7 post cell-isolation, the cells were stained for CD4, IFNγ and IL-17, and 
the proportion of Th17 cells within culture identified. Analysis of the results 
revealed that a significant reduction in the proportion of Th17 cells in culture 
occurred when the inhibitor was added on days one to five after culture, with 
maximal inhibition occurring when the compound was added on day two (Fig. 
4.9). No effect was seen if IC87114 was added at the start of culture, or at the 
end. Complete abrogation of Th17 cell polarisation was also not observed, as 
even at maximum inhibition, 10% of cells in culture were Th17 cells.   
The surprising result that IC87114 has no effect on Th17 cell polarisation if 
added at the start of culture was investigated further. It was theorised that this 
result could be because the inhibitor was degraded after incubation at 37ºC in 
culture for seven days. To test this theory, splenocytes from mice that lacked the 
active isoform of p110δ were used. The lack of p110δ in these mice is 
permanent and so should mimic the addition of IC87114 to Th17 polarisation 
cultures on day 0. p110δ D910A/D910A mice, a kind donation from Klaus 
Okkenhaug at the Babraham Institute, have an alanine for aspartic acid 
substitution in both copies of the gene (Okkenhaug et al., 2002). This 
substitution lies at the C terminal of the kinase domain and renders the protein 
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inactive. This kind of mutation has the advantage over deletion mutations in that 
there is no compensatory expression of other kinases, thus allowing a clear 
picture of the role of p110δ. 
The mice were also on a DO11.10 background so no changes were made to the 
Th17 polarisation protocol. CD4+ splenocytes from wildtype DO11.10 mice and 
p110δ D910A/D910A mice were cultured for seven days. The cultures were 
then analysed by flow cytometry to determine the proportion of Th17 cells 
within the culture (Fig 4.10). The p110δ D910A/D910A mouse culture 
contained a significantly lower proportion of Th17 cells than the wildtype 
culture (11.4% ± 0.5% and 19.4% ± 0.6% respectively). However, similar to the 
IC87114 incubation, a population of Th17 cells remained.  
The culture medium from the two cell cultures was analysed for levels of 
cytokines to confirm the difference in Th17 cell proportions. IL-17 
concentrations were significantly reduced in the D910A mouse culture medium 
(8900 ± 472.3 pg/ml) compared with medium from the wildtype cells (12770 ± 
1153 pg/ml), although levels were generally high (Fig. 4.11A). Levels of TNF­
α, another cytokine produced by Th17 cells, were also slightly reduced in the 
D910A cell culture (1763 ± 99.1 pg/ml) compared with the wildtype cell culture 
(2209 ± 134 pg/ml) (Fig. 4.11B). Interestingly, levels of IFNγ and IL-10, 
cytokines normally associated with Th1 and Th2 cells respectively were 
significantly reduced in D910A mice compared with wildtype mice. IFNγ 
concentrations were 11.5 ± 0.8 pg/ml and 3.7 ± 0.6 pg/ml respectively (Fig. 
4.11C), while IL-10 concentrations were 94.0 ± 8.6 pg/ml and 40.0 ± 5.4 pg/ml 
respectively (Fig. 4.11D). Taken together, these results indicate that the p110δ 
isoform of PI3K is involved in the polarisation of Th17 cells. However, the 
percentage reduction in the proportion of Th17 cells in the culture is not as large 
as seen in Th1 and Th2 cell cultures. This result is borne out by the analysis of 
cytokines within the Th17 cell cultures. Although there is a slight, albeit 
significant, reduction in the levels of IL-17 and TNF-α, a far greater reduction is 
seen in the levels of IFNγ and IL-10, Th1 and Th2 cytokines. These data 
indicate a different role for p110δ in Th17 generation and Th1 / Th2 generation, 
with another kinase involved in Th17 polarisation.  
148
 
%
 IL
-1
7+
 c
el
ls
 in
 c
ul
tu
re
 25 
20 
15 
10 
5 
0 
*** 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 No inhibitor 
Day 10μM IC87114 added 
Figure 4.9 The effect of IC87114 on Th17 polarisation. Flow cytometry was 
used to determine the effect of P110δ inhibition using 10μM IC87114 on the 
polarisation of Th17 cells from CD4+ splenocytes. CD4+ DO11.10 splenocytes 
cultured under Th17 polarising conditions were incubated with 10μM IC87114 
on the day indicated on the graph until day 7 post-isolation.  On day 7, cells 
were stimulated for 3 hours with 50 ng/ml PMA, 500 ng/ml ionomycin, and 
GolgiStop, then stained with antibodies against CD4, IL-17 and IFNγ to 
determine the proportion of Th17 cells. Data were acquired on a Beckman 
Coulter EPICS XL machine using EXPO32 ADC software. Results are 
expressed as mean ± SEM, n=4. One-way ANOVA, *** p<0.001. 
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Figure 4.10 The role of P110δ in Th17 polarisation. Flow cytometry was 
used to determine whether splenocytes from mice lacking a functional P110δ 
isoform of PI3K are able to successfully polarise to Th17 cells. Wildtype CD4+ 
DO11.10 splenocytes or CD4+ DO11.10 splenocytes from mice that lack a 
functional P110δ isoform of PI3K due to a knock-in mutation (p110δ 
D910A/D910A) were cultured under Th17 polarising conditions as described in 
Materials and Methods. On day 7 post-isolation, cells were stimulated for 3 
hours with 50 ng/ml PMA, 500 ng/ml ionomycin, and GolgiStop, then stained 
with antibodies against CD4, IL-17 and IFNγ to determine the proportion of 
Th17 cells. Data were acquired on a Beckman Coulter EPICS XL machine 
using EXPO32 ADC software. Results are expressed as mean ± SEM, n=8 
Students t-test, *** p<0.001. 
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Figure 4.11 Concentrations of cytokines produced by wildtype and P110δ 
KI CD4+ splenocytes cultured under Th17 polarising conditions. Luminex 
assays were used to determine the concentrations of IL-17 (A), TNF-α (B), IFN­
γ (C) and IL-10 (D) produced by CD4+ wildtype splenocytes and CD4+ 
splenocytes from mice that lack a functional P110δ isoform of PI3K. Wildtype 
CD4+ DO11.10 splenocytes or CD4+ DO11.10 splenocytes from mice that lack 
a functional P110δ isoform of PI3K due to a knock-in mutation (p110δ 
D910A/D910A) were cultured under Th17 polarising conditions as described in 
Materials and Methods. On day 7 post culture, cell culture supernatant from the 
cultures was analysed using Luminex, as described in Materials and Methods, 
to determine the concentrations of soluble IL-17, TNF-α, IFN-γ and IL-10. 
Results are expressed as mean ± SEM, n=8. 
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4.9 Summary 
•	 Using splenocytes from DO11.10 mice, this study has shown that a 
significant population of Th17 cells can be generated under the correct 
polarisation conditions. These cells are defined as CD4+, IL-17+, IFNγ­
and can produce significant concentrations of the cytokine IL-17. 
•	 Analysis of chemokine receptor expression on cells cultured under Th17 
polarising conditions revealed that CCR2, CCR6, CCR9, CXCR2 and 
CXCR4 were upregulated compared to nonpolarised cells, while 
CXCR3 was downregulated, consistent with its known upregulation on 
Th1 cells. 
•	 When tested, all three CC chemokine receptors were shown to be 
biochemically active indicating migration of cells cultured under Th17 
polarising conditions, phosphorylation of Akt and loss of surface 
receptor expression. In addition, ligands to all three receptors induced 
Akt activation that was dependent on PI3K. 
•	 By isolating Th17 cells post-migration, it was determined that ligands 
for CCR2 and CCR6 could induce migration of Th17 cells. Interestingly 
ligands for CCR9 failed to induce the migration of Th17 cells, although 
expression of the chemokine receptors on the surface of Th17 cells was 
approximately equal.  
•	 Migration of Th17 cells in response to ligands for CCR2 or CCR6 is 
mediated by PI3K/Akt and is sensitive to inhibitors of these kinases. 
•	 When the role of the p110δ isoform of PI3K in Th17 cell polarisation 
was explored, the data revealed that although p110δ is important for 
Th17 polarisation, a population of Th17 cell remains in the absence of 
p110δ, and therefore it is possibly not as important as it is for Th1 and 
Th2 cell differentiation. 
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 4.10 Discussion 
The aim of this study was to determine what chemokine receptors are expressed 
on the surface of murine Th17 cells, and whether migration of Th17 cells 
through these receptors is dependent on PI3K / Akt. In addition, the role of 
PI3K in the polarisation of Th17 cells was explored. However, first it was 
important to polarise Th17 cells from murine splenocytes and confirm that these 
cells were able to produce IL-17. 
4.10.1 CD4+ splenocytes cultured in an inflammatory 
cytokine milieu polarise to an IL-17 producing phenotype 
Previous studies have shown an important role for TGF-β and IL-6 in the 
polarisation of CD4+ splenocytes to an IL-17 producing phenotype (Veldhoen et 
al., 2006). In addition, IL-4 and IFNγ have been shown to inhibit the 
differentiation of Th17 cells (Harrington et al., 2005; Park et al., 2005), while 
IL-23 is required for the maintenance of pre-existing Th17 populations. Using 
TGF-β, IL-6 and IL-23, as well as IL-1β and TNFα, and neutralising antibodies 
towards IL-4 and IFNγ, a population of Th17 cells were cultured from CD4+ 
murine splenocytes. The Th17 cells were identified using flow cytometry and 
were defined as CD4+, IL-17+, IFNγ-. Analysis of the cell culture supernatant 
revealed significantly greater concentrations of IL-17 in the Th17 polarising 
culture when compared to the nonpolarising cell culture. Interestingly, only 20% 
of cells within the culture polarised to a Th17 phenotype. While this is 
consistent with other groups (Veldhoen et al., 2006) it raises the question of the 
identity of the other cells. 
4.10.1.1 Identity of the other cells within Th17-polarising 
cultures 
Th17 polarisation resulted in a significantly higher proportion of Th17 cells 
when compared to nonpolarising conditions. However, by day 7, a small 
percentage (approximately 6%) of the population expressed IFNγ and not IL-17. 
Although differentiation of Th1 cells and Th17 cells was thought to be mutually 
exclusive, several recent studies have identified populations of cells that share 
features of Th1 and Th17 cells, including IFNγ expression (Annunziato et al., 
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2007; Nakae et al., 2007). In addition, the ability for differentiated cells to alter 
their cytokine expression profile is not without precedent, as cells that produce 
both the Th1 cytokine IFNγ and the Th2 cytokine IL-4 have also been reported 
(Messi et al., 2003). Indeed, a very small but significant population of IL-17+, 
IFNγ+ cells also exists within the total cell population. The phenotype of the 
remaining cells is unclear. The presence of anti-IL-4 antibodies within the cell 
population make it unlikely that Th2 cells would be found within the 
population. While TGF-β has been shown to induce forkhead box p3 
expression, and leads to the polarisation of regulatory T cells (Chen et al., 
2003b), IL-6 has been shown to inhibit this process (Dominitzki et al., 2007), 
making it unlikely that regulatory T cells form a large proportion of the 
population. It is therefore likely that the remaining population of cells consist of 
CD4+ cells that are not expressing cytokines, and hence we are unable to 
categorise them through flow cytometry, or cells that have yet to differentiate to 
a specific subtype. The inability to differentiate greater proportions of Th17 
cells may be due to the failure to separate memory and naive T cell prior to 
polarisation as some studies where this occurs have lead to large populations of 
Th17 cells (costa-Rodriguez et al., 2007b). 
4.10.2 Surface expression of chemokine receptors on Th17-
polarised cells 
Several papers have shown that human Th17 cells express chemokine receptors, 
including CCR2 (Sato et al., 2007), CCR6 (Singh et al., 2008) and CCR4 
(costa-Rodriguez et al., 2007b). However chemokine receptor expression on 
murine Th17 cells had not been investigated (although a paper published 
subsequently identified CCR6 as present of murine Th17 cells (Hirota et al., 
2007). 
Studies showed increased expression of CCR2, CCR6, CCR9, CXCR2 and 
CXCR4 and decreased expression of CXCR3 on the surface of cells cultured 
under Th17 polarising conditions. CXCR3 is classically associated with Th1 
cells, and its decreased expression in this context may reflect the decreased 
proportion of IFNγ+ cells observed under these culture conditions.  
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The increased expression of several chemokine receptors on CD4+ T cells 
maintained under Th17 polarising conditions has several implications for 
inflammatory diseases. For example, CCR6 is a mucosa homing receptor 
present on dendritic cells and effector memory T cells (Greaves et al., 1997; 
Kondo et al., 2007) that has also been implicated in cutaneous, airway and 
intestinal mucosal immunity (Varona et al., 2001; Cook et al., 2000). Moreover, 
it has also been implicated in the recruitment of T cells in several inflammatory 
conditions including airway rheumatoid arthritis (Ruth et al., 2003) and 
psoriasis (Homey et al., 2000), both conditions in which IL-17 has been shown 
to play a role (Nakae et al., 2003; Zheng et al., 2007). Recent evidence has 
revealed that dectin-1-mediated fungal immune recognition preferentially 
induced Th17 cells in both humans and mice. These cells are characterised by 
expression of CCR6, a mucosa homing receptor, as well as the skin homing 
receptor CCR4 (Wilson et al., 2007). Interestingly, the Th17 polarising cytokine 
IL-23 strongly up-regulates CCL20 expression in Th17 cells (Wilson et al., 
2007). This may reflect a positive-feedback loop to ensure sustained recruitment 
of Th17 effector cells. Alternatively, CCL20 is known to possess direct anti­
microbial activity (Hoover et al., 2002). CCL20 also enhances migration of 
Langerhans cells and immature CD11b+ dendritic cells from peyer’s patches as 
well as memory and effector T cells that home to skin and mucosal surfaces 
(Iwasaki and Kelsall, 2000; Schutyser et al., 2003). Thus, CCL20 produced by 
Th17 cells not only directs epithelial immunity via antimicrobial activity but 
also contributes to infiltration of inflammatory cells and IL-23 mediated 
autoimmune diseases. It is interesting to note that CCR6 has also been reported 
to be expressed in IFNγ-producing CXCR3+ Th1 cells following exposure to 
Toll-like receptor ligands, indicating that homing capacity of T helper cells is 
programmed by the nature of innate immune activation via pattern recognition 
receptor activation. The relationship between CCR6 expression and the IFNγ­
producing cells detected under Th17 polarising conditions is unclear, but 
certainly CXCR3 is detected in the Th17 polarised population, albeit at lower 
levels than in the non-polarised cells. 
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The expression of CCR2 on polarised Th17 cells also has implications for 
inflammatory disease. It has previously been shown to be expressed on 
monocytes, activated memory T cells, B cells, and basophils in humans, and 
also in peritoneal macrophages in mice and its increased expression has been 
associated with several inflammatory conditions including Experimental 
Autoimmune Encephalomyelitis (EAE) (Izikson et al., 2000). Interestingly, IL­
17 has been shown to be crucial in the development of EAE. Indeed, an anti-IL­
17A vaccine protected mice against the induction of EAE (Uyttenhove and Van, 
2006). Previously, CCL2 (a major ligand for CCR2) has been implicated in the 
control of Th2 polarisation (Gu et al., 2000), although it is possible that other 
CCR2 ligands such as CCL7 and CCL12 may play distinct and more prominent 
roles in Th17 regulation owing to differences in expression profiles.  
Interactions between CCL25 and CCR9 are involved in thymic development 
and the generation of gut-specific immunological memory (Kunkel et al., 2000; 
Zabel et al., 1999). In the gut, CCL25 is highly expressed by epithelial cells 
lining the small intestinal villi but is less prominently expressed in the colon 
(Kunkel et al., 2000; Zabel et al., 1999). Some T cell subsets are significantly 
reduced within the intestinal epithelium of CCR9-deficient mice, indicating that 
CCR9 is necessary for steady state intestinal T cell development and/or 
migration (Uehara et al., 2002; Wurbel et al., 2001). In addition, adoptive 
transfer experiments reveal that CCR9+/+ lymphocytes are more efficient than 
CCR9-/- lymphocytes at homing to the small intestine (Johansson-Lindbom et 
al., 2003). The demonstration of up-regulated CCR9 expression under Th17 
polarising conditions is interesting as IL-17 levels are elevated in inflammatory 
bowel disease (IBD) (Fujino et al., 2003) while the IL-23R gene is a 
susceptibility factor for IBD (Duerr et al., 2006). Indeed, IL-23 is essential for T 
cell mediated colitis and promotes inflammation via IL-17 and IL-6 in 
experimental models (Yen et al., 2006). Paradoxically however, addition of anti­
IL-17 antibody worsened intestinal inflammation in a mouse model of colitis 
(Ogawa et al., 2004). A study of CCR9+ T cells isolated from mesenteric lymph 
nodes (MLN) draining from the small bowel of patients with Crohn’s disease 
showed they produced more IL-17 in response to anti-CD3 or IL-12/IL-18 
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stimulation, than similar cells from healthy patients, (Saruta et al., 2007) 
indicating that these CCR9+ T cells are pro-inflammatory.  
4.10.2.1 What was the source of the CXCR2? 
Analysis of surface chemokine receptor expression revealed low levels of 
CXCR2 expression. Studies have shown that T lymphocytes do not express 
CXCR2 (Kershaw et al., 2002), which asks the question; what cells were 
expressing this receptor? CXCR2 has been shown to play an important role in 
many diverse signalling pathways such as wound healing, angiogenesis, 
inflammation and leukocyte chemotaxis (Baugher and Richmond, 2008). 
Ligands for CXCR2 are ELR+ angiogenic chemokines. This means that they 
mediate, through CXCR2, the migration and proliferation of endothelial cells, 
thereby promoting angiogenesis (Raman et al., 2007). CXCR2 is also the main 
chemokine receptor on neutrophils and mediates neutrophil recruitment 
(Zarbock et al., 2008). Both endothelial cells and neutrophils are found in the 
spleen, and although cells were sorted to ensure they were CD4+ T lymphocytes 
prior to culture, this process is not 100% efficient. However, endothelial cells 
are adherent cells, meaning that the stick to culture flasks (Liu et al., 2007). In 
normal culture conditions, the cells are treated with trypsin-EDTA to remove 
them from the surface of the flask. During routine culture of Th17 cells, this did 
not occur, ensuring that very few endothelial cells were within the population 
tested. Primary neutrophils do not survive for very long within culture, coupled 
with the sorting for CD4 also means that very few would have been within the 
population tested. While these populations are the likely cells that made up the 
CXCR2+ population, this explains why expression was so low.  
4.10.2.2 Why were levels of CXCR4 so low? 
CXCR4 is widely expressed on CD4+ T lymphocytes (Bleul et al., 1996; 
Loetscher et al., 1994) and is involved in both homeostatic and inflammatory 
trafficking. It is also one of several chemokine receptors that HIV uses to enter 
cells. Interestingly, it has been reported to also be expressed on Th17 cells. 
Studies using Th17 cells isolated from secondary lymphoid tissues in the tonsils 
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revealed that 50% of Th17 cells expressed CXCR4, markedly more than was 
seen in this study. However, 20% of the Th17 cells from the tonsils were also 
IFNγ+, different from the ones used in this study (Lim et al., 2008). Since their 
discovery, several differences between human and murine Th17 cells have been 
revealed (McGeachy and Cua, 2008). Expression of CXCR4 appears to be 
another. 
4.10.3 Are the chemokine receptors functional? 
Having identified several chemokine receptors that are upregulated upon culture 
under Th17 polarising conditions, the ability of their ligands to induce 
migration, receptor internalisation and Akt phosphorylation and activation were 
assessed. All cells cultured under Th17 polarising conditions migrated to 
ligands for CCR2, CCR6 and CCR9, although CCL25 less cells migrated to 
CCR9, consistent with the lower expression of CCR9 on Th17 cells.  
Chemokine receptors undergo a basal level of internalisation, followed by 
degradation or recycling, in the absence of ligand. Upon ligand binding, the rate 
of internalisation is greatly increased (Neel et al., 2005b). This helps to modify 
the response of the cell, helping to determine the level of migration. In addition, 
studies have shown that internalisation is vital for efficient chemotaxis 
(Richardson et al., 1998). While CCR2 (Ogilvie et al., 2001) and CCR6 (Badr et 
al., 2005) have previously been shown to undergo internalisation, CCR9 has 
never been shown to internalise. Further study would be required before it could 
be determined whether this is a unique function in Th17-polarised cells. 
4.10.4 Ligands for CCR2 and CCR6 induce Th17 migration 
through a PI3K / Akt dependent mechanism. 
Ligands for CCR2 and CCR6, although interestingly not CCR9 were able to 
induce the migration of Th17 cells, and did so preferentially to other cells in the 
culture. As discussed above, this may help to explain the recruitment of Th17 
cells to inflammatory areas, as both IL-17 and CCR2 or CCR6 have been 
implicated in inflammatory and autoimmune diseases. Using LY294002, an 
inhibitor of all PI3K isoforms, revealed that PI3K is essential for migration of 
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Th17 cells. PI3K is activated by most chemokine receptors expressed on T cells, 
yet paradoxically it is now clear that activation of PI3K by chemokines can be a 
dispensable signal for directional migration of some T cells particularly after in 
vitro activation and polarisation toward Th2 (Cronshaw et al., 2004) . Studies of 
the specificity of LY294002 have revealed that it also inhibits some non-lipid 
kinases such as CK2 and mTOR. In order to prove that this was a PI3K 
dependent mechanism, another inhibitor Akti-1/2, shown to be very specific for 
the Akt1 and Akt2 isoforms of Akt, was utilised (Zhao et al., 2005a). This 
inhibitor also abrogated chemotaxis, at a very similar concentration to 
LY294002, indicating the PI3K/Akt pathway is essential for murine Th17 cell 
migration.  
Much interest has arisen recently in the role of PI3K and inflammatory diseases, 
especially as two isoforms, p110δ and p110γ appear to be primarily expressed in 
leukocytes (Sujobert et al., 2005). Treatment of mice with inhibitors of p110γ 
suppressed the progression of joint inflammation in mouse models of 
rheumatoid arthritis (Camps et al., 2005), as well as prolonging survival in 
mouse models of systemic lupus erythematosus (SLE) (Barber et al., 2005). 
Both diseases have been shown to have elevated levels of IL-17 (Ziolkowska et 
al., 2000; Wong et al., 2000). The different dependency of Th17 cells vs. Th2 
cell migration on PI3K-dependent signalling offers exciting therapeutic 
opportunities whereby PI3K isoform-selective inhibitors might be used to 
suppress Th17-driven inflammatory/autoimmune responses, while leaving other 
arms of the immune response unaffected. 
4.10.4.1 Why didn’t CCR9 mediate migration of Th17 cells? 
Surface expression of CCR9 was increased in response to Th17 polarising 
conditions, while CCL25 induced migration of cells cultured under Th17­
polarising conditions, as well as internalisation of CCR9 and Akt activation, 
indicating that the receptor was functional. However, when migrated cells were 
analysed, no significant migration of Th17 cells had occurred in response to 
CCL25. One possible explanation for this is that the increased surface receptor 
expression of CCR9 was not on Th17 cells. However analysis of receptor 
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expression on Th17 cells using flow cytometry revealed that a similar 
proportion of Th17 cells expressed CCR9 as CCR6. Therefore the reasons for 
this result are currently unclear, but may reflect differences in the functional 
efficacy of CCL25 verses CCL2 and CCL20. In this regard, CCL25 was much 
less potent that CCL2 or CCL20 in inducing Akt phosphorylation. It could also 
result from a difference between cell types, whereby CCR9 on Th17 cells is 
non-functional, while CCR9 expressed on other cells within the Th17-polarised 
cell culture is functional. Studies on melanoma cells revealed a population of 
cells that express CCR9, but where the CCR9 was not functional. In this case, a 
dysfunctional signaling pathway was suggested as a possible explanation 
(Letsch et al., 2004). 
4.10.5 A role for p110δ in Th17 cell polarisation? 
Differentiation of T lymphocytes occurs upon engagement of the T cell receptor 
(TCR) with APCs, as well as the presence of varying cytokines. Once this has 
occurred, a signalling cascade is initiated involving several tyrosine kinases. 
The transmembrane adapter protein, linker for activation of T cells (LAT), 
nucleates this complex and controls recruitment and activation of phospholipase 
C , which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) to produce 
inositol trisphosphate and diacylglycerol (Zhang et al., 1998). Inositol 
trisphosphate triggers the cytoplasmic release of Ca2+, which induces the 
translocation of NF-AT transcription factors to the nucleus, while diacylglycerol 
activates PKC and Ras guanyl-releasing protein, which in turn activate the Ras­
ERK1/2 pathway and AP-1 nuclear translocation (Genot and Cantrell, 2000). 
Other proteins can influence this system by altering the level of PIP2. One such 
protein is PI3K, which is thought to couple to the TCR through LAT (Ward and 
Cantrell, 2001). Previous work by Okkenhaug et al (Okkenhaug et al., 2006) 
revealed a role for the p110δ isoform of PI3K in the polarisation of Th1 and Th2 
cells. Use of mice lacking a functional p110δ isoform, or IC87114, a p110δ­
specific inhibitor, revealed that loss of p110δ did inhibit Th17 cell polarisation, 
although not to the same extent as in Th1 and Th2 cells.  
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Akt has also been shown to be essential for T helper cell differentiation 
(Arimura et al., 2004), as well as a number of PIP3-dependent kinases such as 
Itk (Fowell et al., 1999), although to-date, Itk has only been reported to have a 
role in Th2 cell polarisation. It is likely that p110δ signals through these 
proteins during T helper cell differentiation. Other proteins have been 
implicated in differentiation of T lymphocytes following TCR engagement 
including the p110α isoform of PI3K (Sauer et al., 2008) and PKCθ (Villalba et 
al., 2000). Further work needs to be completed before it can be determined what 
role these proteins may have in Th17 cell differentiation, and whether they 
account for the 50% of Th17 cells that differentiated in the absence of P110δ. 
4.11 Conclusions 
In this section of the study, I have shown that surface expression of CCR2, 
CCR6 and CCR9 is increased on the surface of CD4+ splenocytes cultured 
under Th17 polarising conditions. I have also shown that surface expression of 
CXCR3 is downregulated on these cells, in line with the reduced numbers of 
IFNγ+ cells in the culture population. Ligands for CCR2, CCR6 and CCR9 were 
able to induce the migration of cells, as well as receptor internalisation, 
indicating that the receptors are functional. It has also been shown that ligand 
binding of these receptors induces Akt phosphorylation and activation. CCR2, 
CCR6 and CCR9 have been implicated in a number a number of inflammatory 
diseases including rheumatoid arthritis, multiple sclerosis and inflammatory 
bowel disease, all diseases that IL-17 has been implicated in. Therefore this 
work describes a model whereby IL-17 producing cells localise to this area 
through their expression of these chemokine receptors. 
Analysis of the cells by flow cytometry post-migration to ligands of CCR2, 
CCR6 and CCR9 revealed that CCR2 and CCR6 mediated the migration of 
Th17 cells, but that CCR9 did not. Further studies would need to be performed 
to determine exactly why, but other studies have also identified the expression 
of non-functional CCR9. The migration of Th17 cells was shown to be via the 
PI3K / Akt pathway, and may help to explain why treatment with p110γ (an 
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isoform of PI3K) inhibitors suppressed joint inflammation in mouse models of 
rheumatoid arthritis, a disease mediated by IL-17. 
In this section of the study, I have also shown that another isoform of PI3K, 
p110δ, is involved in the polarisation of Th17 cells. Studies using mice 
expressing a kinase-dead form of p110δ, or a p110δ inhibitor revealed that 50% 
less cells polarised to a Th17 phenotype. However, further work would need to 
be performed to determine which protein was responsible for the other 50%. 
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5. Final Conclusions and Future Work 
5.1 Final Conclusions 
During the course of this study, a crucial role for Akt has been shown in T 
lymphocytes. Using both primary PBMCs and the T cell line CEM cells, 
inhibition of Akt using the specific inhibitor Akti-1/2 significantly reduced the 
number of cells that migrated to either CCL22 or CXCL12. PI3K, commonly 
thought to be responsible for activation of Akt, was inhibited using three 
separate inhibitors. The results revealed that although PI3K inhibition reduced 
cell migration in CEM cells stimulated with CXCL12, it had no effect on 
CCL22 stimulated CEM cells or CXCL12 stimulated PBMCs. Analysis of Akt 
activity revealed differences in the effects of PI3K inhibition on Akt activity 
depending on the cell type and chemokine. Further experiments are required to 
explain this result, but one possible explanation is that Akt represents a ‘pinch 
point’ in the cell signalling cascade so that inhibition of Akt is more effective 
than inhibition of PI3K for inhibiting migration in certain cell types. Akt also 
has an important role in the regulation of L-selectin, a cell adhesion molecule 
important in lymph-node trafficking. Akt has been shown to phosphorylate 
FOXO, a transcription factor, and thus prevent its entry into the nucleus and the 
subsequent transcription of L-selectin (Fabre et al., 2008). Thus, Akt has 
multiple different effects on cell migration, and another explanation of Akt’s 
crucial role in migration is could be that it’s vital in many different processes.   
The role of other kinases thought to be important in chemokine receptor 
signalling and cell migration was also investigated. Using CCL22 mediated cell 
migration of CEM cells as a model; I have shown that inhibition of GSK-3 leads 
to an increase in cell migration, consistent with Akt’s inhibition of GSK-3 under 
normal cell conditions. In addition, using inhibitors of PKCδ and splenocytes 
from mice containing a kinase-dead mutant of PKCδ revealed a role for PKCδ 
in T lymphocyte migration. The signalling pathways through which PKCδ is 
involved in T lymphocyte migration are still to be determined. However, studies 
have shown that PKC isoforms are involved in several processes crucial to cell 
migration. These include regulation of changes in integrin affinity and lateral 
mobility (Giagulli et al., 2004), effects on actin reorganisation and 
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polymerisation (Sasahara et al., 2002; Hartwig et al., 1992) and phosphorylation 
of myosin light chain (MLC) (Zemlickova et al., 2004; Iwabu et al., 2004a). In 
addition, during lymphocyte function-associated antigen-1-mediated locomotion 
of activated T cells, PKCßI and PKCδ associate with microtubules in the 
uropod, the trailing extension of migrating T cells. (Volkov et al., 2001; 
Fanning et al., 2005a), indicating a role for PKCδ in the migration of T cells.   
Taken together, these results suggest a possible model of the signalling pathway 
in CCL22 mediated migration of CEM cells, and link PI3K / Akt activation to 
cell polarisation and migration (Fig. 5.1). 
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Figure 5.1: Model of a possible intracellular signalling pathway resulting 
from CCL22 binding its receptor in CEM cells. Upon CCL22 binding to 
CCR4, PI3K is activated and converts PIP2 to PIP3 in the cell membrane. This 
allows PDK1 and Akt to bind, resulting in the activation of Akt. Akt then 
phosphorylates GSK-3, inactivating it and preventing GSK-3 from 
phosphorylating APC and NFAT. NFAT can therefore translocate to the nucleus 
where it promotes migration through the transcription of other proteins, while 
APC can associate with microtubules and promote cell polarisation. In addition, 
PLC converts PIP3 into IP3 and DAG. DAG binds to PKCδ, activating it in 
association with phosphorylation by PDK-1. PKCδ then phosphorylates other 
proteins to promote cell polarisation and migration. Akt can also directly 
influence migration. By phosphorylating FOXO and excluding it from the 
nucleus, Akt prevents transcription of L-selectin. The black triangle denotes the 
relative quantities of each protein within the cell.  
Further studies are required to determine whether this model is applicable to all 
chemokine receptors, although this study has already shown differences in the 
susceptibility of cell migration to PI3K inhibition in different cells. This 
difference in signalling pathways could be a method by which cells that receive 
multiple stimuli from different chemokine receptors prioritise their response to a 
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specific signal, i.e. signals from homeostatic chemokines versus inflammatory 
chemokines, by down regulating specific proteins.   
Many cells have been shown to express specific chemokine receptors on their 
cell surface, targeting them to specific regions of the body or allowing them to 
participate in specific inflammatory responses. A new type of T helper cell, 
Th17 cells, was investigated in this study to determine whether they also 
express a unique chemokine receptor profile. Using murine splenocytes 
polarised to a Th17 phenotype, this study has shown that murine Th17 cells 
express the chemokine receptors CCR2 and CCR6. Following on from the 
previous section, it was also shown that CCR2 and CCR6 mediated migration is 
PI3K and Akt dependent. Further study is required to determine whether CCR2 
and CCR6 are expressed on the same cells, or whether they represent two 
distinct populations of cells. In humans, CCR2 has been shown to be expressed 
on cells that are also CCR5- while CCR6 has been shown to be co-expressed 
with CCR4. 
However, some caution should be taken in drawing conclusions between human 
Th17 cells and the murine cells used in this study. Several recent studies have 
highlighted differences between human and mouse cells, one of the most basic 
of which is the requirement for TGF-β. While murine Th17 cells require the 
presence of TGF-β and IL-6 to differentiate, studies have shown that in human 
Th17 cells, TGF-β is dispensable. A study by Acosta-Rodriguez et al has shown 
that human Th17 cells only require IL-1β and IL-6 (costa-Rodriguez et al., 
2007b), while Wilson et al showed that Th17 cells derive from naïve precursors 
in Man in response to either IL-1β or IL-23, with no synergistic effect occurring 
when both were used (Wilson et al., 2007). However, some recent studies have 
contradicted these results, suggesting that TGF-β is required and that previous 
studies were flawed as they used media containing bovine serum, a source of 
TGF-β. (Volpe et al., 2008; Yang et al., 2008). Murine Th17 cells appear to 
have the same developmental origin as FoxP3+ Treg cells, with both requiring 
TGF-β to differentiate. Indeed, FoxP3+ Treg cells have been shown to produce 
IL-17A in the presence of TGF-β. However human Th17 cells appear to be 
more closely linked to Th1 cells, with studies showing the existence of large 
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numbers of cells that produce both IL-17 and IFNγ (Annunziato et al., 2007), as 
well as human Th17 cells that express T-bet (the Th1 transcription factor) in 
addition to RoRγt (Annunziato et al., 2007). 
This study has identified a role for PI3K in both the migration of Th17 cells and 
their polarisation. Inhibition of PI3K or Akt greatly reduced the migration of 
Th17 cells to ligands of both CCR2 and CCR6. Several companies are currently 
investing in inhibitors of PI3K for use in inflammatory diseases (Medina-Tato et 
al., 2007) and with Th17’s major role in these diseases, this result makes PI3K 
an even more attractive target. In addition, the p110δ isoform of PI3K has been 
shown to be involved in the polarisation of Th17 cells. While this could also be 
an attractive target for anti-inflammatory drugs, it is worth noting that these 
results have also been shown in other CD4+ cells including Tregs (Patton et al., 
2006), preventing specific targeting of Th17 cells. Thus significant side-effects 
could result from the administration of PI3K-inhibiting compounds.  
5.2 Future Work 
5.2.1 Confirm the specificity of Akti-1/2 
The Akti-1/2 compound had raised some interesting questions regarding Akt 
and whether it lies solely downstream of PI3K. A lot of these conclusions are 
based around the assumption that this inhibitor is specific for Akt at the 
concentrations used. Analysis of the inhibitor’s effects on the MAPK family of 
proteins has revealed no inhibition. However, it would be useful to run a much 
wider screen against this inhibitor, to confirm that there are no other kinases 
mediating these effects in T lymphocyte chemotaxis.  This could be achieved 
though, for example, a high-throughput kinase screen that detects binding 
against a wide range of different kinases. Such screens are commercially 
available, although expensive. 
5.5.2 Explore whether Akt is activated independently of PI3K 
One of the most interesting outcomes of this work was the discovery that Akt 
inhibition can still inhibit PI3K inhibitor resistant migration. There are two 
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possible explanations for this: i) that Akt is being activated independently of 
PI3K, ii) that there is a difference in the relative abundances of the two kinases 
within the cell, allowing Akti-1/2 to have a much more potent effect than the 
PI3K inhibitors. Therefore, it would be useful to inhibit PI3K using siRNA or a 
similar system and then repeat the chemotaxis experiments. If PI3K is non­
functional but the cells still migrate and can be inhibited by Akti-1/2 then this 
indicates a PI3K-independent role for Akt. Also, it would be interesting to 
monitor the activity of PI3K directly, after adding the PI3K inhibitors. If some 
PI3K is still active, it could indicate a difference in the abundance of the two 
kinases within the cell. If it turns out that Akt is activated independently of 
PI3K, the next logical step would be to try and determine what kinases are 
responsible for activating it. Some evidence has been published that shows that 
PKC isoforms can phosphorylate Akt after activation through GPCR induced 
activation of PLC and the subsequent production of DAG. These isoforms 
would make a good first target for the investigation. 
5.5.3 Further investigate the expression of chemokine receptors 
on the surface of Th17 cells 
Several questions remain unanswered regarding the expression of chemokine 
receptors on the surface of Th17 cells. Limitations with equipment and 
commercially available antibodies meant that I was unable to determine whether 
any of the chemokine receptors were co-expressed on the surface of the Th17 
cells. This could be of particular importance in identifying a Th17-specific 
marker. In addition, further work also needs to be carried out to determine why 
CCR9 does not induce chemotaxis of Th17 cells. The expression of CCR9 on 
Th17 cells, as well as the intracellular signals generated upon ligand binding, 
need to be investigated. 
5.5.4 Determine what proteins are vital for Th17 cell 
polarisation 
During the course of this study it was determined that Th17 cells, unlike Th1 
and Th2 cells are not completely dependent on the p110δ isoform of PI3K to 
polarise. This could be of particular interest in identifying anti-inflammatory 
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drug-targets and so it would be useful to determine what proteins are vital for 
Th17 cell polarisation. 
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